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1. Aging: a Common Suspect in 
Common Disease
A steadily growing life expectancy of the 
general western population1 urges further 
research into age-associated mechanisms 
responsible for the gradual decline of health 
throughout the course of life. Calendar 
age is the major risk factor for the onset 
and progression of virtually all common 
disease affecting the general population 
of the western world today2, suggesting 
that processes of aging are involved in 
the etiology of many diseases. Indeed, 
aging is characterized by a progressive 
and systemic loss of function, which 
gradually leads to a state of senescence on 
the cellular, tissular and organismal level, 
thus affecting the general capacity for 
maintaining bodily homeostasis3. Though 
seemingly inevitable, aging does not occur 
at an equal pace across species4 or even 
within our own species. Whereas some 
experience an accelerated rate of aging, 
as exemplified by patients suffering from 
progeroid syndromes5, others seem capable 
of delaying or evading at least some of the 
detrimental aspects of aging, as observed 
in members of long-lived families6-8. Hence, 
by studying the factors affecting the rate of 
aging, we expect to identify determinants 
that modulate the capacity for maintaining 
the bodily homeostasis as the common 
denominator of age-associated disease.
2. Factors Affecting the Rate of 
Human Aging
Unlike other traits, aging itself is 
not driven by any specific molecular 
mechanism per se, but instead seems to be 
the integrated result of all corrective and 
compensatory mechanisms failing to deal 
with the stochastic damage accumulated 
over life9. Despite its stochastic 
origin, the accumulation of damage 
does converge into some consistently 
observed processes characterizing the 
aging phenotype. In a landmark paper 
titled “The Hallmarks of Aging”10 these 
processes of aging are comprehensively 
described and conceptualized around nine 
main processes co-occurring with aging 
(Figure 1). Though the causality of some 
of these nine hallmarks has yet not been 
irrefutably proven, each of them is likely 
to occur during aging and is thought to at 
least aggravate the consequences of aging 


















Figure 1: Nine recurrently observed processes 
that occur with aging. Processes that are commonly 
observed during aging are: genomic instability, 
telomere attrition, epigenetic alterations, loss 
of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, stem 
cell exhaustion and perturbed signalling. Figure 
adapted from López-Otín et al.10.
Thus far, human aging and its relation 
to health have predominantly been 
studied in the context of two parallel 
though complementary lines of research: 




of information comes from systems 
approaches mainly performed in cell 
systems and model organisms in which 
physiological processes related to 
aging can be perturbed, measured from 
numerous biological perspectives and 
integrated to understand the response of 
the system to the challenge. Here we will 
focus on biomarker and genetic research 
into human aging.
2.1  Biomarkers of human aging 
Biomarker research is aimed at discovering 
quantitative parameters that mark 
biological age. Levels of such biomarkers 
do not only correspond with the absolute 
quantity of time that has passed (calendar 
age), but also mark the mechanisms 
responsible for the deteriorating health 
and increasing frailty that occurs with 
advancing age. Hence, as outlined by Deelen 
et al.11, ideal biomarkers for biological 
aging should correlate with calendar age in 
cross-sectional or in longitudinal studies 
with repeated measurements, while also 
displaying correlations with established 
physiological parameters of health such 
as systolic blood pressure or insulin 
resistance. Furthermore, ideal biomarkers 
of aging are able to discriminate individuals 
with either accelerated (e.g. progeroid 
syndromes) or decelerated (e.g. familial 
longevity) aging phenotypes from those 
derived of the general population, and are 
prospective of future clinical endpoints 
such as morbidity and mortality. Hence the 
identification of ideal biomarkers of aging 
would enable us to objectively monitor 
the rate of biological aging of individuals 
and potentially allows us to differentiate 
and understand different mechanisms 
promoting aging.
2.1.1  Existing biomarkers of human 
aging: A compelling example of the use 
of biomarkers associated with health 
and aging employed in epidemiological 
research is the Framingham risk score 
(FRS), which is the estimated individual 
risk for development of a cardiovascular 
event within 10 years12. The FRS is a 
composite score taking into account 
blood pressure, total cholesterol level, 
HDL cholesterol level and smoking status. 
Future composite scores for aging should 
not only incorporate biomarkers indicative 
for cardiovascular health, but also for 
many other pathophysiological processes 
such as aging of the neuromuscular system. 
By studying aging populations or by 
comparing members of long-lived families 
with population controls, potential 
additional and independent biomarkers 
of aging are currently being investigated. 
Biomarkers that distinguish healthy from 
unhealthy aging groups are for example 
cortisol13, free triiodothyronine14 and 
fasting glucose serum levels15,16. However, 
risk prediction at the individual level 
on the basis of these biomarkers is not 
possible yet. Though each of these traits 
can be used to objectively assess particular 
aspects of the aging human system, it is not 
immediately apparent how they are caused 
by the hypothesized aging mechanisms 
listed earlier (Figure 1). Therefore, a 
challenge remains in translating the 
molecular events that occur during aging 
to the age-associated deterioration that 




level and which is marked by the existing 
biomarkers for biological aging.
2.1.2  Omics-derived biomarkers of 
human aging: In contrast to the existing 
biochemical and physical parameters, 
use of genomic, metabolic or proteomic 
data sources may have the benefit that 
they directly probe at the molecular level 
with an unbiased approach. However, 
the construction of age-associated 
signatures that are both consistent as 
interpretable has proven to be challenging 
with these types of data sources. For 
instance, limited mutual overlap has been 
reported thus far for studies probing 
the aging transcriptome17,18. Possible 
reasons for this could lie in the variable 
technical circumstances under which 
these studies have been performed, but 
also the limited study sizes, low expected 
signal-to-noise ratios and the high tissue 
specificity are likely to contribute to the 
observed inconsistency. Some compelling 
similarities have been observed on the 
pathway level across tissues and even 
across species19,20 incriminating amongst 
others electron transport chain and 
ribogenesis as potential aging promoting 
mechanisms. Hence, studies into the 
aging transcriptome have provided some 
interesting insights into the mechanisms 
promoting aging. However, significant 
progress in this field, let alone future 
translation to the clinic, is severely 
hampered by the large inconsistencies 
generally observed between studies.
Another popular omics platform for 
discovery of biomarkers of biological aging 
is Illumina’s HumanMethylation450k 
BeadChip array, designed for probing the 
human methylome. Using this platform, 
highly robust and tissue independent 
methylation markers for chronological 
age have been identified21,22. However, 
whereas gene expression arrays provide 
interpretable though noisy age-associated 
signatures, methylation arrays provide 
highly predictive though poorly understood 
signatures of aging. Quite unexpectedly, 
loci coming from large-scale meta-analyses 
on age-associated changes of methylation 
levels hardly shed any insights in the age-
associated changes in gene regulation, 
be it either by affecting the expression of 
nearby genes directly21 or by targeting 
hub-genes in regulatory networks23. This 
remarkable absence of any relation with 
regulatory mechanisms thus questions the 
importance of DNA methylation changes 
in the biology of aging. Hence, it has been 
shown that methylation signatures are 
highly predictive of calendar age though 
as of yet are highly uninformative on the 
processes driving biological aging.
To conclude, many challenges still lie 
in the field of omics-based biomarkers 
for aging as the current combination of 
platforms and methods provide signatures 
that either lack the robustness or have as of 
yet a highly disputable role in the etiology 
of aging. Therefore, additional efforts 
should go into increasing our capacity to 
comprehend the results coming from such 
sources before aging processes observed 
at the molecular level can be translated to 
effects for health on the whole body level.
2.2  Genetics of human aging
Since lifespan regulation has a heritable 
component of approximately 25%24,25 in the 




aging research focuses on the identification 
of genetic determinants that specifically 
characterize cases exhibiting either 
accelerated (e.g. progeroid syndromes) 
or decelerated (e.g. human longevity) 
phenotypes of aging. Genetic studies into 
human longevity are mostly inspired by the 
findings of lifespan regulating genes using 
a systems approach in animal studies, 
such as the insulin-like receptor daf-16, 
initially discovered to modulate life span 
regulation in C. elegans26. Interestingly, 
many more genes in C. elegans and D. 
melanogaster that are functionally related 
to this homologue of human FOXO3A have 
been found to consistently modulate life 
span across multiple species27. Hence, such 
systems genetics approaches into aging 
provide valuable starting points for the 
search of genetic loci modulating the rate 
of human aging and life span regulation.
Novel loci for human aging and longevity 
may be identified by comparing the 
frequencies of common variants between 
long-lived cases and younger population 
controls in an association analysis. Such 
association analyses performed using 
either a candidate approach, or on a 
genome-wide scale (GWAS) has yielded 
thus far three robust and independently 
confirmed longevity loci: FOXO3A28-31, 
APOE32-36 and an intergenic locus on 
chromosome 5q33.337. 
A relatively unexplored second 
option for obtaining longevity loci is to 
sequence the genome of extremely long-
lived individuals for rare variants with 
a large predicted impact. Though very 
promising, this approach has thus far only 
been applied on a candidate gene basis 
in a cohort of long-lived individuals38 or 
on a whole genome scale in very limited 
numbers of individuals39-43, which makes 
its use for research into human aging at 
this point hard to assess.
A third source of potential human 
longevity loci might come from family-
based studies (linkage analysis) with a 
history of extended survival6,44. Thus far, 
several linkage studies into longevity 
have been performed45-48, however, 
none of the reported loci display any 
mutual consistency, nor have they been 
independently confirmed36. Hence, genetic 
studies into aging and life span regulation 
have known a very limited number of 
successes judged by the standards set in 
the genetics field and have been far less 
successful as compared to other commonly 
studied multifactorial traits.
2.3  Challenges and opportunities in 
aging research
Thus far many of the available genetic, 
transcriptomic, methylome and 
metabolome data sources on human aging 
have been analysed in isolation. Whereas 
this approach has lead to the identification 
of some biochemical biomarkers for aging, 
considerably less progress is made with 
the analysis of genomic data sources on 
aging. As a result, little is known how aging 
mechanisms on the molecular and cellular 
level affect health and aging on the whole 
body level. Reasons for the lagging insights 
derived from genomic data sources surpass 
the relative novelty of these data types, 
since similar tools for genomic research 
have been very successfully applied in 
studying other complex traits. For instance 
the era of GWAS has brought many novel 




but not in human longevity research. 
In effect, the analysis of genomics 
data on aging is hampered for two main 
reasons affecting either the discovery of 
molecular biomarkers or genetic markers. 
First, the stochastic nature of aging makes 
biomarker research into this field very 
distinct from studying other traits, as it 
is an intrinsically passive mechanism that 
acts on many processes in parallel and on 
all systemic levels simultaneously. Hence, 
much signal is expected to correlate in the 
analysis for aging biomarkers, though few 
molecular entities are actually independent 
or causal for the studied aging phenotype.
Secondly, investigation of the genetic 
determinants modulating health, the rate 
of aging and ultimately life span regulation 
is hampered by the extreme heterogeneity 
of the studied traits. This poses the 
possibility that the non-consistent results 
of genetic screens for life span regulation 
each constitute actual independent 
mechanisms for modulating the rate of 
biological aging. 
Interestingly, both the issues of 
stochasticity and heterogeneity refer 
to a lack of power that can be solved by 
analysing data sources on aging jointly 
instead of analysing each of them in 
isolation, as is currently the standard. 
Hence, a huge opportunity lies in the 
application and development of methods 
for the integrated analysis of genomic 
aging data resources.
3. Approaches for Data 
Integration
Analyses of genomic data sources 
directed to investigating aging and life 
span regulation are especially prone to 
overfitting and therefore deserve special 
attention from a methodological point of 
view. An analysis is said to overfit when 
features are extracted from the data that 
do not reflect the general characteristics 
of the studied phenotype, but instead 
focus on irrelevant features that happen 
to coincide with the studied phenotype 
in that particular experimental setting 
only. Approaches with a reduced chance 
of fitting noise are indicated as robust 
and can generally be achieved by applying 
either two of the following concepts for 
data integration: the joint analysis of 
genomic data sources, or the incorporation 
of prior knowledge. 
A very commonly used example of a joint 
analysis of genomic data sources is a so-
called eQTL analysis, which is sometimes 
performed in addition to a normal GWAS 
or a whole genome expression analysis 
(Figure 2A). The aim of such an analysis is 
to determine whether SNPs influence the 
expression of (nearby) genes, hence the 
term expression Quantitative Trait Loci 
or eQTLs. Besides inferring clues for the 
mechanistic causality of an observed trait 
association, the rational for this approach 
was exemplified by a study of Nicolae et 
al.50 showing that eQTLs, as a subset of all 
SNPs, are enriched for trait-associations. 
Incorporation of eQTL analyses is thus 
likely to reduce false positive findings, 





Another example of a joint analysis on 
omics data sources is a so-called genomic 
convergence approach51 in which the 
relatively low-resolution results coming 
from genome wide linkage analysis are fine 
mapped using a differential gene expression 
analysis (Figure 2B). The original paper 
coining this term successfully used Serial 
Analysis of Gene Expression (SAGE) data, 
to prioritize the thousands of candidate 
genes that were identified with a linkage 
analysis on families suffering from 
Parkinson’s disease51. Later the concept 
of genomic convergence was extended 
to the sequential use and intersection of 
significant results of any combination 
of omics data sources that also included 
whole genome gene expression profiling, 
as exemplified by Wheeler et al.52. Here, 
loci influencing kidney aging where found 
by a sequential use of a differential gene 
expression profiling on age, followed by 
Figure 2: Examples of approaches for data integration. A) False positive findings are reduced by enforcing 
significant correlations between trait-SNP (GWAS), SNP-expression (eQTL) and trait-expression. B) Genomic 
Convergence as originally applied by Hauser et al.51. Loci displaying significant linkage are scrutinized using a 
differential gene expression analysis. Note that in this example only three out of seven genes are expressed in 
the studied tissue (A, E and G) of which gene E seems to exhibit the largest differences between cases (red) and 
controls (blue). C) Hits coming from GWASs (ASSOC) are interpreted in their genomic context in HaploReg, which 
integrates various publically available resources. The top associated SNV (red) is in strong Linkage Disequilibrium 
(LD) with other nearby SNVs (red, yellow and white indicate respectively high, mediocre and low R2). Histone 
marks for enhancers have been found (REG: grey) in the studied tissue and an eQTL for the upstream region has 
been reported (REG: purple). Together, these results link the top SNV (red) to the upstream gene. D) DAPPLE58 maps 
GWAS hits to Protein-Protein Interaction to identify functionally coherent clusters of genes involved in the studied 
trait. These modules serve several purposes, for instance, candidate loci 1 and 2 (ASSOC) can be prioritized using 
their proximity to other significantly associated genes (red) in the Protein-Protein Interaction Network. In this 






























































an eQTL analysis for the significantly age-
associated genes, which delivered the final 
101 prioritized loci to be tested with the 
actual phenotype of interest. The aim of 
such an approach is again to control the 
statistical power, while gaining additional 
mechanistic insights. Many more examples 
exist for the joint interpretation of multiple 
genomic data sources, but in general all 
these approaches are aimed at improving 
the power by including data on additional 
measurements, and not additional samples 
per se. Hence, whenever the number of 
available samples is limited, as is often the 
case when studying human aging and life 
span regulation, additional power can be 
gained by applying approaches for the joint 
analysis of data sources.
Multiple genomic data sources assayed 
on an overlapping group of individuals are 
not always available, but fortunately, much 
can also be gained from results created 
in previously performed independent 
experiments. The number and types of such 
annotations stored by online databases is 
rapidly expanding, as are the number of 
algorithms employing this information that 
can be readily applied for improving one’s 
own analysis. The incorporation of such 
prior knowledge is in general performed to 
aid in the interpretation or prioritization 
of results or for introducing additional 
constraints in the analysis of genomics data 
(regularization) to prevent overfitting. A 
very straightforward example is that of 
databases integrating results of genomic 
approaches to aid in the interpretation of 
GWAS results. For instance, HaploReg53 
not only contains results of eQTL studies54, 
but also employs genetic data from the 
1000 Genomes Project55 for inferring 
correlations with nearby genetic markers 
and epigenetic data from the ENCODE56 
and Roadmap Epigenomics57 projects 
for inferring overlaps with regulatory 
domains (Figure 2C). Other well-known 
examples of algorithms incorporating 
prior knowledge is DAPPLE58, an algorithm 
developed to test for functional coherence 
between hits derived from GWAS studies 
using previously measured networks of 
Protein-Protein Interaction data59 (Figure 
2D). Using this algorithm, it was shown 
that genes in loci associated to height and 
lipid levels assemble into significantly 
interconnected modules. Hence, both these 
examples for GWAS result interpretation 
imply that false positive rates can be 
reduced using measures derived from 
prior knowledge. 
Many algorithms exist for prioritising 
variants obtained from sequencing 
experiments using prior information. 
Besides predicting the putative impact of 
coding variants using established gene 
models (e.g. SIFT60 or PolyPhen61) or cross-
species conservation (e.g. GERP62), more 
recent algorithms are also able to prioritise 
variants residing in non-coding regions by 
exploiting public genetic data resources 
for inferring the relative sensitivity of 
genomic regions to perturbations63,64. The 
latter concept was elegantly exploited 
for prioritizing candidate cancer driver 
mutations by revisiting previously assayed 
sequencing data and assessing which 
motifs where under strong negative 
selection in the general population, but 
recurrently disrupted in tumour samples63. 
To conclude, a positive side effect of many 
of the methods for data integration is that 




gained, by revealing some of the molecular 
interactions. Therefore, approaches for 
data integration are not only useful in 
aging research for the purpose of dealing 
with statistical issues related to power, but 
for probing the essence of molecular aging 
mechanisms as well.
4. Aim and Outline of this 
Thesis
The aim of this thesis was to develop 
state-of-the-art integrative algorithms for 
the comprehensive and robust analysis 
of omics data sets, and to apply them to 
elucidate molecular pathways driving the 
rate of human aging.
To develop methodology for a 
comprehensive and robust analysis of 
gene expression data in Chapter 2, we 
explored employing Protein-Protein 
Interaction (PPI) data for grouping gene-
expression data into comprehensive 
modules of functionally related genes 
(Figure 2D). We investigated whether the 
expression of such gene modules jointly 
could serve as robust biomarkers. In this 
chapter we revisited six expression data 
sets previously assayed for investigating 
indicators of prospective outcome of 
patients undergoing breast cancer 
surgery. Like the aging phenotype, breast 
cancer outcome is a very heterogeneous 
and complex phenotype that demands 
advanced methodology for the robust 
analysis and comprehensive interpretation 
of assayed omics data. Novel methodology 
for calling co-expressed PPI modules from 
gene expression data was introduced and 
cross-study reproducibility, cross-study 
prediction accuracy and comprehensibility 
of the thus obtained biomarkers was 
investigated.
In Chapter 3 the methodology for 
calling co-expressed PPI modules was 
further developed adopting a meta-
analysis framework for both the module 
inference and following associations 
with phenotypes of interest. Aim was to 
investigate the benefits for studying the 
aging transcriptome with aid of the newly 
developed methodology for a module based 
meta-analysis as opposed to the traditional 
individual gene meta-analysis. For this 
purpose, we revisited four transcriptomic 
datasets previously measured in blood 
(~2.500 samples) and employed an 
additional independent dataset (~3.500 
samples) for replicating the obtained 
associations with chronological age. The 
potential application of the thus obtained 
age-associated co-expressed PPI modules 
as biomarkers for healthy aging was 
further studied in a small independent set 
of nonagenarians (~50 samples) derived 
from the Leiden Longevity Study (LLS).
To dive deeper into the genetics 
underlying the rate of aging and longevity, 
the whole genome sequence of 218 long-
lived cases of the Leiden Longevity 
Study (LLS) was compared with that 
of 98 population controls provided by 
the BBMRI-NL biobanking initiative65 in 
Chapter 4. The analysis of whole genome 
sequencing data in the current study, but 
also in general for other studies, is heavily 
underdetermined and the objective was 
to investigate strategies for including 
prior knowledge to appropriately deal 
with this statistical issue. In this chapter 
prediction tools, similarly as discussed in 




prior knowledge to limit the initial 
analysis to those variants with the highest 
prior probability of disrupting a gene’s 
functioning. Moreover, variant frequencies 
from a large-scale sequencing project, 
the Exome Sequencing Project66 were 
incorporated to assess the significance 
of the joint presence, or burden, of these 
disruptive variants in long-lived cases.
Long-lived families are characterized 
by an attenuated thyroid function14,67, 
suggesting a shared genetic basis for 
attenuation of the thyroid function and 
the longevity phenotype. In Chapter 5 
we set out to elucidate this pleiotropic 
genetic mechanism by investigating the 
239 nonagenarian sibships from the LLS 
displaying the most profound family 
history of excess survival (FH(+)), a trait 
previously associated with attenuation 
of the thyroid function67. For the analysis, 
we pursued a variation on the two-step 
genomic convergence approach (Figure 
2B). First, genome-wide linkage analyses 
for familial longevity in the whole LLS (415 
sibships) identified suggestive linkage 
at chr13q34, that was highly specific to 
the FH(+) subset and almost absent in 
the remaining 176 sibships without such 
a marked family history (FH(-)). For the 
second fine-mapping step of the variants 
under the linkage peak, we investigated 
which of the thyroid parameters was 
most characteristic to the FH(+) subset. 
The FH(+) subset exhibited a significantly 
lower serum free triiodothyronine 
level, the active thyroid hormone itself 
(fT3), as compared to the FH(-)) subset. 
Therefore we hypothesized that variants 
at chr13q34 might explain the observed 
pleiotropic interaction between longevity 
and an attenuated thyroid signalling, by 
lowering serum fT3 levels. Hence, the 
second fine-mapping step was performed 
by Quantitative Trait Loci (QTL) analyses, 
correlating free triiodothyronine (fT3) 
serum levels to NGS variants, to probe 
for causal variants underlying both the 
attenuated fT3 signalling as human 
longevity in this locus.
Finally, during this thesis we have 
encountered several bioinformatics tasks 
that are routinely performed during 
projects for genomic data integration. To 
generalize and standardize the execution 
of such highly similar though demanding 
tasks over different types of omics data 
sets, we implemented the R package 
SATORi (Standardized Access To Omics in 
R). In Chapter 6 we exemplify its use with 
publically available omics data sets and 
comment on some of the considerations 
made in the design of this package. 
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Multiple studies have illustrated that gene expression profiling of primary breast cancers 
throughout the final stages of tumor development can provide valuable markers for risk 
prediction of metastasis and disease sub typing. However, the identification of a biologically 
interpretable and universally shared set of markers proved to be difficult. Here, we propose 
a method for de novo grouping of genes by dissecting the protein-protein interaction 
network into disjoint sub networks using pair wise gene expression correlation measures. 
We show that the obtained sub networks are functionally coherent and are consistently 
identified when applied on a compendium composed of six different breast cancer studies. 
Application of the proposed method using different integration approaches underlines 
the robustness of the identified sub network related to cell cycle and identifies putative 
new sub network markers for metastasis related to cell-cell adhesion, the proteasome 
complex and JUN-FOS signaling. Although gene selection with the proposed method does 
not directly improve upon previously reported cross study classification performances, it 
shows great promises for applications in data integration and result interpretation.




A crucial step in breast cancer diagnosis 
and subsequent therapy is the assessment 
of the tumor’s capacity to metastasize. 
An erroneous diagnosis can either lead to 
overtreatment or could potentially allow 
already spread tumors to develop in distant 
tissues. Since the first leads to a significant 
amount of unnecessary burden for the 
patient, while the latter is the predominant 
cause of death in breast cancer patients1, a 
lot of effort has been invested to improve 
personalized risk profile predictions 
by employing gene expression assays. 
However, as whole genome assays 
are delivering an increasing list of 
transcriptomic disease markers, the low 
mutual overlap between different studies 
becomes apparent. More importantly, 
obtained sets of prognostic markers 
from one study show a significant drop in 
prediction performance when applied to 
another study2. Current methods for gene 
set grouping may be less successful when 
performed on a single gene basis, due to the 
underlying heterogeneity of the disease 
as well as the fact that due to secondary 
effects many genes seem to correlate with 
the phenotype2. Consequently, resulting 
gene sets purely selected on single gene 
ranking are often uninformative from a 
biological point of view.
In response, several types of analyses 
were developed, which incorporated 
prior biological knowledge to ensure the 
biological interpretability of the selected 
gene set3-5. Genes can for instance be 
grouped on similar function, localization 
or pathway membership. However, as 
many genes are still not assigned to 
relevant groupings and moreover, all 
relevant groupings themselves might still 
not be known, the effectiveness of such an 
approach might be severely compromised6. 
To deal with the low coverage of 
predefined functional groupings, several 
methods have been developed to create 
groupings de novo, by, for instance, 
exploiting data on physical interactions 
between proteins. Over the last few 
years, this type of data has consistently 
been gathered and integrated with other 
types of interactions7, like lethal-lethal8, 
co-citations, or cellular co-localization 
interactions to produce large interaction 
networks. These so called Protein-Protein 
Interaction (PPI) networks contain 
modules that can be linked to cellular 
functions9. The use of these networks for 
the simultaneous task of relevant gene set 
discovery and prediction optimization was 
popularized by the work of Chuang et al.6. 
In this method, sub networks are seeded 
once at every node in the network and 
are iteratively grown by greedily adding 
the best neighbor, until a certain gene set 
summary statistic no longer improves. 
Resulting sub networks have been used 
as input for classification showing an 
improvement in cross study classification 
compared to single gene based signatures 
as well as providing hypothetical biological 
mechanisms underlying the studied 
phenotype6.
Although this is clearly an improvement 
over previously published methods, we fear 
that the capacity to generalize over studies 
is compromised by the greedy aspect with 
which the seeded sub networks are grown. 
Given the fact that many genes seem to 




they are most probably co-expressed due 
to downstream effects, a considerable 
part of the data may be viewed as intrinsic 
biological replicates independently 
assessing the state of a select number of 
ongoing cellular processes. In view of this, 
we would rather like to use all informative 
genes involved in such a process to robustly 
characterize the cell’s transcriptomic state 
instead of using the genes from a local 
greedy search only.
A second drawback of greedy network 
approaches becomes apparent with 
the growing amount of protein-protein 
interactions that becomes available. New 
data predominantly interconnects genes 
within existing networks, rather than that 
it connects previously unlinked genes to 
existing networks. This contributes to the 
‘small-world’ phenomenon10, referring to 
a situation where almost every gene in a 
network is only a few connections away 
from any other gene. As a consequence, the 
informative property of localized network 
sub selection is lost to global and thus less 
interpretable sub network solutions. A 
proper biological interpretation is even 
further compromised if overlap between 
identified sub networks is allowed. Under 
these circumstances, numerous highly 
similar and equally likely solutions will be 
produced, biasing the selection towards 
a select set of predictive network hubs, 
thereby basically reducing the algorithm 
to a computationally inefficient global 
ranking method.
Anticipating the previously described 
problems in selecting genes, we here 
propose a non-greedy method for 
dissecting the interaction network in a 
set of disjoint sub networks. We expect 
that by incorporating both pair wise 
gene expression correlation measures, as 
protein-protein interactions functionally 
more coherent sub networks will be 
selected. We hypothesize that building 
such sub networks will not only generalize 
better across datasets in predicting the risk 
of metastasis as they exploit the available 
information maximally, but as well be more 




In this study six publicly available 
microarray data sets of breast cancer 
samples measured on the HG U133A 
platform (Affymetrix) were employed 
to test our hypothesis. Raw expression 
data was downloaded at the NCBI’s ftp 
server11 under the accessions: GSE739012, 
GSE349413, GSE653214, GSE145615, 
GSE203416 and GSE1112117. Data was 
normalized, log2 transformed and 
summarized per probe set using the RMA 
procedure in the Affy package18 of R19,20 at 
default settings. Replicate and duplicate 
samples were removed. See Table 1 for an 
overview of the employed studies.
A recent annotation was downloaded 
from the Affymetrix website21 to map 
all “_at”, “_s_at” and “_x_at” probe sets 
to Ensembl Transcript IDs. Mappings 
to Ensembl gene IDs and protein IDs 
obtained from the Ensembl site22 and 
protein-protein interactions obtained 
from STRING23 were used to map probe 
sets to the protein-protein interaction 
network. Probe sets missing annotations 
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to genes, transcripts or proteins, as well 
as probe sets mapping to multiple genes 
or probe sets not associated with any 
interaction data were excluded for further 
analysis. When multiple probe sets were 
annotated to the same gene, “_at” probes 
were preferred over “_s_at” probes and 
“_s_at” probes over “_x_at” probes. When 
this did not enforce a decision the probe 
set with the highest standard deviation 
was selected. Preprocessing resulted in a 
mapping of 9,290 probe sets representing 
9,290 unique genes to a network of 169,566 
undirected interactions.
“POOR” and “GOOD” prognosis of 
samples was assessed using metadata 
obtained from the NCBI’s ftp server11 as 
well. “POOR” refers to the occurrence of 
a distant metastatic event or a relapse 
within five years after surgery. Subjects 
were selected for the “GOOD” prognosis 
subgroup when an event free survival of 
at least five years was reported. Whereas 
some studies contained information on 
distant metastatic events, others reported 
relapses of breast cancer. When both were 
available, the reports on distant metastatic 
events were used.
3.2  Methods
3.2.1  Proposed method for dissecting 
the protein-protein interaction network 
in disjoint co-regulated sub networks: 
Sub networks are created through 
evidence-based filtering of edges between 
genes using two types of evidence: 
physical interaction data and expression 
correlations between any pair of genes. 
Let Eij be the gene expression matrix with 
probe set i and subject j, where i = 1 to M 
and j = 1 to N. An M × M correlation matrix C 
is computed, where Cpq is defined to be the 
correlation between gene p and gene q over 
all N samples. Threshold Tcor is applied on 
C to obtain a binary matrix CT, where CTpq = 
1 indicates sufficient and CTpq = 0 indicates 
insufficient correlation between genes p 
and q.
Based on a distance matrix equal to 
1-abs(C), the genes are hierarchically 
clustered (average linkage). The 
clustering dendogram is thresholded at 
1-Tcor, creating a grouping matrix G with 
dimensions M × M, where Gpg = 1 indicates 
co-membership of a gene cluster, and Gpg 
Study Accession # # Rep/Dup Missing “POOR” “GOOD”
Desmedt GSE7390 198 1741 24 31 119
Miller GSE3494 251 2322 37 37 158
Loi GSE6532 327 1863 47 32 107
Pawitan GSE1456 159 156 6 35 115
Wang GSE2034 286 286 11 95 180
Schmidt GSE11121 199 199 19 27 153
Table 1: Overview of studies. Statistics on the six studies employed. Accession, #, # Rep/Dup, Missing, “POOR” 
and “GOOD” refer to the accession code and the number of samples available at GEO, the number of samples after 
removal of replicates and duplicate samples, the number of samples with incomplete metadata or prematurely 
ended censoring, the number of “POOR” prognosis samples and the number of “GOOD” samples respectively. 1) 
Replicates (Desmedt/Loi) were removed from Desmedt. 2) Replicates (Desmedt/Miller) were removed from Miller. 




= 0 indicates an assignment to different 
clusters of gene p and q. 
Let matrix P contain the protein-
protein interactions, with Ppq ranging 
from 1 to 999 indicating the confidence 
level associated in case an interaction is 
reported and Ppq = 0 if no interactions 
are known. Threshold Tppi is applied to P 
to obtain a binary matrix PT, where PT = 1 
indicates a presence and PT = 0 indicates 
an absence of known interactions with 
a sufficient confidence level. The binary 
correlation matrix CT
 
is overlayed with the 
grouping matrix G and the binary protein-
protein interaction matrix PT
 
to yield sub 
network matrix S:
                          (1)
where Spq = 1 indicates an absolute 
correlation equal to or exceeding Tcor 
between genes p and q, they are assigned to 
the same cluster and a physical interaction 
with a confidence level exceeding Tppi 
between the proteins of these genes has 
been reported. Spq = 0 indicates that at 
least one of these conditions is not met.
Correlations between the breast cancer 
outcome status and gene-expression data 
per sub network were evaluated using the 
global test as summary statistic5. This test 
uses ridge regression to model the relation 
between breast cancer outcome (response 
variable) and a set of gene expressions 
(input variables), while correcting for the 
mutual correlation structure between the 
input variables. Obtained sub networks 
were filtered on significance by applying 
threshold Ts. Genes within significant 
sub networks rendered the gene sets 
used to determine cross study prediction 
performances and similarities in feature 
selection.
Since the thresholded gene expression 
(GE) network (CT) is overlaid with the 
thresholded PPI network (PT), both 
thresholds, Tppi and Tcor are crucial 
in determining the connectivity of 
the resulting network. To balance the 
influence of both sources of information, 
Tppi and Tcor are chosen such that roughly 
equal amounts of interactions are obtained 
for the thresholded GE and PPI networks. 
As the overlay network rapidly becomes 
sparser at PPI quality scores exceeding 500 
(‘medium confidence score’ in STRING), 
Tppi was set to 500 and consequently Tcor 
was set to 0.6.
3.2.2  Competing methods for gene 
selection: Forward filters were trained 
as described by van Vliet et al.24. In short, 
a double cross fold loop procedure25 was 
employed splitting the data in a validation 
and a training set (5 folds). The latter is 
split in an inner training set and an inner 
test set (10 folds). The additional cross fold 
setting within the training set implements 
a strict separation between data used 
for optimizing the predictor and its 
evaluation. The optimal number of genes is 
determined within the inner set by training 
and evaluating a classifier for up to 200 
top ranking genes. Gene ranking was done 
using absolute Welch’s t-statistic. Once 
the optimal signature size is determined 
a classifier is trained on the ranked outer 
training set, which in turn is evaluated in 
the left out validation set. This procedure is 
repeated 20 times, thus producing 20 × 10 × 
5 = 1000 unbiased estimates of the optimal 
signature size. A final predictive gene set 
𝑺𝑺!" = 𝑮𝑮!"𝑪𝑪!"!𝑷𝑷!"!   ∀  𝑝𝑝𝑝𝑝	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was produced by thresholding the ranked 
gene list learned on the whole study with 
the mean over all optimal signature sizes.
Greedy network signatures were 
obtained by re-implementing the work by 
Chuang et al.6 in R20 using identical settings 
for all parameters, with the exception that 
sub network performances were evaluated 
using a Welch’s t-statistic instead of the 
Mutual Information. Gene sets were 
obtained by enlisting all unique genes 
within significant sub networks.
3.2.3  Measures of gene set similarity: The 
Jaccard index26 and odds ratio27 were used 
to assess the similarity in gene selection 
between two different studies. The Jaccard 
index is used to assess the overlap in gene 
selection and equals the probability for 
a gene being implicated by both studies, 
given that it was implicated by at least one 
study. The odds ratio is used to indicate 
the consistency in gene selection and is 
a relative measure of risk representing 
the increase in likelihood for a gene to be 
selected, when also selected in another 
study, compared to a gene being selected, 
when not selected in another.
3.2.4  Evaluation of Cross Study 
Prediction Performances: All prediction 
performances were determined by 
employing a Nearest Mean Classifier 
using the cosine-correlation as a distance 
measure and the Area Under the Curve 
(AUC) of the Receiver Operator Curve 
(ROC) as an evaluation measure. Cross 
study evaluation of the prediction 
performance was done using two different 
settings. In the first setting, denoted as 
“passing GeneSet”, a classifier was trained 
in a five cross fold setting on the gene 
set indicated by the first study while 
employing data of the second study. This 
procedure was repeated 100 times and 
the mean classification performance 
over 100 × 5 folds was reported as the 
final performance. In the second setting, 
denoted as “passing Classifier”, a classifier 
was trained on data of the first study and 
was evaluated using data of a second study. 
Prediction performances of integration 
approaches were determined by using five 
studies as input while evaluating on the 
sixth. In the “early” integration approach, 
data integration occurs at the beginning 
as five studies are jointly analyzed to 
select the genes. The “late” integration 
approach creates a consensus gene set by 
intersecting the results of selected genes 
per study.
3.2.5  Sub network visualization: Sub 
networks were visualized using the 
RCytoscape28 package in R20 to connect 
to Cytoscape version 2.8.129. Nodes were 
colored according to the sign and magnitude 
of respectively the calculated Welch’s t-test 
statistic and the accompanying p-value 
(green: higher expressed in “POOR” 
outcome compared to “GOOD” and red vice 
versa).
4. Results
4.1 Data is dissected in functionally 
coherent sub networks
Using the proposed methodology, disjoint 
sub networks were created for six well 
studied publically available breast cancer 




Ts = 0.05. Resulting sub networks were 
visualized using Cytoscape29 (Figure 1). 
Obtained sub networks varied in sizes 
ranging from 2 up to 192 genes and were 
either enriched (e.g. Figure 1: B) or depleted 
(e.g. Figure 1: A) of predictive markers. 
Furthermore, genes within resulting sub 
networks showed a preference to be either 
jointly down or up-regulated, leading to 
the observation that hardly any significant 
sub network (sub networks with a red 
bounding box in Figure 1) contained 
oppositely correlating gene expressions 
with respect to the studied phenotype.
In order to assess whether application of 
the method led to a biologically meaningful 
dissection of the data, DAVID30 was used 
to test for enrichments in functional gene 
annotations using GO FAT categories. 
GeneRIF descriptions were inspected 
for common denominators in case the 
enrichment analysis returned a-specific or 
no functional annotations. Sub networks 
that showed significant associations with 
respect to the studied phenotype often 
also showed significant GO enrichments 
for hallmark processes of breast cancer. 
For example, for the Desmedt study in 
Figure 1: B is enriched for cell cycle phase; I 
for response to estrogen stimulus; and J for 
DNA replication. When not related to breast 
cancer, sub networks could be attributed to 
processes in lymphocytes or fat tissue. Sub 
networks enriched for the terms cell cycle 
phase (GO:0022403), leukocyte activation 
(GO:0045321) and proteinaceous 
extracellular matrix (GO:0005578) 
were seen in all six studies (Figure 1 sub 
networks A, B and C respectively).
4.2  Eight sub networks are 
consistently identified
To get a more thorough view whether 
the observed dissection in functionally 
Figure 1:  An overview of sub networks identified in the Desmedt study. Disjoint sub networks of varying 
sizes were obtained from the Desmedt study of which the largest are depicted here. Genes are colored according to 
the p-value of the Welch’s-t-test on the expression between “POOR” and “GOOD” outcome subjects (green is higher 
expressed in “POOR”). A red bounding box around a sub network indicates a significant sub network score obtained 
with the global test on the gene set indicated by the sub network.
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coherent sub networks was consistent 
between studies, we extended our analyses 
beyond overlaps in Gene Ontology terms by 
employing pair wise similarity. For this 
analysis we calculated Jaccard indices26 
between sub networks extracted from 
the six studies and clustered the obtained 
similarity matrix. The analysis was limited 
to sub networks with a minimal size of 7 
genes yielding 9 to 16 sub networks per 
study and a total of 83 sub networks (Figure 
3). Cluster analysis shows groupings 
of six sub networks each derived in a 
different study implicating a high degree 
of consistency of detected sub networks 
between the studies (Figure 2). Besides 
the previously consistently identified 
functionalities: leukocyte activation, 
proteinaceous extracellular matrix and cell 
cycle phase (Figure 2, clusters VII, VI and 
V respectively), five other sub networks 
with a-specific or no GO enrichments 
were consistently identified. Common 
denominators extracted from GeneRIF 
indicated functionalities related to JUN 
/ FOS signaling for cluster I, interferon 
induced proteins including ubiquitins for 
cluster II, Adiponectin / lipid storage for 
cluster III, Chains of immunoglobulin for 









V: Cell Cycle Phase
Figure 2: Pair wise similarities were calculated between sub networks obtained from the six
studies using Jaccard indices. The resulting similarity matrix was hierarchically clustered and
was depicted as a heat map in the upper left corner. The heatmap is symmetric along the
diagonal and each row or column represents a unique sub network identified in one of the
studies. The grouping belonging to cluster V (Cell Cycle Phase) is blown up to the right.
Numbers on the diagonal indicate the number of genes within the identified sub networks.
Extensive similarities are observed between sub networks from the six studies except for
comparisons involving Loi, caused by the low number of genes found in the Loi study. Icons of
sub networks at the bottom represent the sub networks for the different studies that were
clustered together in cluster V, which are all also enriched for Cell Cycle Phase. Note that
whereas for the Loi study two small sub networks were identified, others studies only returned a



















Figure 2:  Overlap between breast cancer st dies. Pair wise similarities were calculated between sub 
networks obtained from the six studies using Jaccard indices. The resulting similarity matrix was hierarchically 
clustered and was depicted as  eat map in the up r left corner. The h atmap is symmetric along the diagonal and 
each row or column represents a unique sub network identified in one of the studies. The grouping belonging to 
cluster V (Cell Cycle Phase) is blown up to the right. Numbers on the diagonal indicate the number of genes within 
the identified sub networks. Extensive si ila ities ar  observed between sub n tworks from th  six studies except 
for comparisons involving Loi, caused by the low number of genes found in the Loi study. Icons of sub networks at 
the bottom repre ent the sub net rks for the different studies that were clustered together in cluster V, which are 
all also enriched for Cell Cycle Phase. Note that whereas for the Loi study two small sub networks were identified, 




Figure 3:  Schematic overview of the construction of a consensus network. Detected sub networks are 
depicted at the top from left to right for the Desmedt, Muller, Loi, Pawitan, Wang and Schmidt study respectively. A 
consensus sub network was constructed with genes present in significant sub networks (α = 0.05) in all six studies 
and is depicted at the bottom. Edges in the consensus sub network are drawn when confidence values of reported 
PPI interactions exceed Tppi.
4.3  A “late” integration approach 
reveals a functionally coherent set of 
consensus genes putatively involved in 
metastasis
A consensus gene set of 29 interconnected 
proteins was retrieved by selecting the 
genes that were part of a significant sub 
network throughout all six studies (“late” 
integration, Figure 3). Closer inspection 
revealed that the majority of these genes 
have already been implicated as potential 
therapeutic targets in the treatment of 
either breast cancer or other types of 
cancer. This consensus gene set appears to 
play a pivotal role in the regulation of the cell 
cycle as not only a considerable enrichment 
for terms involving the cell cycle (p = 2.6 
× 10-16), but as well an enrichment for 
proteins with known activating capacities 
was found (5 out of 29 are protein kinases, 
p = 0.0033). Interestingly, all genes are 
on average higher expressed within the 
“POOR” labeled samples compared to 
the “GOOD” labeled samples, fitting the 
cancer’s hallmark of a shortened cell 
cycle time. Moreover, all these genes are 
connected to each other by at least one 
(predicted) physical interaction exceeding 
Tppi = 500, thereby suggesting a plausible 
molecular mechanism how primary 
breast tumors acquire or maintain their 
metastatic capacities.
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4.4  An “early” integration approach 
reveals new sub network markers
We showed that application of the 
proposed method to six different data 
sets studying an identical phenotype led 
to a highly reproducible dissection of the 
data in at least eight distinct processes. 
Besides these eight broadly picked up 
processes, additional smaller clusters 
are visible along the diagonal in Figure 
2, suggesting that there might be more 
ongoing processes in primary breast 
tumor tissue that are harder to detect. 
By applying the proposed method to the 
data from the six studies concatenated 
(“early integration”), three new putative 
sub network markers for metastasis were 
identified in addition to the eight previously 
established sub network markers (Figure 
4). These three new putative sub network 
markers for metastasis (Figure 4: A to 
C) could be related to: unfolded protein 
binding (GO:0051082), cell-cell adhesion 
(GO:0016337) and proteasome complex 
(GO:0000502). All previously established 
sub network markers now dropped below 
the set significance threshold Ts <= 0.05 
and showed a significant enrichment 
for at least a single GO term. The newly 
established sub networks B (cell-cell 
adhesion) and C (proteasome complex) and 
the previously established sub network 
markers I (JUN & FOS signaling) and V (Cell 
Cycle Phase) remained significant even 
after a Bonferroni correction for multiple 
testing (sub networks with red bounding 
box in Figure 4). All genes identified by 
the “late” integration approach were again 
part of significant sub networks found in 
the “early” approach, predominantly sub 
network V (26 out of 29), except for the gene 
STMN1. We therefore can view cluster V in 
Figure 4 as an extension of the consensus 
sub network in Figure 3, containing 22 
more candidate genes.
4.5  A more consistent gene selection is 
performed compared to other methods
Consistency in gene selection by the 
proposed method was compared to a 
classical gene ranking approach known 
as forward filtering, as described by van 
Vliet et al.24 (Experimental Procedures 
3.2.2) and a greedy network approach, as 
described by Chuang et al.6. Forward filters 
were used to find optimal predicting gene 
sets using either all available probes on 
the array (Table 2: FWD, n = 22,283) or 
all genes mapped to the protein-protein 
interaction network (Table 2: FWDNetw, 
n = 9,290). When starting with a reduced 
set of initial genes (FWDNetw), only a 
few additional genes were required for 
obtaining predictors with very similar 
prediction performances than when 
started with the set of all genes (FWD). Both 
network approaches selected considerably 
more genes as compared to both settings 
in which the forward filter was employed. 
This observation was most extreme for 
the greedy network approach of Chuang et 
al. (Table 2: ChuangNetw) for which from 
11.6% to 23.0% of the genes mapped to 
the PPI network (n = 9,290) were selected 
in hundreds of overlapping sub networks. 
Application of the proposed method 
(Table 2: CoRegNetw) resulted in the 
identification of comprehensible numbers 
of disjoint co-regulated sub networks and 
implicating only 1.4% to 5.5% of the genes 




Figure 4:  Sub network markers identified with an early integration approach. Data of the six studies 
was concatenated prior to applying the procedure for sub network identification. Resulting sub networks marked 
with black roman numerals correspond to the reported eight consistently identified sub networks, also indicated 
in Figure 2. Sub networks A, B and C were newly identified and were enriched for the GO terms: unfolded protein 
binding (GO:0051082), cell-cell adhesion (GO:0016337) and proteasome complex (GO:0000502) respectively. 
Significant sub networks (Ts <= 0.05) showing a functional enrichment for at least one GO category were reported 







FWD FWDNetw ChuangNetw CoRegNetw
# genes [%] # genes [%] # genes [%] # netw. [μ] # genes [%] # netw. [μ]
Des 49 (0.22) 51 (0.55) 1437 (15.5) 356 (14.4) 130 (1.4) 25 (5.2)
Mil 21 (0.09) 28 (0.30) 2137 (23.0) 662 (14.2) 240 (2.6) 35 (6.9)
Loi 59 (0.26) 75 (0.80) 1098 (11.8) 317 (13.0) 515 (5.5) 80 (6.4)
Paw 48 (0.22) 44 (0.47) 1237 (13.3) 293 (13.7) 290 (3.1) 52 (5.8)
Wan 55 (0.25) 60 (0.65) 1004 (10.8) 423 (11.6) 184 (2.0) 38 (4.8)
Sch 65 (0.29) 56 (0.60) 1696 (18.3) 331 (14.8) 172 (1.9) 22 (7.8)
Table 2: Results of selecting predictive genes using different methods on six breast cancer studies. 
Forward filters (following van Vliet et al.24) were used to extract the optimal number of predictive genes (columns 
# genes (%) refer to the number and percentage of selected genes) when initially starting with all genes on the 
array (FWD) or all genes mapped to the PPI network (FWDNetw). The method proposed in this article (CoRegNetw) 
was also compared to the network approach of Chuang et al.6 (ChuangNetw) and for methods the number of sub 
networks (# netw.) and average sub network sizes (μ) were reported also.
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Consistency of selected genes across 
different studies using the four previously 
introduced methods was assessed by 
calculating (1) Jaccard indices indicating 
gene set similarities and (2) odds 
ratios indicating the increase in risk for 
genes of being selected as a result of a 
previous selection in another study. The 
proposed network approach (CoRegNetw) 
considerably outperformed both ranking 
settings (FWD and FWDNetw) for all pair 
wise comparisons between studies for 
both criteria (Table 3). Whereas the mean 
Jaccard index was 2.5% and 2.7% for the 
ranking approaches, respectively, our 
method showed a mean Jaccard index of 
25.9%. Chuang’s greedy network approach 
was outperformed for all odds ratios 
(Table 3, panel C and D below diagonal), 
but not for all Jaccard indices (Table 3, 
panel C and D above diagonal). Although 
pair wise comparisons involving the Loi 
study showed lower similarities for our 
method compared to those observed when 
employing the method proposed by Chuang 
et al., the mean Jaccard index of our method 
still substantially outperformed the means 
calculated on all other methods (21.9% for 
CoRegNetw versus 2.7%, 2.5%, and 16.7% 
for respectively FWD, FWDNetw and 
ChuangNetw).
4.6  Network approaches do 
not outperform classical ranking 
approaches in a cross study prediction 
evaluation
We next were interested whether 
our method for a highly reproducible 
dissection in functionally coherent sub 
networks would improve the robustness 
of cross study prediction performances. 
We evaluated the prediction performances 
in two settings. In both settings a gene 
set is derived from a first study. In the 
first setting, denoted “passing GeneSet”, 
this gene set is than passed to a second 
study, where the actual prediction rule is 
build and evaluated using a proper cross 
validation. In the second setting, this gene 
set is used to train a prediction rule with 
the first study and is evaluated only on the 
second study. This setting is denoted as 
“passing Classifier” (Figure 5 and 6).
In the “passing GeneSet” setting (Figure 
5), network approaches either outperform 
or show comparable classification 
performances as compared to classical 
rankings. Notably, when evaluating on the 
Loi study Chuang’s approach, it shows a 
considerable improvement compared to 
the other methods and when evaluating on 
the Schmidt study our method considerably 
outperforms other methods. Prediction 
performances of the two integration 
approaches “early” and “late” were 
evaluated as well. Whereas the “early” 
integration approach (dark blue diamonds) 
improves or at least not significantly 
worsens the prediction performances upon 
the mean single study approaches (yellow 
diamonds), the “late” integration approach 
shows an adverse effect. Especially for the 
Loi study, the “late” integration approach 
seems to fail.
In the clinically more relevant “passing 
Classifier” setting (Figure 6), variations 
in prediction performances have 
increased, as expected, compared to the 
“passing GeneSet”. Now, classical ranking 





OR\JI Des Mil Loi Paw Wan Sch
Des 0.01 0.00 0.08 0.09 0.05
Mil 9.6 0.00 0.03 0.00 0.02
Loi 1.0 1.0 0.00 0.01 0.00
Paw 37.3 21.1 1.0 0.04 0.05
Wan 44.8 1.0 2.9 16.4 0.02
Sch 17.4 15.4 1.0 17.8 5.5
B: FWDNetw
OR\JI Des Mil Loi Paw Wan Sch
Des 0.04 0.00 0.09 0.09 0.02
Mil 23.0 0.00 0.01 0.00 0.04
Loi 1.0 1.0 0.01 0.01 0.00
Paw 47.4 7.9 2.9 0.03 0.02
Wan 38.5 1.0 2.1 11.8 0.02
Sch 6.9 20.8 1.0 8.1 5.9
C: ChuangNetw
OR\JI Des Mil Loi Paw Wan Sch
Des 0.21 0.16 0.20 0.15 0.19
Mil 3.3 0.16 0.19 0.17 0.22
Loi 3.0 2.6 0.14 0.12 0.15
Paw 3.9 3.2 2.6 0.13 0.18
Wan 3.0 3.1 2.5 2.5 0.14
Sch 3.0 2.9 2.5 3.0 2.4
D: CoRegNetw
OR\JI Des Mil Loi Paw Wan Sch
Des 0.25 0.07 0.25 0.32 0.33
Mil 71.3 0.07 0.42 0.20 0.38
Loi 8.8 4.7 0.08 0.08 0.05
Paw 76.2 123.1 4.7 0.22 0.35
Wan 117.6 32.2 6.9 39.3 0.22
Sch 126.7 139.1 5.6 120.6 44.3
Table 3: Gene set similarities. Gene set similarities calculated between gene sets obtained from significant 
gene lists (FWD and FWDNetw) or significant sub networks (the method of Chuang et al. ChuangNetw and the 
method proposed in this paper CoRegNetw) within each single study. Shown similarity measures are the Jaccard 
index (above diagonal, italic) or odds ratio (below diagonal, not italic) grouped per method (Panels A to D). Pair wise 
comparisons depicted in bold are outperforming all competing methods, the comparisons depicted not in bold are 
outperformed by at least one other method.




Figure 5:  Cross study prediction performances of several methods grouped per evaluation study 
in the “passing GeneSet” setting. Circles indicate results of cross study prediction performances involving 
a single study for training, diamonds show results involving five studies for training. The latter can either be a 
summarization statistic (mean) or be the result of an integration approach (CoRegNetwEarly and CoRegNetwLate).
Figure 6:  Cross study prediction performances of several methods grouped per evaluation study 
in the “passing Classifier” setting. Circles indicate results of cross study prediction performances involving 
a single study for training, diamonds show results involving five studies for training. The latter can either be a 




network approaches. Notably, Chuang’s 
method applied to the Loi study now shows 
the worst overall performance. The “early” 
and “late” integration approaches now 
show a correlated behavior across data 
sets, improving upon mean single study 
performances (yellow diamond) in four 
out of six times and improving upon both 
ranking approaches in three out of six 
evaluations. The integration approaches 
especially seem to deteriorate prediction 
performances for the Loi and Wang Study.
5. Discussion
We proposed a method for de novo grouping 
of genes by dissecting the protein-protein 
interaction network into disjoint sub 
networks using pair wise gene expression 
correlation measures. By selecting sub 
networks significantly correlated with 
phenotypic outcome, we expected that 
this would result in a functionally more 
coherent gene selection as compared to 
competing risk profile predictors. We 
verified this by applying the proposed 
method and two competing methods to 
a breast cancer compendium composed 
of six different studies. Furthermore, 
we investigated whether the expected 
consistency in gene selection would have 
benefits for risk prediction of metastasis.
Experiments on the breast cancer 
compendium have shown that the proposed 
methodology leads to a functionally coherent 
dissection of genes into sub networks. 
Furthermore, similarity analyses showed 
that a considerable amount of these sub 
networks are picked up consistently 
across studies, suggesting that previously 
reported low overlaps in predictive gene 
sets can not be attributed to differences 
in ongoing basal processes picked up by 
the different studies. The observation that 
sub networks were consistently identified 
underlines the weaknesses of previous 
methods that purely rely on pre-defined 
functional groupings for their analyses and 
interpretation.
Quite contrary to classical gene ranking 
approaches, extensive overlap between 
predictive gene sets derived from different 
studies is observed when employing the 
proposed method. A consensus gene set 
that consisted of genes that were part of 
significant sub networks in all six studies 
was predominantly composed of genes 
previously implicated in a wide variety of 
cancers, and was heavily enriched for both 
the GO term “cell cycle phase” as for the 
presence of proteins with known regulatory 
capacities (kinases). This so called “late” 
integration approach improves robustness 
in gene selection but at the cost of power 
to detect potential candidate genes. This 
was clearly illustrated by the fact that the 
Loi study alone was most decisive for the 
gene composition of the consensus gene 
set, due to its relatively small significant 
sub network representing cell cycle phase.
A consistent overlap between studies 
also cleared the way for an “early” 
integration approach where the data of all 
studies is concatenated before detecting 
sub networks. This approach confirmed 
and extended the consensus sub network 
found by the late integration approach 
and identified potential new sub network 
markers involved in JUN & FOS signaling, 
cell-cell adhesion and the proteasome 
complex.
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When comparing consistency in gene 
set selection across studies over different 
methods, the proposed method always 
significantly outperforms classical 
ranking approaches. Chuang’s greedy 
network approach6 is outperformed as 
well except for comparisons involving the 
Loi study. However, on average Chuang’s 
method is outperformed using this metric. 
Moreover when odds ratios for the risk of 
reselection over the risk of no reselection 
were compared, our method substantially 
outperforms Chuang’s method for all pair 
wise comparisons. This suggests that once 
a gene is implicated by our method in one 
study, the chance that it will be implicated 
again in another study is much higher.
Despite the observed consistency in 
selection of gene sets, no improvements 
in classification performance were 
observed when compared to competing 
methods in the clinically most relevant 
evaluation setting (“passing Classifier”). 
Moreover, when no integration approach 
was employed to exploit the presence of 
multiple studies, all network approaches 
were outperformed by the classical gene 
ranking approaches, suggesting that 
the higher interpretability comes at the 
expense of predictive power. In the work 
of Chuang et al.6 an evaluation setting 
similar to the one denoted as “passing 
GeneSet” was used. Indeed we confirmed 
that in such a setting, network approaches 
either outperform or show comparable 
classification performances as compared 
to classical rankings. However, we would 
like to issue a word of caution when 
interpreting the classification results 
while employing the “passing GeneSet” 
setting. The results with the overall 
highest prediction performance in the 
“passing GeneSet” setting were created 
by applying Chuang’s feature selection on 
the Loi study. Meanwhile, these results 
also show the largest discrepancy with 
the setting denoted as “passing Classifier”, 
where it shows the overall lowest 
prediction performance. We hypothesize 
that other studies might be particularly 
uninformative about the Loi study, as this 
study is the only one in which the majority 
is treated with tamoxifen, thereby negating 
or possibly reversing previously observed 
relations between gene expressions and 
outcome.
When considering the “passing 
Classifier” setting, integration approaches 
seem to deteriorate prediction 
performances especially for two studies: 
Loi en Wang. In case of the Loi study, 
integration approaches are expected to 
be even more sensitive for the previously 
described disruptive effects of tamoxifen 
on relations between gene expressions 
and outcome. Due to the larger amounts 
of training data, more specific predictors 
are obtained, which are less capable to 
generalize when underlying processes 
are differing. The drop in prediction 
performance can be explained by the fact 
that the Wang study is the only one with a 
balanced number of “POOR” and “GOOD” 
outcomes. Other studies have a much lower 
incidence of “POOR” outcome class and 
therefore training on these studies will 
focus the classifier mainly on recognizing 
the more heterogeneous subset of “GOOD” 
outcome subjects.
Whereas integration approaches 
showed some adverse effects in the 




correlated prediction performances were 
observed in the “passing Classifier” setting. 
When ignoring the Loi and Wang study, 
“early” integration approaches seem to 
only slightly outperform “late” integration 
approaches. This observation is especially 
relevant when considering integration of 
data measured on different platforms in 
which an “early” integration approach is 
not feasible.
Employing several analytic strategies, 
we consistently found a gene sub network 
involved in an established hallmark 
of cancer, cell cycle phase, which is 
persistent over-expressed in all six 
breast cancer studies in the “POOR” 
labeled samples compared to the “GOOD” 
labeled samples. Moreover, application 
of the proposed method in an “early” 
integration approach revealed new 
putative sub network markers, implicating 
molecular mechanisms involved in cell-
cell adhesion, proteasome complex 
and JUN & FOS signaling to be involved 
in metastasis. Although not directly 
improving previously reported cross study 
classification performances, knowledge-
based decomposition of measured gene 
expression data into co-regulated modules 
seems to result in a consistent and 
biologically relevant feature selection and 
might therefore have a general applicability 
beyond the field of breast cancer.
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The bodily decline that occurs with advancing age strongly impacts on the prospects for future 
health and life expectancy. Despite the profound role of age in disease etiology, knowledge 
about the molecular mechanisms driving the process of aging in humans is limited. Here, we 
used an integrative network-based approach for combining multiple large-scale expression 
studies in blood (2,539 individuals) with protein–protein Interaction (PPI) data for the 
detection of consistently co-expressed PPI modules that may reflect key processes that change 
throughout the course of normative aging. Module detection followed by a meta-analysis on 
chronological age identified fifteen consistently co-expressed PPI modules associated with 
chronological age, including a highly significant module (p = 3.5 × 10-38) enriched for ‘T-cell 
activation’ marking age-associated shifts in lymphocyte blood cell counts (R2 = 0.603; p = 1.9 
× 10-10). Adjusting the analysis in the compendium for the ‘T-cell activation’ module showed 
five consistently co-expressed PPI modules that robustly associated with chronological age 
and included modules enriched for ‘Translational elongation’, ‘Cytolysis’ and ‘DNA metabolic 
process’. In an independent study of 3,535 individuals, four of five modules consistently 
associated with chronological age, underpinning the robustness of the approach. We found 
three of five modules to be significantly enriched with aging-related genes, as defined by 
the GenAge database, and association with prospective survival at high ages for one of the 
modules including ASF1A. The hereby-detected age-associated and consistently co-expressed 
PPI modules therefore may provide a molecular basis for future research into mechanisms 
underlying human aging.




A steadily growing life expectancy of the 
general western population throughout the 
past two centuries1 has imposed the urgency 
for understanding the adverse effects of 
aging for public health and its relation to 
the observed large variation in healthy 
lifespan2. Age-dependent detrimental 
processes strongly attenuate prospects for 
future health, with chronological age being 
the major risk factor for mortality and 
virtually all common diseases in the western 
world3. Aging is a systemic ailment marked 
by a gradual metabolic decline eventually 
leading to a state of senescence on both the 
cellular and organismal level that seems to 
be caused by the accumulation of damage 
over time4. Despite their profound role for 
disease etiology, the existing knowledge 
concerning the molecular mechanisms 
driving biological aging processes in humans 
is limited.
Construction of consistent age-
associated signatures has proven to be 
challenging as a multitude of gene expression 
studies have identified age-associated genes 
so far, though with limited mutual overlap5,6. 
This inconsistency is most likely due to 
variable technical circumstances, small 
study sizes, and low signal-to-noise ratios, 
typically observed when analyzing the aging 
transcriptome. More similarity was observed 
at the pathway level, across tissues and even 
species7,8 suggesting that the analysis of the 
aging transcriptome by functionally grouped 
gene sets is a promising alternative for the 
classical individual-gene analyses.
Rather than employing literature-
based sets of genes sharing similar 
biological functions, so-called network 
approaches are increasingly used, which 
infer functional clusters of genes from the 
expression data itself by exploiting gene 
co-expression patterns hidden within the 
data9. Alternatively, changes in these gene 
co-expression patterns that occur with age 
might be used for inferring a functional 
grouping from the data10. However, co-
expression patterns may contain spurious 
gene–gene correlations11, which makes the 
use of multiple data sources simultaneously 
or the integration with other additional 
information sources on functional 
relationships between genes desirable.
Established modulators of aging 
processes in model organisms were 
reported to spatially cluster within networks 
constructed of protein-protein interaction 
(PPI) data12,13. Hence, PPI networks can 
be exploited for prioritizing new aging-
associated genes14,15 or for refining modules 
of co-expressed genes that are correlated 
during the course of aging16. We previously 
demonstrated that the inference of these so-
called co-expressed PPI modules has a high 
reproducibility across multiple expression 
datasets in breast cancer17, and here we 
extend this algorithm to combine multiple 
gene expression datasets on aging.
Though many algorithms for network 
inference exist18, relatively little attention 
has gone to the problem of network 
inference and subsequent associations with 
a phenotype using multiple heterogeneous 
expression data sources simultaneously. 
Merging the expression data into a single 
set and using this for network inference 
clearly surpasses the differences in 




dataset. Irrespective of the type of network 
inference chosen, we propose to handle 
such heterogeneity by integrating the gene-
gene similarity measures obtained across 
expression datasets using a suitable meta-
analysis setting. Thus, in the approach 
described in this paper, we employ a meta-
analysis for inferring a consistent gene-gene 
network that serves as a basis for identifying 
consistently co-expressed PPI modules, 
which are subsequently analyzed with 
respect to chronological age across datasets 
using again a meta-analysis.
To robustly characterize the changes 
of the blood transcriptome associated 
with chronological age, we have build 
a compendium using three large-scale 
transcriptomic studies19-21 generated in 
blood comprising 2,539 individuals on 
which we applied our integrative network 
approach. For comparison, two types 
of individual-gene meta-analyses were 
performed as well, which in combination 
with an enrichment analysis yielded only 
broad terms for age-associated cellular 
processes. Application of our integrative 
network-based approach, yielded five 
consistently co-expressed PPI modules 
showing robust age associations and 
functional enrichments for ‘Translational 
elongation’, ‘Cytolysis’ and ‘DNA metabolic 
process’, which seem to reflect downstream 
mTOR signaling events or cell-cycle 
checkpoints. Finally, we show that four of 
five modules replicate in an independent 
cohort, and that they are enriched for known 
longevity- and aging-related genes and that 
the expression of one module associates 
with prospective survival at old age.
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518B 454 195 
(43.0%)
51.6 30 70
Table 1: Descriptives of the datasets composing the compendium.
(*) Expression and phenotypic data were obtained from ArrayExpress under accessions: E-TABM-305
(††) Number of individuals with matching phenotypic data per study when obtained.
(A) Data of IFB was measured in two batches. This figure indicates the total number of individuals before 
preprocessing or removal of duplicates across batches.
(B)  A small batch was detected and all samples belonging to it were removed. 
(†)  Statistics computed after preprocessing.




3.1 The largest transcriptome 
compendium for normative aging
To robustly characterize the changes of the 
blood transcriptome throughout the course 
of normative aging in the range of 15-94 years, 
we built a gene expression compendium 
using three large-scale transcriptomic 
studies performed in blood: the San Antonio 
Family Heart Study (SAFHS)19, the Icelandic 
Family Blood (IFB) cohort20 and the Dietary, 
Lifestyle, and Genetic determinants of 
Obesity and Metabolic syndrome (DILGOM) 
study21. Data of IFB were measured in two 
roughly equally sized batches, from this 
point on referred to as IFB_A and IFB_B, 
and was treated as two separate datasets 
in the downstream analysis. Data quality 
was critically reassessed and re-annotated 
yielding a compendium of 9,047 unique 
genes expressed in 2,539 individuals 
divided over four datasets (SAFHS: 1,240, 
IFB_A: 411, IFB_B: 435, DILGOM: 454; Table 
1 & Experimental Procedures).
3.2 Limited overlap of age-associated 
genes between studies within the 
compendium 
The most straightforward method for an 
integrative analysis across datasets is to 
first compute the age-association genes 
per dataset and subsequently inspect the 
overlap of significant results. A linear model 
adjusted for gender yielded between 111 
(1.2%) and 1,103 (12.2%) significantly age-
associated genes per dataset (Bonferroni 
correction, α ≤ 0.05), of which 26 genes 
were significantly associated with age in 
all four datasets (Figure 1 and Table S1, 
Supplemental Materials). These results 
confirmed the high discrepancy between 
lists of age-associated genes previously 
reported in literature, even though now 
observed in equal or similar tissues5,6.
Figure 1:  Significantly age-associated genes in 
studies of the blood compendium. A Venn analysis was 
performed for inspecting the overlap of the significantly 
age-associated genes found within different studies. The 
majority of the consistently detected age-associated 
genes (24 of 26) show a decreased expression with 
advancing age and include the following: ARH, BACH2, 
CCR7, ECRG4, EDAR, EPHA1, EPHX2, FAM102A, FAM134B, 
FBLN2, FCGBP, FLNB, IL24, LRRN3, NELL2, NMT2, NRCAM, 
OXNAD1, PDE9A, PHGDH, PIK3IP1, SIRPB2, SUSD3, and 
TSGA14. The remaining 2 consistently age-associated 
genes showing increased expressions are ARP10 and 
SYT11. See Table S1 (Supplemental Materials) for more 
details.
3.3 Rank-based integration of age-
associated genes improves consistency 
between studies
As repeatedly applied cutoffs across 
multiple heterogeneous datasets may 
lead to high false exclusion rates of age-
associated genes, we investigated whether 
age-association rankings were consistently 
high across datasets by applying a rank 
integration approach6,22. From the 9,047 
genes present in the compendium, 247 
consistently showed highly ranked 
differential expressions with age across 




significant after permutation tests (both at 
FDR <= 0.05) (Experimental Procedures). 
Of these 195 genes, 128 (65.6%) showed 
decreased and 67 (34.4%) showed increased 
expression levels with age. The top 25 genes 
with increased and decreased expression 
are displayed in Tables 2 and 3, respectively, 
and include many of the age-associated 
genes previously identified, like LRNN3, 
LEF1, and SYT1123-25. Results for all 9,047 
genes in the compendium are provided in 
Table S2 (Supplemental Materials).
3.4 Functional enrichments of 
individual-gene analysis are not 
informative for normative aging
We next identified enriched functional 
groupings among genes significantly 
associated with normative aging using 
DAVID focusing on GO_FAT terms. Whereas 
the 26 genes from the overlap did not 
yield any significantly enriched terms, 
the 195 significant genes obtained with 
the rank integration approach yielded 
11 significant enriched groupings when 
run at default settings (Tables S3 and S4, 
Supplemental Materials respectively). 
Interestingly, enriched terms include 
‘Glycosylation site: N-linked’ (p = 6.1 × 
10-5, Benjamini corrected), previously linked 
to the inflamm-aging theory26. However, as 
most of the 11 identified terms are rather 
broadly defined, like ‘disulfide bond’ or 
‘signal peptide’, little detailed knowledge is 
gained on potential molecular mechanisms 
underlying normative aging following the 
individual-gene analysis approach.
3.5 A novel integrative network 
approach for detecting consistent co-
expressed PPI modules
To improve robustness against noise and 
increase power, we used a novel integrative 
network-based approach to explore 
functional age-associated groupings of 
genes. The proposed approach detects 
consistently co-expressed PPI modules 
across multiple datasets (for details see 
Experimental Procedures and Data S1, 
Supplemental Materials). Using the four 
transcriptomic datasets mapped onto the 
PPI network, we detected a total of 162 
consistently co-expressed PPI modules 
ranging in size from 2 to 37 genes (see 
Figure S1, Supplemental Materials for a 
complete overview). The following steps 
in our analysis were limited to the subset 
of 27 co-expressed PPI modules counting 
at least five genes. Application of DAVID 
yielded significant functional enrichments 
for 19 of the 27 identified co-expressed PPI 
modules (Table S5, Supplemental Materials), 
suggesting that the applied approach 
grouped genes according to plausible 
biological functions.
3.6 Age-associated co-expressed PPI 
modules point toward T-cell activation
To test whether transcriptional changes 
of the 27 identified modules associate 
with chronological age, an expression 
profile for each module was constructed 
by determining the mean expression of 
the genes within a detected co-expressed 
PPI module per individual. As with the 
individual-gene analysis, we proceeded by 
computing the associations of the module 
expressions with age while adjusting for 
gender for each dataset separately. Only 
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Symbol GeneID p-value1 q-value1 p-value2 q-value2
GPR56 9289 5.3 × 10-09 4.8 × 10-05 1.0 × 10-06 0.0018
HF1 3075 2.3 × 10-08 8.1 × 10-05 1.0 × 10-06 0.0018
SYT11 23208 2.7 × 10-08 8.1 × 10-05 ≤ 5.0 × 10-7 0.0018
ARP10 164668 7.3 × 10-08 1.7 × 10-04 1.0 × 10-06 0.0018
B3GAT1 (CD57) 27087 1.1 × 10-07 2.0 × 10-04 3.0 × 10-06 0.0021
SLC1A7 6512 1.8 × 10-07 2.6 × 10-04 3.2 × 10-05 0.0110
IFNG 3458 5.0 × 10-07 6.4 × 10-04 1.1 × 10-05 0.0065
DSCR1L1 10231 6.1 × 10-07 6.8 × 10-04 2.0 × 10-06 0.0021
ARK5 9891 7.9 × 10-07 7.9 × 10-04 3.0 × 10-06 0.0021
PIG13 81563 9.3 × 10-07 8.8 × 10-04 1.0 × 10-06 0.0018
SPUVE 11098 1.1 × 10-06 8.8 × 10-04 1.2 × 10-05 0.0067
PDGFRB 5159 1.2 × 10-06 8.8 × 10-04 1.5 × 10-06 0.0021
EDG8 53637 1.4 × 10-06 9.4 × 10-04 7.8 × 10-05 0.015
MARLIN1 152789 1.5 × 10-06 9.4 × 10-04 5.0 × 10-06 0.0032
TGFBR3 7049 2.0 × 10-06 0.0012 2.8 × 10-05 0.011
GZMB 3002 2.4 × 10-06 0.0013 5.0 × 10-04 0.050
CX3CR1 1524 2.9 × 10-06 0.0014 2.9 × 10-05 0.011
STYK1 55359 3.3 × 10-06 0.0015 4.8 × 10-05 0.013
ADRB2 154 3.7 × 10-06 0.0016 3.0 × 10-06 0.0021
GAF1 26056 7.1 × 10-06 0.0029 7.2 × 10-05 0.015
CTSL 1514 7.7 × 10-06 0.0030 3.2 × 10-04 0.040
GFI1 2672 1.1 × 10-05 0.0040 3.0 × 10-06 0.0021
TTC38 55020 1.1 × 10-05 0.0040 7.6 × 10-05 0.015
AGPAT4 56895 1.2 × 10-05 0.0041 2.5 × 10-06 0.0021
GZMA 3001 1.4 × 10-05 0.0045 3.3 × 10-04 0.040
Table 2: Top 25 genes according to the gene statistic (Ui) having increased expression with age.
(1) p- and q-values determined using the gamma-distribution of the gene statistic, Ui 
(2) p- and q-values determined using permutation of the gene statistic, Ui 
one module (Figure 2A), enriched for ‘T-cell 
activation’, was significantly associated 
with age in each of the four datasets of 
the compendium. This module A contains 
genes commonly employed as markers for 
assessing the differentiation status of T-cell 
lineages, such as CCR7, CD28, and TNFRSF7 
(CD27). A fixed-effect meta-analysis on the 
expression of the different modules across 
the datasets showed again that the ‘T-cell 
activation’ module was most significantly 
associated with age (Bonferroni corrected 
p = 3.5 × 10-38) (see also Experimental 
Procedures). The consistent age association 
of the ‘T-cell activation’ module, however, 
raises the concern that the identified 
modules reflect age-related changes in the 




Symbol GeneID p-value1 q-value1 p-value2 q-value2
LRRN3 54674 1.3 × 10-12 1.2 × 10-8 ≤ 5.0 × 10-7 3.2 × 10-4
FCGBP 8857 3.2 × 10-10 1.5 × 10-6 ≤ 5.0 × 10-7 3.2 × 10-4
CCR7 1236 1.1 × 10-9 3.2 × 10-6 ≤ 5.0 × 10-7 3.2 × 10-4
NELL2 4753 2.0 × 10-8 4.5 × 10-5 1.0 × 10-6 3.8 × 10-4
NRCAM 4897 3.1 × 10-8 5.6 × 10-5 ≤ 5.0 × 10-7 3.2 × 10-4
IGJ 3512 1.5 × 10-7 2.3 × 10-4 2.6 × 10-4 0.019
LEF1 51176 1.9 × 10-7 2.5 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
FAM134B 54463 2.2 × 10-7 2.5 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
PACAP 51237 2.5 × 10-7 2.5 × 10-4 1.5 × 10-6 4.8 × 10-4
ITM2C 81618 2.8 × 10-7 2.5 × 10-4 3.5 × 10-6 8.1 × 10-4
PIK3IP1 113791 3.0 × 10-7 2.5 × 10-4 1.0 × 10-6 3.8 × 10-4
PDE9A 5152 5.1 × 10-7 3.8 × 10-4 1.0 × 10-6 3.8 × 10-4
BACH2 60468 6.9 × 10-7 4.8 × 10-4 1.0 × 10-6 3.8 × 10-4
FLJ12895 65982 9.5 × 10-7 6.0 × 10-4 1.5 × 10-6 4.8 × 10-4
FAM102A 399665 1.1 × 10-6 6.0 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
FBLN2 2199 1.1 × 10-6 6.0 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
FLNB 2317 1.2 × 10-6 6.0 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
APEG1 10290 1.2 × 10-6 6.0 × 10-4 1.0 × 10-6 3.8 × 10-4
EPHX2 2053 1.3 × 10-6 6.0 × 10-4 1.5 × 10-6 4.8 × 10-4
TNFRSF17 608 1.3 × 10-6 6.1 × 10-4 1.2 × 10-4 0.011
MYC 4609 1.6 × 10-6 6.6 × 10-4 3.5 × 10-6 8.1 × 10-4
NT5E 4907 1.7 × 10-6 6.6 × 10-4 1.0 × 10-6 3.8 × 10-4
TOSO 9214 1.7 × 10-6 6.6 × 10-4 1.0 × 10-6 3.8 × 10-4
ARH 26119 3.2 × 10-6 0.0012 2.0 × 10-6 6.2 × 10-4
OXNAD1 92106 3.3 × 10-6 0.0012 ≤ 5.0 × 10-7 3.2 × 10-4
Table 3: Top 25 genes according to the gene statistic (Ui) having decreased expression with age.
(1) p- and q-values determined using the gamma-distribution of the gene statistic, Ui 
(2) p- and q-values determined using permutation of the gene statistic, Ui 
previously reported27, rather than changes 
in gene expression.
3.7 T-cell activation module expression 
marks blood lymphocyte counts
To investigate the relation between 
the expression of the ‘T-cell activation’ 
module and the proportions of blood 
cell populations, for which we have no 
data in the compendium, we revisited a 
transcriptomic dataset on peripheral blood 
measured in the Leiden Longevity Study 
(LLS)25 (Data S1, Supplemental Materials). 
Using the expression data of 50 middle-
aged and 50, 90-year-old individuals, we 
first confirmed the association with age 
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of the expression of the ‘T-cell activation’ 
module (p = 3.7 × 10-5), and subsequently 
observed a significant correlation between 
the expression of the ‘T-cell activation’ 
module and lymphocyte counts (R2 = 0.603, 
p = 1.9 × 10-10). These findings suggest that 
the previously observed age associations in 
the blood compendium are most probably 
confounded by the age-associated decline 
in lymphocyte counts. We also conclude 
that the expression of the ‘T-cell activation’ 
module could serve as a proxy for the age-
associated decline in lymphocyte counts in 
the compendium.
3.8 Five co-expressed PPI modules 
associate with age independent of T-cell 
activation
Based on these findings, we adapted the 
fixed-effect meta-analysis to reanalyze the 27 
modules in the compendium while adjusting 
for gender as well as the expression of the 
‘T-cell activation’ module. This revealed 
nine modules significantly associated with 
chronological age, of which five also showed 
a significant association without adjusting 
for ‘T-cell activation’ (Figure 2B–F). These 
five modules thus exhibit the most robust 
expression changes with age and include 
(i) a large consistently down-regulated 
ribosomal module (p = 9.4 × 10-19), enriched 
Figure 2: Overview main results of the integrative network-based approach. Panel 1: Overlap of the PPI 
network and cluster analysis of the transcriptomic data reveals 27 modules, 15 are significantly associated with 
age, 9 are significantly associated with age when corrected for the ‘T-cell activation’ module expression, and the 
5 most robust findings are found in the overlap. Panel 2: Legend: Genes are represented by nodes, whose shape 
and color reflect the results of the individual-gene statistic (Ui). The red and green colors denote a correlating or 
anti-correlating relationship of gene expression with age, respectively. The intensity of the coloring indicates the 
significance of the gamma-distributed transformed rank product statistics. Nodes marked by a thick bordering or 
a hexagon shaped bordering represent genes with FDR adjusted p-values ≤ 0.05 for respectively the analytical and 
permutation-based approach. Panel 3: The co-expressed PPI module that is enriched for ‘T-cell activation’. Panel 4: 
B-F: 5 co-expressed PPI modules with expressions robustly associated with age. B, C and D: modules enriched for 
‘Translational elongation’, ‘Cytolysis’, and ‘DNA metabolic process’, respectively. Node’s shape and color reflect the 




for ‘Translational elongation’ (p = 4.5 × 10-
46); (ii) an up-regulated module containing 
among others several granzymes and the 
perforin gene (p = 2.9 × 10-24), enriched for 
‘Cytolysis’ (p = 9.4 × 10-05); and (iii) a down-
regulated module containing the PARP1 
(ADPRT) gene (p = 3.1 × 10-39) enriched for 
‘DNA metabolic process’ (p = 0.0036). The 
two remaining modules were both down-
regulated with advancing age and lacked 
any significant functional enrichments 
(Figure 2E,F; p = 3.9 × 10-11 and p = 2.5 × 10-
18, respectively).
3.9 Replication of co-expressed PPI 
modules as robust markers for aging
We conducted an independent replication 
study of the identified network modules 
as robust markers for chronological age 
using gene expression data from the 
Netherlands Twin Register and Netherlands 
Study of Depression and Anxiety (NTR & 
NESDA) consortium (N = 3535)28 assayed 
on individuals within age range 17-79 
years (Data S1, Supplemental Materials). 
An association analysis between the mean 
expression of a module and chronological 
age, adjusted for sex and the mean 
expression of the ‘T-cell activation’ module, 
yielded significant results for four of the 
five identified modules, all with directions 
corresponding to those found in the 
compendium (Table S6, Supplemental 
Materials). These results emphasize the 
robustness of the findings produced by our 
approach and confirm that the mean module 
expression in whole blood of module B, C, E, 
and F may be considered as robust markers 
of chronological age.
3.10 Co-expressed PPI modules are 
enriched for GenAge longevity and aging 
genes
As a validation of the identified modules, 
we computed whether aging-related genes 
stored by GenAge12, a database providing a 
comprehensive overview of aging-related 
genes in humans and model systems, were 
enriched within modules A–F (Figure 
2) (Data S1, Supplemental Materials). 
Whereas module A was supported by 
human derived annotations only (OR = 
12.1, 95% CI 2.88-39.2, p = 6.95 × 10-4), 
module B was solely based on knowledge 
derived from model organisms (OR = 16.9, 
95% CI 7.26–39.1, p = 2.52 × 10-10) (Table 
S7, Supplemental Materials). Modules D, E, 
and F had annotations balanced over both 
sources, and therefore, the significance 
of the joint enrichment was assessed by 
using a resampling approach (Data S1, 
Supplemental Materials), which yielded 
significant enrichments for modules E (p = 
0.016) and F (p = 0.0029). These findings 
provide additional evidence that the joint 
expression of these modules may play a 
relevant role in human aging.
3.11 Module F associates with 
prospective survival at old age
To investigate whether the identified 
modules could potentially serve as 
biomarkers, we studied the microarray data 
assayed on 50 nonagenarian individuals 
from the Leiden Longevity Study25. A left 
truncated Cox proportional hazard model 
adjusted for sex and cell counts indicates 
that the mean expression of module F 
associates with prospective survival beyond 
the age of 90 years (N = 50, N
death = 45, HR 
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= 0.265, 95% CI 0.12-0.57, p = 0.001). By 
showing that module F associates with 
prospective survival at old age, we illustrate 
its potential biological relevance.
Interestingly, the ASF1A gene is part 
of module F and has previously been 
identified by our group as one of the genes 
that was differentially expressed in blood of 
members of long-lived families as compared 
to similarly aged controls at middle age25. To 
confirm that the expression of the ASF1A gene 
in module F also associates with prospective 
survival at old age, we analyzed the gene 
expression of ASF1A measured with RT-
qPCR in 74 nonagenarians from the Leiden 
Longevity Study (of which 24 overlapped 
with the micro-array experiment) for 
association with prospective survival. 
Because we observe a similar association 
(N
death = 64, HR = 0.54, 95% CI 0.34-0.85, p = 
0.008) (Figure 3), these results indicate that 
modules, of which the expression in blood is 
consistently associated with chronological 
age across various datasets, may associate 
with variation in lifespan, and therefore 
provide valid gene targets for studying 
relevant biological endpoints in human 
aging.
4.  Discussion
Age-associated changes in gene expression 
may provide meaningful leads to pathways 
affected by and involved in aging, 
though are generally difficult to detect 
consistently6. Therefore, we constructed a 
large compendium of human whole blood 
expression studies19-21 comprising 2,539 
individuals on which we performed a novel 

























Figure 3:  Expression of ASF1A associates with 
prospective survival in nonagenarians. High 
expression of ASF1A confers a prospective survival 
benefit at old age.
yielded fifteen consistently age-associated 
co-expressed PPI modules. Because the most 
significant age-associated module appeared 
to correlate with lymphocyte cell counts in 
an independent gene expression dataset, 
the expression of this module, enriched for 
‘T-cell activation’, was subsequently used 
as a proxy for possible confounding shifts 
in the distribution of lymphocyte subsets. 
This enabled the identification of five age-
associated modules (Figure 2 Panel I and 
IV), including three modules enriched for 
‘Translational elongation’, ‘Cytolysis’ and 
‘DNA metabolic process’ (Figure 2B–D). 
Replication in an independent cohort 
confirmed these findings for four of five 
modules (Figure 2B, C, E and F), underpinning 
the robustness of the proposed approach. 
The enrichments against a database for 
aging-related genes (Figure 2B, E and F) 
emphasize the relevance of these biological 
findings for aging research, which is even 




mean expression of module F associates 
with prospective survival at old age.
4.1 Mitochondrion-related aging
Two of the identified modules are down-
regulated with age and seem to be related 
to the mitochondrion, though lacking 
any significant functional enrichment 
(Figure 2E and F). Despite the absence of 
functional enrichments, both modules were 
significantly enriched for aging-related 
genes, as defined by GenAge, implying that 
known age-related single genes can be put 
into a novel biological perspective by our 
network approach.
Module F (Figure 2F) contains several 
mitochondrial factors and enzymes, like, for 
instance, the mitochondrial transcription 
termination factor MTERF, the ACADM 
enzyme used for fatty acid metabolism, or 
the mitochondrial tRNA synthetase IARS2, 
whose homolog was shown to increase 
lifespan upon disruption in worms29. 
This module also includes several genes 
previously associated with age or age-
associated diseases such as the mitotic 
checkpoint protein BUB3, previously 
associated with accelerated aging in mice30, 
and the cell-cycle checkpoint protein APPBP1 
found in increased quantities in the brain 
affected by Alzheimer’s disease31. This broad 
range of gene characteristics composing 
the module could be explained by the fact 
that the functionality of mitochondria is 
not confined to cellular energy metabolism 
alone, but also seems to make up an integral 
part of multiple cell signaling cascades 
including cell-cycle control and cell death32.
Interestingly, module F also includes 
the ASF1A histone chaperone of which we 
previously have shown that its expression 
associates with familial longevity in the 
Leiden Longevity Study25. We revisited the 
RT-qPCR data assayed on 74 nonagenarians 
and now show that the expression of ASF1A 
also associates with prospective survival. 
This result illustrates that modules, of which 
the expression in blood is consistently 
associated with chronological age across 
various datasets, may associate with 
variation in lifespan, and therefore provide 
valid gene targets for studying relevant 
biological endpoints in human aging.
The other mitochondrion-related module 
(Figure 2E) contains the heat shock protein 
HSPCA (HSP90) and the mitochondrial 
receptor TOMM20, which jointly play a 
central role in translocating pre-proteins 
into the mitochondria33. They seem to be 
consistently co-expressed in blood with 
EIF4A2, a eukaryotic translation initiation 
factor and DDX18, an ATP-dependent RNA 
helicase, of which the worm homologs were 
shown to extent lifespan upon disruption29,34. 
To summarize, this module seems to relate 
to aging by influencing protein translation 
and mitochondrial translocation efficiency.
4.2 Age-associated limitation of 
protein synthesis
One of the identified modules predominantly 
consisted of ribosomal proteins and 
translation elongation factors comprising 
part of the ribosomal complex (Figure 2B). 
The module was significantly enriched for 
‘Translational elongation’ and for previous 
findings in model organisms with respect to 
aging and longevity. In addition, the module 
was down-regulated with advancing age 
fitting previous observations of the aging 
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blood transcriptome23-25, which could be 
interpreted as an attempt of the cell to limit 
global protein synthesis in response to 
stress arising from damage accumulating 
throughout lifespan35. Whether caused 
by response to stress or other factors, the 
change in protein translation may be ascribed 
to the mTORC1 complex36. This complex 
modulates cellular growth and metabolisms 
by determining the balance between protein 
synthesis and degradation in response to 
nutrient availability. Inhibition of mTOR 
signaling through the mTORC1 complex not 
only inhibits protein synthesis, but also has 
been shown to positively affect the lifespan 
in various invertebrates and mammals37. 
Moreover, human blood transcriptome 
studies showed that the gene expression 
of mTOR pathway is down-regulated with 
chronological age24,38 and is even associated 
with human familial longevity25. Hence, a 
consistently down-regulated ribosomal 
module with advancing age corresponds 
with the age-associated demise of mTOR 
signaling. Although it is well established 
that mTOR signaling links to both lifespan 
regulation and ‘Translational elongation’, it 
remains to be determined whether down-
regulation of ‘Translational elongation’ is 
causal for human aging.
4.3 WRN-related cell-cycle checkpoint 
on DNA integrity
A module down-regulated with age and 
enriched for ‘DNA metabolic process’ 
identified in the compendium could not be 
replicated in the NTR & NESDA cohort (Figure 
2D). Interestingly, this module contains the 
PARP1 (ADPRT) gene, which directly binds 
to WRN to induce apoptosis upon oxidative 
stress induced DNA damage and is as such 
a prime suspect for Werner syndrome39, a 
premature aging disease. Furthermore, the 
activity of the Parp1 protein in mononuclear 
cells has previously been shown to 
positively correlate with the species-specific 
lifespan across 13 mammalian species40. 
Taken together, findings in the compendium 
suggest that the lowered transcription rate 
of PARP1 negatively affects DNA integrity 
and thus lifespan, though more experiments 
are required to investigate this hypothesis.
4.4 Age-associated shifts in T-cell 
composition
Another identified module is up-regulated 
with age and enriched for ‘Cytolysis’ (Figure 
2C). It contains several genes used to 
dispatch virus-infected cells and may reflect 
the decreased competence for fighting 
infections in an early stage, caused by an 
age-related deterioration of the immune 
system, known as immuno-senescence41. 
We can, however, not rule out that the age-
associated expression of GZMA, GZMB, and 
PRF1 that are part of this module point to an 
age-associated shift in T-cytotoxic cells27.
Though identified co-expressed PPI 
modules may show extensive correlation 
with confounding factors, we should be 
careful to dismiss modules as such only. 
For instance, the ‘T-cell activation’ module 
(Figure. 2A), which is down-regulated with 
age, also contained BNIP3, an inhibitor of 
the mTORC1 complex shown to modulate 
lifespan in worms, flies, and mice37; and 
FOXO1, also displaying an intricate interplay 
with both complexes of mTOR36, and shown 
to extent lifespan in various invertebrates42. 




play a central role in orchestrating T-cell 
maturation and T-cell fate decisions43, 
and could thereby also explain the age-
associated decline in lymphocytes as marked 
by the ‘T-cell activation’ module. Taken 
together, these examples illustrate that what 
is confounding the analysis of the blood 
transcriptome for molecular mechanisms 
associated with aging is subjective to debate 
and might even not be possible to determine 
given the complex interplay between the 
different biological levels on which aging 
acts.
4.5 The proposed network approach 
into perspective
Network analyses have clear advantages 
over individual-gene analyses, as they 
enable the incorporation of useful prior 
knowledge, which can be exploited for 
improving the robustness of the analysis 
and the subsequent interpretation of the 
results. The improved robustness of the 
network approach over the individual-
gene analyses was reflected by the low 
mutual overlap between the individual-gene 
results (Figure 1) as opposed to the high 
concordance between the results obtained 
in the compendium and replication cohort. 
The advantages for the interpretation were 
clearly illustrated by the modest insights 
gained from the two different strategies for 
individual-gene analysis (‘Glycosylation site: 
N-linked’), as opposed to the detailed gene 
modules produced by our approach that can 
serve as a novel basis for further investigation 
into the molecular mechanisms underlying 
normative aging. Moreover, our approach 
is capable of inferring biological coherence 
from the data, without the explicit need of 
predefined functional groupings, as was 
shown by the enrichments of the identified 
modules found for genes within the GenAge 
database.
Though the analysis benefits from 
incorporating protein–protein interaction 
data, the type, and source clearly affect 
the results. To be as inclusive as possible 
for types and sources of PPI data, we have 
chosen to employ data obtained from the 
STRING database, which systematically 
collects and integrates interaction data 
derived from various sources for predicting 
functional relations between gene pairs. This 
choice results in a vast and comprehensive 
source of data. However, STRING data are 
not confined to physical interactions, as is 
the case with for instance IntAct (http://
www.ebi.ac.uk/intact/) and unlike KEGG 
(http://www.genome.jp/kegg/), STRING 
data are not manually curated. For network 
inference, a trade-off exists between the 
sparsity and the quality of the employed 
gene–gene interactions. We made use of 
a threshold on the quality of reported 
interactions that are created by STRING by 
benchmarking the different interaction data 
sources to KEGG. Varying this threshold 
would affect the size and nature of the 
obtained co-expressed PPI modules. As 
the threshold determines the scale of the 
analysis, an interesting observation is that 
the results can be confounded to parts of 
the global network that do not necessarily 
overlap with the predefined known 
biological pathways. The latter is illustrated 
by the fact that some of our modules are not 
enriched for biological pathways and could 
basically be valued as a strong point of our 
data-driven approach.




By applying a network approach to multiple 
blood transcriptomics datasets, we have 
identified five co-expression PPI modules 
that associate with chronological age 
in humans. The confirmation of most of 
our findings in an independent dataset 
underpins the robustness of our approach. 
The modules are significantly enriched 
for aging-related genes as curated by the 
GenAge database. This implies that these 
age-related single genes, in the absence 
of a clear understanding of their joint 
functioning belong to a network that finds 
its basis in protein–protein interactions and 
will serve as novel input for aging research. 
We reinforced the biological relevance of one 
of the modules by showing that it associates 
with prospective survival beyond 90 years 
in humans as was observed also for a single 
known age-related gene in this module 
(ASF1A). These findings collectively warrant 
further investigations into the biological 
function of module F and its potential as a 
biomarker for healthy aging and human 
longevity.
5. Experimental Procedures
5.1 Creating the blood expression 
compendium
Analyses were based on gene expression data 
derived from individuals enrolled in three large 
cohort studies for which details on sample 
inclusion and employed expression protocols are 
provided in depth in the original publications19-21. 
Gene expression and accompanying phenotypic 
data was obtained from either the original authors 
or from the public data repository ArrayExpress. 
Data quality was stringently reexamined per 
dataset for the presence of outlier samples 
or outlier measurements and annotated to a 
common annotation standard (EntrezGeneID). A 
detailed description of the data processing and 
an overview on the resulting sample statistics is 
given in the Data S1 (Supplemental Materials) and 
Table 1, respectively.
5.2 Rank integration approach
A rank integration approach6,22 was used to identify 
genes consistently up- or down-regulated with 
age across multiple heterogeneous datasets. This 
type of meta-analysis integrates individual-gene 
statistics across datasets, by ranking the statistics 
per dataset and assessing the significance of 
the observed combined ranking using a Gamma 
distribution44 or through permutation. Gender 
adjusted linear fits between expression and age 
were used as gene statistics that were obtained by 
fitting the following multivariate linear regression 
model:
                                                                                    (1)
where E
ijk is the gene expression of gene i 
for individual j in the kth dataset, with 1 ≤ i ≤ M, 
1 ≤ j ≤ N and 1 ≤ k ≤ K, where G
jk and Ajk are the 
gender and age of individual j in the kth dataset, 
respectively, and where ε
ijk is the residual error of 
gene i for individual j in the kth dataset. Genes were 
ranked on the regression coefficients between 
age and expression, β
2ik
. The rank position of gene 
i in dataset k is denoted by R
ik
. Ranks across the 
datasets were integrated per gene by computing 
rank product statistics as previously defined by 
Koziol44:
                                                          (2)
The significance of the observed rank 
products was assessed in two ways. Following 
Koziol, rank products RPi were transformed using:
                                                                            (3)
The significance of the U-statistics could be 
assessed by employing the gamma distribution44 
	  















or through permutation as described in the Data 
S1.
5.3 Extracting co-expressed PPI 
modules
Genes were mapped to the protein–protein 
interaction network (STRING v9.0, http://string-
db.org/), which yielded a compendium of about 
81.3% of the initial set of genes (N = 7,353) in 
the compendium. Ranked co-expression matrices 
were computed for each dataset separately 
by computing a correlation matrix composed 
of first-order partial correlations between all 
pairs of genes adjusted for sex and subsequently 
assigned a rank to each of them. A higher positive 
correlation resulted in a higher ranking. The 
ranked co-expression matrices were integrated 
by computing rank products as in the section 
on individual-gene analysis. The resulting gene–
gene rank product matrix together with the PPI 
network matrix was subsequently used as input 
for the method that identifies co-expressed PPI 
sub networks as described in Van den Akker et 
al.17, see also Data S1 (Supplemental Materials). 
In short, a cluster analysis on the gene-gene rank 
product matrix yielded co-expressed modules 
of genes. High confidence co-expressed genes 
were obtained by applying a threshold on the 
gene-gene rank product matrix. We obtained 
co-expressed PPI modules by intersecting 
the co-expressed gene modules with the PPI 
network matrix. Co-expressed PPI modules were 
subsequently visualized using Cytoscape (Data 
S1, Supplemental Materials).
5.4 Fixed-effect meta-analysis on 
module expressions across the blood 
compendium
Gene expression data were summarized per co-
expressed PPI module for each dataset separately 
by taking the mean expression per individual over 
all genes in the module, resulting in a module 
expression for each dataset. Associations with age 
were tested for each co-expressed PPI module, by 
performing a fixed-effect meta-analysis across the 
four datasets using a first-order partial correlation 
between age and the module expression, 
computed with the controlling variable gender to 
adjust for sex differences. Per dataset k, we thus 
computed:
  
                                                                                    (4)
where 
	  
ρakmk  is the correlation between 
age and the expression of the nth module across 
individuals of the kth dataset; 
	  
ρakgk  is the 
correlation between age and gender across 
individuals of the kth dataset and 
	  
ρmkgk  is 
the correlation between expression of the mth 
module and gender of individuals in the kth 
dataset. To correct for multiple controlling 
variables, higher order partial correlations were 
computed by repeatedly computing first order 
partial correlations as described above. The 
function metacor of R package meta was used 
for integrating and testing the meta correlation 
statistic between age and module expression 
across the four datasets using default settings. 
Modules with significant correlations (bonferroni 
corrected p-value ≤ 0.05) were considered age 
dependent.
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Human longevity has an estimated heritability of approximately 25% in the population 
at large, which remains largely unexplained by known common genetic variation. The 
missing heritability in the longevity phenotype might be explained by rare disruptive 
variants that can be readily measured by the current sequencing techniques. Here we 
report the results of a whole genome sequencing study into familial longevity comparing 
the genomes of 218 independent nonagenarians originating from families with a multi-
generational history of extended survival into old age and 98 ethnicity-matched random 
population controls. An exome-wide comparison did not reveal any robust differences 
in the overall prevalence of rare disruptive variants between the genomes of long-lived 
cases and random population controls. In contrast, recurrent rare disruptive variants 
were identified in two key epigenetic genes, e.g. TET2 and DNMT3A, in long-lived cases 
exclusively, which suggests that a reduced functionality in these genes relates to longevity. 
Read depth evidence and Sanger re-sequencing data, however, indicated that the variants 
identified in TET2 and DNMT3A were in general of somatic origin, and should therefore be 
discarded as potential heritable factors underlying familial longevity. Somatic variation in 
these genes is generally regarded as an indicator of age-associated outgrowth of myeloid 
progenitor cells, a pre-malignant phase, that marks the aging hematopoietic stem cell 
compartment and an increased susceptibility to leukemia. Although nonagenarian carriers 
of somatic disruptive variants in TET2 and DNMT3A may exhibit signs of a shift in blood 
cell composition, they did not display a significantly compromised survival during a 10-
year follow up. To conclude we found no robust evidence for the long-lived genome to carry 
either an overall excess or depletion of germ line rare disruptive variants. We do observe 
an increased prevalence of somatic variation in specific loci likely to stimulate clonal 
outgrowth. 




In western societies, life expectancy has 
been steadily growing over the past two 
centuries1, yet striking variations in life 
span are observed among the population 
at large2. Human life span regulation is 
an extraordinary complex outcome and is 
largely determined by chance and factors 
from the environment, though a modest 
contribution of heritable components 
(~25%) is also expected in the general 
population3. The propensity to become 
long-lived nevertheless clearly runs in 
families4-6 and seems to relate to the 
capacity to delay or evade age-associated 
disease. Offspring of nonagenarians, 
centenarians and super centenarians 
display a lower prevalence of 
cardiovascular disease, type II diabetes 
and cancer4-6, as compared to the general 
population, thus suggesting that human 
longevity is caused by genetic factors 
modifying risk of age-associated disease. 
However, compared to the general 
population, the genomes of nonagenarians 
do not show a depletion of common disease 
susceptibility alleles identified by genome-
wide association studies (GWASs)7, nor did 
GWASs for longevity revealed sufficient 
loci to explain the heritability of longevity8. 
Since GWASs predominantly focus on 
analysing common variants (Minor Allele 
Frequency>=1%), we hypothesize that 
the missing heritability of the longevity 
phenotype might be explained by rare 
coding variants with disruptive impact on 
the gene’s functioning.
Rare disruptive variants can modify 
disease risk, like common variants, by 
affecting the expression or structure of 
translated proteins, which may contribute 
to longevity in two ways. First, the genome 
is reported to contain on average about 
100 rare disruptive variants per individual 
that severely limit or totally negate the 
functionality of the associated proteins9. 
Hence a genome-wide depletion of such rare 
disruptive variants might implicate a more 
complete or better functioning proteome, 
improving the capacity to maintain the 
bodily homeostasis. Moreover, such a 
genome-wide depletion of variants might 
also point to an improved fidelity of the 
DNA repair system as compared to the 
general population10,11. Secondly, a targeted 
knockdown of a single gene in model 
organisms can already give rise to a long-
lived species12. Hence, a local enrichment 
of rare disruptive variants in the genomes 
of long-lived individuals might implicate 
that a similar loss of function of the gene 
originating from that particular locus 
promotes longevity in humans. Though 
both genetic mechanisms are plausible, 
little evidence exists to date whether the 
genetic propensity for human longevity 
relates more closely to a fitter proteome or 
the targeted disruption of particular gene 
functions.
The first NGS efforts to study rare 
variants in longevity involve study designs 
with few extreme cases. The genomes of 
super-centenarians and centenarians were 
sequenced in order to describe genetic 
features of exceptional longevity13-17. 
Obviously, these analyses have a very 
limited statistical power for revealing 
evidence in favour of any of the two 
proposed genetic mechanisms for longevity 
mentioned above. However, also these very 




common disease susceptibility alleles as 
identified by genome-wide association 
studies (GWASs), in line with work of 
Beekman et al.7.  Using a more targeted 
approach, 988 candidate longevity genes 
were sequenced in 6 centenarians to 
identify novel non-synonymous SNVs18, 
which were subsequently tested in larger 
case control studies and suggested PMS2 
and GABRR3 as novel candidate longevity 
genes. These initial studies provide some 
first insights into genetic backgrounds that 
are conductive to exceptional longevity.
To investigate potential genetic 
mechanisms for human longevity 
involving rare disruptive variants, whole-
genome sequencing was performed by 
Complete Genomics on DNA derived of 
218 nonagenarian participants of the 
Leiden Longevity Study (LLS). The Leiden 
Longevity Study consists of sib pairs of 
which female members reached at least 91 
years of age and male members 89 years 
of age. First-degree family members of 
these nonagenarian siblings show a 30% 
survival advantage as compared to their 
birth cohort19. Moreover, offspring of these 
nonagenarians exhibit a propensity for 
healthy aging already at middle age, as 
indicated by their significantly lowered 
incidence of hypertension, type II diabetes 
and use of cardiovascular medication, 
as compared to population controls4. We 
therefore hypothesize that LLS families 
show healthy aging and longevity by 
their genetic predisposition. To further 
identify genetic variation that predisposes 
to familial longevity, we compared the 
genomes of these 218 unrelated long-
lived cases with those of 98 younger 
population controls of the Biobanking 
and Biomolecular Resources Research 
Infrastructure of the Netherlands (BBMRI-
NL) consortium20,21.
3. Results
3.1 Study design and variant detection
We explored the human genome for rare 
variants contributing to human longevity 
using whole genome sequencing data of 
218 independent long-lived cases from the 
LLS (median age 93.7, Nmale = 82 (37.6%)) 
and 98 population controls of the BBMRI 
biobanking initiative (median age 57, Nmale= 
39 (39.6%)) (Experimental Procedures 
5.1). DNA sequencing and subsequent 
variant calling was performed by Complete 
Genomics (Complete Genomics Inc., 
Mountain View California) (median read 
depth >30x) on genetic material isolated 
from peripheral blood. Sequencing data 
were subjected to a stringent quality 
control prior to performing the analyses. 
For the following analysis we considered 
Single Nucleotide Variants (SNVs), small 
deletions (DELs) and insertions (INSs) 
called at high quality and with a minimal 
call rate of 95% in both long-lived cases 
and population controls. For a more 
detailed description of variant detection 
and quality control see Experimental 
Procedures 5.2.
3.2 Depletion of coding variation in 
longevity genomes
The genome-wide burden of disruptive 
genetic variants in long-lived cases 
compared to the population controls was 
investigated for all variants in the coding 
sequence (CDS) jointly and for variants 
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Figure 1: Depletion of coding variants in genomes of long-lived individuals. Distributions of 
proportions of variants annotated to the CDS (coding sequence) or sequence upstream of the Transcription Start 
Site (TSS, 0-7.5kb) for each of the three small variant types (SNV, DEL, INS) are displayed for long-lived cases (LLS; 
red) and random population controls (BBMRI; blue) respectively. Test results for differences in these distributions 
are reported in the upper right corner (Wilcoxon Rank-Sum test). Whereas a significant depletion of coding variants 
was observed for all small variant types in long-lived cases (LLS) compared to population controls (BBMRI), no 
such association was observed for the proportion of variants annotated to TSS. 
X1 X1
X1

























































categorized per impact (e.g. missense or 
nonsense) and type (single nucleotide 
variant: SNV, small deletions: DEL or 
insertions: INS). Counts per thus formed 
categories were normalized per individual 
on the totals of variants observed for each 
variant type to negate biases from overall 
differences in variant calling between the 
cohorts. Using this approach, we detect a 
lowered proportion of variants annotated 
to the CDS in nonagenarians cases 
compared to the population controls for all 
types of variants (Wilcoxon Rank-Sum test: 
SNV: p=5.09×10-5, DEL: p=4.15×10-15 and 
INS: p=1.62×10-5; Figure 1, left column). As 
a negative control, we tested for differences 
in proportions of variants annotated up 
































Figure 2: Depletion of disruptive variants in 
genomes of long-lived individuals. A heatmap 
displaying the results of all variant-categories created 
by cross tabulating variant-types (columns: SNV, DEL 
and INS) and variant-impacts (rows: TSS-UPSTREAM 
(Transcription Start Site and 7.5 kb upstream), UTR5 
(UnTranslated Region at 5’)), CDS_DELETE (in frame 
deletion), CDS_FRAMESHIFT (out of frame deletion 
or insertion), CDS_INSERT (in frame insertion), CDS_
MISSENSE (amino acid substitution), CDS_MISSTART 
(start removed), CDS_NONSENSE (stop created), 
CDS_NONSYNONYMOUS (no change to protein), 
DONOR_DISRUPT (2 bp of essential splice donor 
site), DONOR (12bp of splice donor site), INTRON, 
ACCEPTOR_DISRUPT (2 bp of essential splice acceptor 
site), ACCEPTOR (8 bp of splice acceptor site), UTR3 
(UnTranslated Region at 3’). The intensity of each 
cell represents the significance of the Wilcoxon Rank-
Sum test computed on the difference in proportions 
of a particular variant-type annotated to a variant-
category between the long-lived cases and the 
population controls. P-values are displayed in the cells. 
Cells are empty if no or to little data were available 
for testing. Note that the frameshift variants are 
most significantly depleted in the long-lived cases as 
compared to the random population controls.
significant differences (SNV: p=0.157, DEL: 
p=0.575 and INS: p=0.887, Figure 1, right 
column). Since total numbers of variants 
might also reflect the quality of alignment 
and depth of sequencing, we inspected 
the correlation between the proportions 
of variants annotated to the CDS and the 
total numbers of variants discovered in 
cases and controls (Supplemental Figure 
1), but found no significant biases. Hence, 
compared to the general population, long-
lived cases show a depletion of variation in 
the coding part of the genome.
When applying the testing to the 
more fine-grained annotations of the 
coding sequence, as provided by Complete 
Genomics22 we observe that the depletion of 
CDS variants in long-lived cases compared 
to population controls can be explained by 
a few categories in particular. DELs and 
INSs inducing frameshifts, and missense 
and synonymous SNVs were present in 
significantly lower proportions in the long-
lived cases as compared to the population 
controls (Figure 2, Supplemental Table 1). 
In addition, SNVs residing in splice donor 
sites and the 5’ untranslated regions 
(5UTR) displayed a similar depletion. Of 
the depleted variant categories, we expect 
the most disruptive variant categories to 
show the highest depletion in long-lived 
cases. To verify this, counts of frameshift 
DELs and INSs were re-analyzed, while 
normalizing for frame preserving DELs 
and INSs and counts of missense SNVs or 
SNVs residing in splice donor sites or 5UTR 
were normalized on counts of synonymous 
SNVs (Figure 3). Indeed frameshift DELs 
(p = 1.84×10-26) and INSs (p = 2.60×10-09) 
and SNVs residing in splice donor sites 
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(p = 4.51×10-04) displayed an additional 
significant depletion on top of the general 
depletion of coding variation in long-lived 
cases compared to population controls.
High impact variants calls made with 
short-read sequencing platforms are 
associated with an increased false positive 
rate. To investigate the rates of truly 
reported high impact variants in long-lived 
cases and random population controls, 
we randomly selected 15 frameshift 
variants in each of the two cohorts and 
validated these using Sanger sequencing. 
Of the 15 assays for frameshift variants 
only observed in the long-lived cases, 12 
returned good data, which confirmed 
the presence of seven (58.3%) frameshift 
variants (Supplemental Table 2). Whereas 
all of the 15 assays for frameshift variants 
observed in the population controls that 
could be successfully designed, only two 
(13.3%) validated the presence of its 
targeted variant (Supplemental Table 3). 
Thus, the ratio of falsely reported variants 
within the two small samples of high impact 
variants is considerable, and notably, 
highest amongst population controls. DNA 
of long-lived cases and population controls 
was sequenced on the same platform, be 





































































Figure 3: The higher the impact, the more depleted. When normalizing the counts in the more disruptive 
variant categories on those in the less disruptive variant categories of the same variant type, e.g. by normalizing 
counts on frame shifting DELs on frame preserving DELs, we confirm our previous findings of a depletion of the 
most disruptive variants in long-lived cases compared to those population controls. Frameshift DELs (p = 1.84 × 
10-26) and INSs (p = 2.60 × 10-09) and SNVs residing in splice donor sites (p = 4.51 × 10-04) displayed an additional 





2 years), possibly leading to a technical 
bias. From the validation experiment we 
conclude that the previously observed 
difference in prevalence of disruptive 
variants is most likely due to an elevated 
false discovery rate in the controls rather 
than a depletion of rare disruptive variants 
in the long-lived cases.
























Figure 4:  Longer genes are more likely to catch 
frameshift variants. When plotting the length 
of the coding sequence as a function of the number 
of frameshift indels we observe a clear positive 
correlation.
3.3 Rare disruptive variants cluster 
at TET2 and DNMT3A in nonagenarian 
genomes
Moving away from the whole genome 
depletion of variants, we next investigated 
whether genes are preferentially hit by 
disruptive variants as postulated in the 
second proposed genetic mechanism 
for human longevity. To investigate 
which genes are preferentially hit by 
the disruptive frameshift variants, 
irrespective of the study, i.e. in long-lived 
cases and in population controls, we 
collapsed the deletions and insertions to 
gene annotations. This yielded a total of 
2,193 unique deletions and 1,764 unique 
insertions in respectively 1,970 and 1,601 
genes. Assuming a coding transcriptome 
of 18,000 independent transcript clusters, 
we used a resampling approach to assess 
the significance of the joint presence 
of the numbers of frameshift deletions 
and insertions per gene (Experimental 
Procedures 5.3). The 27 genes hit by at 
least four unique frameshift mutations are 
presented in Table 1 and jointly comprise 
3.2% of the total number of frameshift 
variants observed. A strong trend between 
the length of the coding sequence and the 
number of frameshift variants present 
in genes in cases and controls jointly was 
observed (Figure 4), with the largest gene 
present in the genome, TTN, showing the 
most significant enrichment of frameshift 
variants. Hence, few relatively long genes 
accumulate multiple frameshift variants.
Next we investigated whether any of 
the 27 genes with four or more frameshift 
indels was preferentially hit by mutations 
unique to either the long-lived cases or 
the population controls. By again using 
a resampling approach, we assessed the 
significance of the observed number of 
private frameshift deletions and insertions 
present in each of the genes (Experimental 
Procedures 5.4). Interestingly, we note 
that the most significant gene-specific 
accumulations of frameshift variants 
occur in two genes hit in long-lived cases 
only: TET2 and DNMT3A (Table 2). Other 
categories variant types, e.g. nonsense 
SNVs, confirmed the burden of disruptive 
variants in TET2 and DNMT3A present in 
only long-lived cases (Table 3). In total, 
TET2 was hit by six frameshift indels and 
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GeneSymbol EntrezGeneID DEL INS DEL + INS p.perm
TTN 7273 7 (2/5/0) 2 (0/2/0) 9 (2/7/0) <1.00 × 10-6
DNAH14 127602 8 (4/2/2) 0 (0/0/0) 8 (4/2/2) <1.00 × 10-6
FSIP2 401024 1 (1/0/0) 6 (3/2/1) 7 (4/2/1) <1.00 × 10-6
LOC100506072 100506072 3 (2/0/1) 4 (1/2/1) 7 (3/2/2) <1.00 × 10-6
TET2 54790 4 (4/0/0) 2 (2/0/0) 6 (6/0/0) 5.00 × 10-6
SSPO 23145 5 (2/0/3) 1 (1/0/0) 6 (3/0/3) 6.00 × 10-6
VPS13C 54832 3 (0/3/0) 2 (1/1/0) 5 (1/4/0) 1.90 × 10-5
IL3RAY 8218 0 (0/0/0) 4 (3/0/1) 4 (3/0/1) 9.90 × 10-5
SYNE1 23345 0 (0/0/0) 4 (2/2/0) 4 (2/2/0) 9.90 × 10-5
UGGT2 55757 0 (0/0/0) 4 (2/2/0) 4 (2/2/0) 9.90 × 10-5
SLFN12L 100506736 1 (1/0/0) 3 (3/0/0) 4 (4/0/0) 1.27 × 10-4
ZBTB1 22890 1 (1/0/0) 3 (2/1/0) 4 (3/1/0) 1.27 × 10-4
SPATA3E1 286234 1 (1/0/0) 3 (2/1/0) 4 (3/1/0) 1.27 × 10-4
PNPLA7 375775 1 (1/0/0) 3 (2/0/1) 4 (3/0/1) 1.27 × 10-4
HECTD4 283450 1 (1/0/0) 3 (1/2/0) 4 (2/2/0) 1.27 × 10-4
PTCHD3 374308 1 (0/0/1) 3 (2/0/1) 4 (2/0/2) 1.27 × 10-4
POLQ 10721 2 (0/1/1) 2 (0/2/0) 4 (0/3/1) 1.36 × 10-4
NOTCH3 4854 2 (0/2/0) 2 (1/1/0) 4 (1/3/0) 1.36 × 10-4
ADAM8 101 2 (0/1/1) 2 (2/0/0) 4 (2/1/1) 1.36 × 10-4
NIN 51199 2 (0/2/0) 2 (2/0/0) 4 (2/2/0) 1.36 × 10-4
ZNF469 84627 2 (0/2/0) 2 (2/0/0) 4 (2/2/0) 1.36 × 10-4
MUC16 94025 2 (0/1/1) 2 (1/1/0) 4 (1/2/1) 1.36 × 10-4
LMOD2 442721 3 (0/3/0) 1 (0/1/0) 4 (0/4/0) 1.91 × 10-4
PIK3C2G 5288 3 (3/0/0) 1 (0/1/0) 4 (3/1/0) 1.91 × 10-4
TNRC18 84629 3 (2/1/0) 1 (1/0/0) 4 (3/1/0) 1.91 × 10-4
DNMT3A 1788 4 (4/0/0) 0 (0/0/0) 4 (4/0/0) 2.11 × 10-4
ABCA10 10349 4 (1/1/2) 0 (0/0/0) 4 (1/1/2) 2.11 × 10-4
Table 1: The 27 genes accumulating at least 4 frameshift variants. Counts of variants are given for 
DELetions and INSertions separately according to the following format: A (B/C/D) indicate respectively the total 
(A), private in case (B), private in control (C) and shared number of variants (D).
GeneSymbol DELs INSs Totals p_case p_cont
TET2 4 (4/0/0) 2 (2/0/0) 6 (6/0/0) 0.0049 1
DNMT3A 4 (4/0/0) 0 (0/0/0) 4 (4/0/0) 0.019 1
Table 2: Genes with a private burden in long-lived cases. Within the top 27 genes accumulating at least 4 
frameshift variants, TET2 and DNMT3A exhibited a study specific preference. Noteworthy is that both these genes 




Gene Chrom Start End Type Ref Alt Impact LLS BBMRI
TET2 chr4 106155736 106155737 DEL T - FRAMESHIFT 1 0
TET2 chr4 106155765 106155766 DEL G - FRAMESHIFT 1 0
TET2 chr4 106156685 106156686 SNV C A NONSENSE 1 0
TET2 chr4 106156758 106156758 INS - C FRAMESHIFT 1 0
TET2 chr4 106157246 106157246 INS - A FRAMESHIFT 1 0
TET2 chr4 106157781 106157782 DEL G - FRAMESHIFT 1 0
TET2 chr4 106157913 106157914 SNV C T NONSENSE 1 0
TET2 chr4 106158107 106158108 SNV G A NONSENSE 1 0
TET2 chr4 106196212 106196213 SNV C T NONSENSE 1 0
TET2 chr4 106196221 106196222 SNV G T NONSENSE 1 0
TET2 chr4 106197352 106197353 DEL A - FRAMESHIFT 1 0
DNMT3A chr2 25463181 25463182 SNV G A NONSENSE 2 0
DNMT3A chr2 25463296 25463296 INS - A NONSENSE 1 0
DNMT3A chr2 25468153 25468154 DEL G - FRAMESHIFT 1 0
DNMT3A chr2 25468921 25468923 DEL AC - FRAMESHIFT 1 0
DNMT3A chr2 25469921 25469922 SNV G A NONSENSE 1 0
DNMT3A chr2 25469990 25469991 DEL A - FRAMESHIFT 1 0
DNMT3A chr2 25470930 25470931 DEL G - FRAMESHIFT 1 0
Table 3: Frameshift and nonsense mutations identified in TET2 and DNMT3A, exclusively present in 
long-lived cases. 
five nonsense SNVs and DNMT3A by four 
frameshift indels, two nonsense SNVs and 
a single nonsense insertion, all in the 218 
genomes of long-lived cases only. Moreover, 
a look-up on the Exome Variant Server 
(http://evs.gs.washington.edu/EVS) in 
exome sequencing results in ~4,125 U.S. 
participants of European ancestry revealed 
that TET2 and DNMT3A were hit with 
unique frameshift indels or nonsense SNVs 
with a significantly lower frequency (TET2: 
Ndisrupt_EVS=9, OR: 24.2 95% CI: 9.0-67.0, 
p=4.5×10-10; DNMT3A: Ndisrupt_EVS=7, OR: 19.5 
95% CI: 5.8-65.6, p=1.9×10-6, Fisher’s Exact 
tests, Supplemental Table 4).
Unlike the poor validation rates 
observed for frameshift variants sampled 
from the whole genome, frameshift variants 
identified within TET2 and DNMT3A in the 
long-lived were generally confirmed using 
Sanger sequencing (9 out of 10). A closer 
inspection of these Sanger sequencing 
results showed in general a much lower 
signal for the mutant allele as compared 
to the wild-type allele, an observation 
supported by the whole genome sequencing 
results for the frameshifting indels in 
TET2 and DNMT3A (Table 4). This clear 
deviation from the 1:1 ratio (Experimental 
Procedures 5.6), as expected for 
heterozygous germ line variants, suggests 
that the identified variants are present in 
only a part of the measured cells. These 
results support the impression that the 
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Gene Chrom Start End Type # Ref # Alt % Alt psom
TET2 chr4 106155736 106155737 DEL 30 11 26.8% 0.017
TET2 chr4 106155765 106155766 DEL 60 9 13.4% 2.7 × 10-7
TET2 chr4 106156758 106156758 INS 33 10 23.3% 0.0047
TET2 chr4 106157246 106157246 INS 24 9 27.3% 0.034
TET2 chr4 106157781 106157782 DEL 36 13 26.5% 0.0083
TET2 chr4 106197352 106197353 DEL 47 22 31.9% 0.016
DNMT3A chr2 25463296 25463296 INS 47 17 26.6% 0.0028
DNMT3A chr2 25468153 25468154 DEL 34 10 22.7% 0.0035
DNMT3A chr2 25468921 25468923 DEL 30 8 21.1% 0.0039
DNMT3A chr2 25469990 25469991 DEL 34 21 38.2% 0.12
DNMT3A§ chr2 25470930 25470931 DEL 47 4 7.8% 0.0019
Table 4: Number of reads supporting the reference and alternative alleles of frameshift variants 
in TET2 and DNMT3A. All Frameshift variants identified in the long-lived cases could be confirmed by Sanger 
sequencing except the variant marked by §. Since this non-confirmed variant had a relatively low % Alt of 7.84% it 
leaves the possibility that this variant may have gone undetected, as it was not present in a sufficient proportion 
of the sequenced cells.
long-lived cases, as compared to the 
younger population controls, have a higher 
prevalence of somatic frameshifting indels 
in TET2 and DNMT3A.
Somatic mutations in TET2 and 
DNMT3A have previously been associated 
with aging of hematopoietic stem cells 
(HSCs)23, which is characterized by a 
skewing of progenitor cells towards the 
myeloid fate that compromises immune 
function and increases the risk for myeloid 
malignancies24,25. Hence, we investigated 
whether carriership of the identified 
disruptive variants (Table 3) in long-
lived cases was reflected by their blood 
cell composition. Whereas no signs of 
skewing in the blood cell composition was 
observed for the carriers of disruptive 
variants in TET2 (β=1.29, 95% CI: -1.04-
0.78, p=0.78), we observed that carriers 
with disruptive variants in DNMT3A have 
significantly higher granulocyte counts 
than non-carriers (β=1.29, 95% CI: 0.24-
2.43, p=0.016, Experimental Procedures 
5.7). Since this may indicate an underlying 
risk for a compromised immune-capacity 
or hematopoietic malignancies, we 
compared the prospective survival of 
long-lived carriers versus long-lived non-
carriers. A prospective survival analysis 
with a ten years follow-up did not indicate 
a significantly increased risk on mortality 
for the carriers of disruptive variants in 
either TET2 (Ntot=214, Ndeath=190, HR=1.30, 
95% CI 0.68-2.47, p=0.424) or DNMT3A 
(Ntot=214, Ndeath=190, HR=0.37, 95% CI 0.15-
0.91, p=0.031, Experimental Procedures 
5.8). In fact, a modest protective effect 
was observed for DNMT3A mutant carriers 
(Figure 5) and noteworthy, 4 out of the 9 
carriers were still alive at our most recent 





In the current study we analysed the 
genome of 218 independent nonagenarians 
for rare disruptive variants contributing to 
familial longevity. Although our sequencing 
study is the largest amongst the oldest old, 
we found no decisive evidence for either 
an excess or depletion of rare disruptive 
germ line variants to contribute to familial 
longevity. In contrast, we did observe and 
validate recurrent somatic variants in 
TET2 and DNMT3A, exclusively present in 
the genomes of long-lived cases. Hence, 
we conclude that within this limited 
sample size, the characteristics most 
discriminative for the long-lived genome 
are acquired during life, which, to our 
current understanding, seem unlikely 
to constitute a heritable component 
predisposing to familial longevity.
The genomes of long-lived cases 
exhibited a gene-specific burden of rare 
somatic disruptive variants from multiple 
categories in TET2 and DNMT3A. Somatic 
mutations in TET2 and DNMT3A were first 
reported in patients suffering from myeloid 
malignancies26,27, but also appear in 
elderly exhibiting myelodysplasia without 
overt hematopoietic malignancies23. This 
suggests that somatic mutations in TET2 
and DNMT3A in hematopoietic stem cells 
confer enhanced self-renewal and clonal 
expansion leading to an age-related 
myeloid lineage bias. Indeed significantly 
elevated levels of granulocytes were 
observed in carriers of somatic mutations 
in DNMT3A. Surprisingly, neither the 
carriers of somatic disruptive mutations 
in DNMT3A, nor in TET2, did exhibit a 
significantly increased mortality risk over 
10 years time, while similar mutations 
have previously been associated with 
an increased risk of progression to and 
poor outcome of acute myeloid leukaemia 
(AML)27. This either suggests that clonal 
expansion of the myeloid lineage in itself 
may not necessarily contribute to cancer 
risk in the highest ages, or alternatively, 
it may suggest that additional genetic 
factors, absent in long-lived, may be 
required for transforming into AML, in 
which case carriership may accelerate 
disease progression. Since these somatic 
mutations are typically found in elderly 
patients, it is reasonable to assume that 
the genetic burden at these loci should 
in effect be interpreted as markers of 
chronological age, rather than heritable 
factors underlying human longevity.
Assuming that the disruptive 
mutations in TET2 and DNMT3A have been 
acquired during life, in absence of any overt 

























Figure 5:  Prospective survival on carriers 
of disruptive variants in DNMT3A. Kaplan-
Meier curves for the long-lived cases carrying either 
a nonsense SNV or frameshift indel in DNMT3A, as 
compared to long-lived non-carriers. 
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these somatic variants in fact could have 
contributed to the observed extension in 
lifespan. Both TET2 and DNMT3A are factors 
for epigenetic control28,29 and are thought 
to silence hematopoietic stem cell self-
renewal to permit efficient hematopoietic 
differentiation30,31. Therefore, loss of 
functionality in these genes is likely to 
underlie an enhanced self-renewal leading 
to the observed age-related myeloid 
lineage bias. This skewing towards the 
myeloid lineage is assumed to have 
adverse effects on immune functionality 
in normal healthy individuals, but in the 
oldest old the increase of the myeloid 
compartment might be compensative for 
the age-related decrease in naive T-cells, 
known as immuno-senescence32. Hence on 
condition that the enhanced self-renewal, 
instigated by somatic disruptive mutations 
in TET2 and DNMT3A, leads to increased 
levels of competent immune cells, be 
it of the myeloid lineage though, might 
partly compensate for the age-related 
loss of immuno-capacity of the lymphoid 
compartment.
Initial analyses of the whole-genome 
sequencing data lead us to the false 
impression that the long-lived genome 
was characterized by a depletion of coding 
variation, most evidently present amongst 
SNVs residing in splice donor sites or indels 
leading to a frameshift. The prevalence of 
these disruptive variants per individual 
is generally very low, which indicates that 
these types of variants are generally not 
tolerated. This also explains the increased 
false positive rate amongst the variant 
calls of disruptive variants generally 
observed in sequencing studies, including 
the current one. Validation experiments 
indicated that the few disruptive variants 
observed in the long-lived cases and 
population controls combined, were 
almost as likely to be erroneous as to be 
genuine and notably that the false positive 
rate was considerably higher amongst 
population controls. We therefore conclude 
that a genome-wide depletion of germ line 
disruptive variants in the genomes of long-
lived individuals could not be decisively 
shown.
We conclude, that nonagenarian 
members of long-lived families have an 
increased prevalence of somatic disruptive 
variants in TET2 and DNMT3A. Given their 
somatic origin, however, these variants 
seem unlikely to represent the heritable 
component of familial longevity. Previously, 
somatic mutations in these loci have been 
associated with risk on progression to33,34 
and poor prognosis of AML27,35. In the 
long-lived cases of our study, however, 
disruptive somatic variants in TET2 and 
DNMT3A do not seem to compromise the 
10-year survival. Implications of this 
finding are twofold. First, clinical risk 
assessments based on the mutational 
status of TET2 and DNMT3A might not 
be accurate for the oldest old. Secondly, 
elderly carrying the somatic disruptive 
mutations in TET2 and DNMT3A in absence 
of any overt malignancies may provide 
key insights in the factors most decisive 
for oncogenic transformation. Hence, the 
implications of somatic mutations in either 
TET2 or DNMT3A for health in the oldest 
old remain illusive and therefore warrant 







The Leiden Longevity Study4 is a family based 
study consisting of 421 Dutch Caucasian 
nonagenarian sibships and is designed to 
investigate the genetic determinants of human 
longevity. To maximally enrich for genetic signal 
predisposing to human longevity within the 
sample of sequenced genomes, we selected those 
sibships (N=218) displaying the most profound 
family history of excess survival36. For each of 
these sibships, the DNA sequence of the genome 
of the sib with the highest age at censoring was 
determined using Next Generation Sequencing 
(Complete Genomics Inc.). As controls for our 
study, we employed sequencing data assayed 
on 100 individuals of Dutch Caucasian origin 
aged below 65 and collected by the Dutch 
Biobanking and Biomolecular Resources 
Research Infrastructure initiative20,21 (BBMRI). 
Participants of BBMRI are not selected for 
particular characteristics other than that 
they should reflect a random sample of the 
apparently healthy Dutch population. 
5.2 Data preprocessing and quality 
control
Complete Genomics performed whole genome 
sequencing (>30x), read alignment and 
variant calling for both the long-lived cases as 
population controls, though at different time 
points. To minimize the technical variance 
between datasets, raw sequencing data 
created on the LLS samples was reprocessed by 
Complete Genomics to match the version of the 
preprocessing pipeline used for calling variants 
in the genomes of the BBMRI participants. The 
quality of the resulting data was re-checked 
(Supplemental Figures 2-6) per study separately 
and in combination.
One of the population controls was excluded 
beforehand for its distant familial relationship 
with one of the nonagenarian cases. Another 
population control displayed excessive 
proportions of unique variants indicating either 
a potential contamination of the sample before 
sequencing or a mixed ancestry of one of the 
BBMRI participants. Multidimensional scaling 
was performed with 10,000 randomly selected 
common SNVs (MAF ≥ 5%), and did not indicate 
the presence of population substructure. In 
effect, all following comparisons reported in 
this paper have been performed using 218 
nonagenarian cases (median age 93.7, Nmale = 82 
(37.6%)) and 98 population controls (median 
age 57, Nmale = 39 (39.6%)). 
5.4 Assessing the significance of a 
genic burden of frameshift indels
To assess the significance of the presence of 
kj,D unique frameshift deletions and kj,I unique 
frameshift insertions jointly giving rise to 
kj unique frameshift mutations in gene j, 
irrespective whether observed in long-lived 
cases or population controls, the following 
resampling approach was used. Assuming a 
coding transcriptome of 18,000 independent 
transcript clusters, we determined the prior 
probabilities of a gene being hit by a frameshift 
deletion (pD = 2,193/18,000 = 0.122) or a 
frameshift insertion (pI = 1,764/18,000 = 
0.098). To assess the empirical probability 
P(Kj>kj,D+kj,I|pdel,pins) we repeatedly resampled 
(Z=1,000,000) kj,D deletions and kj,I insertions 
with prior probabilities pD, and pI and counted 
the number of times where the resampled 
numbers of frameshift variants ksj equaled or 
exceeded the number of observed frameshift 
variants kj, yielding kSj. The estimated p-value is 
then obtained using: 
  (1)
Computations were performed in R37 and 
repeated with different random seeds to verify 
the stability of the sampling experiments.
5.5 Assessing the significance of a 
case or control specific genic burden of 
frameshift indels
When inspecting the repeatedly hit genes, we 
noted that some genes were hit by frameshift 
mutations exclusively present (private) in either 
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the long-lived cases or the population controls. 
To assess the significance of the preference of 
a gene for being hit by kpj,D private frameshift 
deletions and kpj,I private frameshift insertions 
jointly giving rise to kpj unique and exclusive 
frameshift mutations in gene j, all observed in 
either long-lived cases or population controls, 
the following resampling approach was used. 
First we determined the prior probabilities of a 
frameshift deletion to be exclusively observed in 
long-lived cases (pD,case = 814/2,193 = 0.370) or 
population controls (pD,ctr = 1,122/2,193 = 0.512) 
and a frameshift insertion to be exclusively 
observed in long-lived cases (pI,case = 896/1,764 = 
0.508) or population controls (pI,ctr = 729/1,764 
= 0.413). Note that these probabilities do not 
add up to one as some deletions and insertions 
are observed in both the long-lived cases as the 
population controls and thus are not exclusive 
to any of the two. Furthermore, let kj,D and kj,I 
respectively be the total numbers of unique 
frameshift deletions and unique frameshift 
insertions observed for a particular gene j. 
Then we assess the empirical probability Ppriv(kpj 
>= kpj,D + kpj,I |pD,case,pD,ctr,pI,case,pI,ctr) for a given 
gene j by repeatedly resampling (Z=1,000,000) 
ki,1 deletions and ki,2 insertions with prior 
probabilities pD,case, pD,ctr, pI,case and pI,ctr for 
respectively obtaining private deletions (kp,si,d) 
and insertions (kp,si,i) in cases and controls for 
each sampling and subsequently counted the 
number of times the number of sampled private 
mutations kp,si equaled or exceeded the observed 
number of private mutations kpi (kp,Si). The 
p-value was then estimated by:
 (2)
5.6 Somatic calls
Heterozygotic variant calls with read evidence 
deviating from the expected 1:1 ratio might 
point to the presence of a somatic variant 
that is present in part of the sequenced DNA. 
Alternatively, it might comprise either a 
sequencing error, or an under-sampling of a 
truly heterozygotic variant, which both can be 
modeled by employing Poisson distributions. 
First we model the probability of sequencing 
errors explaining the observed disbalance 
in ratio’s, by assuming an error rate E = 1% of 
reads falsely supporting a variant call. Hence, a 
Poisson model P(λ,K) with mean λ = E × Rtot and 
K = Rvar is used to estimate the probability phom 
that a variant, called with reads Rtot of which 
at least Rvar support the variant, is likely to 
comprise a homozygous reference variant with 
some noisy reads. Similarly, we employ a Poisson 
model with mean λ = 0.5 × Rtot and K = Rvar, to 
estimate the probability phet that the alternative 
allele, supported by Rvar or less reads, is likely 
to be a truly heterozygotic variant of which the 
alternative allele is under-sampled relative to 
the reference. In case both these hypotheses 
are rejected, we may assume that the variant is 
indeed a somatic variant, thus: psom = max(phom, 
phet).
5.7 Associations with granulocyte 
counts
Absolute counts of granulocytes in long-lived 
cases were computed by summing counts of 
neutrophils, eosinophils and basophils derived 
from whole blood cell counts. Differences 
in granulocyte counts between carriers of 
disruptive variants in TET2 or DNMT3A were 
tested using a linear model as implemented in 
the lm package of the statistical language R37: 
G ~ β1 × age + β2 × sex + β3 ×carrier                      (3)
where the covariates age is provided in 
years, sex as either 1 (male) or 2 (female), carrier 
as either 0 or 1 to indicate carriership of a 
disruptive variant.
5.8 Associations with prospective 
survival
Associations with prospective survival were 
performed with the Survival package38 of R37 
using an age at inclusion and sex-adjusted, left-
truncated Cox proportional hazards model to 
adjust for late entry into the dataset according 























p > kj,D + kj,I








and non-carriers of disruptive variants in TET2 
were performed using:
λ(t) ~ λ0(t) × exp(β1 × age + β2 × sex + β3 × carrier)      (4)
where the covariates age designates age at 
inclusion and is provided in years, sex as either 
1 (male) or 2 (female), carrier as either 0 or 1 to 
indicate carriership of a disruptive variant.
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Type Location Impact BBMRI LLS stat.W p
DEL CDS FRAMESHIFT 40 32 19378 5.53E-31
INS CDS FRAMESHIFT 31.5 28 15414.5 3.00E-10
SNV DONOR 358 354 14145 4.05E-06
SNV CDS MISSENSE 7182 7131 13846 2.54E-05
SNV UTR5 2637.5 2625 13510 1.67E-04
SNV CDS SYNONYMOUS 8051 8026 13034 1.75E-03
DEL CDS DELETE 44 45 8894 0.02
SNV UTR3 18785.5 18762.5 12194 0.04
SNV CDS NONSTOP 10 9 11983 0.08
INS UTR3 793 791 9560 0.14
INS CDS INSERT 34 34 9572.5 0.14
SNV CDS NONSENSE 53 52 11766 0.15




104542.5 104644 11746 0.16
SNV ACCEPTOR DISRUPT 20 21 9629 0.16
SNV ACCEPTOR 1733 1730 11734 0.16
INS ACCEPTOR 60 61 9802 0.24
DEL INTRON 35412.5 35148.5 9824 0.25
INS UTR5 74 73 11402 0.34
SNV DONOR DISRUPT 34 35 11261 0.44




3787.5 3767 10260 0.57
INS DONOR 13 13 11015.5 0.66
DEL UTR3 920 912 10363 0.67
INS INTRON 28921.5 28725 10381 0.69
SNV INTRON 1036737 1037931 10449 0.76
DEL ACCEPTOR 100 99 10454 0.76




3199 3183.5 10575 0.89
Supplemental Table 1: Median counts per variant category. Median counts of variants observed per 
variant category in long-lived cases (LLS) and population controls (BBMRI). Comparisons with median counts < 10 
for both long-lived cases (LLS) as population controls (BBMRI) were not considered (NONSTOP SNV). Differences 




AssayID Chrom Start End Type Ref Alt Carrier
LLS_01 chr2 113479780 113479780 INS C FAILED
LLS_02 chr11 120198285 120198287 DEL CT Yes
LLS_03 chr19 16976264 16976264 INS G FAILED
LLS_04 chr17 62038698 62038698 INS C No
LLS_05 chr17 7323945 7323946 SUB C AA Yes
LLS_06 chr1 151372104 151372104 INS C No
LLS_7 chr4 95496888 95496888 INS A No
LLS_08 chr2 27730169 27730169 INS A Yes
LLS_09 chr10 55568865 55568867 DEL TG Yes
LLS_10 chr17 5404003 5404004 DEL A FAILED
LLS_11 chr9 90500990 90500992 DEL CT Yes
LLS_12 chr9 134398412 134398412 INS G Yes
LLS_12 chr9 134398412 134398412 INS G Yes
LLS_13 chr13 113980131 113980135 DEL AAAC Yes
LLS_13 chr13 113980131 113980135 DEL AAAC No
LLS_14 chr7 76828864 76828867 SUB GAC AGGT No
LLS_15 chr17 41174273 41174274 SUB T AA No
Supplemental Table 2: Sanger sequencing experiments on frameshift variants identified within the 
long-lived cases. Of the 15 independent assays designed, 12 returned good data, which confirmed the presence 
of 7 variants.
AssayID Chrom Start End Type Ref Alt Carrier
BBMRI_01 chr3 121208840 121208840 INS T No
BBMRI_02 chr2 11696893 11696897 DEL GAAG Yes
BBMRI_03 chr10 118305625 118305629 SUB TCAC GGACT No
BBMRI_04 chr1 100207825 100207825 INS T No
BBMRI_05 chr22 37964284 37964285 DEL G No
BBMRI_06 chr7 134719554 134719554 INS C No
BBMRI_07 chr9 35738865 35738865 INS A No
BBMRI_08 chr13 97639501 97639501 INS AAGAAGGTCATCT Yes
BBMRI_09 chr18 29122734 29122734 INS G No
BBMRI_10 chr18 55322554 55322555 SUB C AA No
BBMRI_11 chr1 11008274 11008275 DEL C No
BBMRI_12 chr16 46695701 46695702 DEL G No
BBMRI_13 chr9 113457714 113457714 INS A No
BBMRI_14 chr4 122741747 122741748 DEL A No
BBMRI_15 chr17 7369290 7369291 DEL C  No
Supplemental Table 3: Sanger sequencing experiments on frameshift variants identified within the 
population controls. Of the 15 independent assays designed only 2 confirmed the presence of the targeted 
variant.
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Supplemental Figure 2: Singleton Check BBMRI. Depicted are the proportions of singletons (SNVs unique for 
one sample) and overall numbers of identified SNVs per sample within the BBMRI study. The grey area marks the 
3 SD thresholds, indicating that sample GS0000018542-ASM has a disproportionately high number of variants not 
observed in the rest of the study, suggesting either a distinct ancestry or a sample contamination.
Gene Chrom Position Type Ref Alt Impact Allele Counts 
(Alt|Ref)
TET2 chr4 106156278 DEL G FRAMESHIFT 1|8251
TET2 chr4 106156687 SNV C T NONSENSE 1|8599
TET2 chr4 106157504 DEL C FRAMESHIFT 1|8251
TET2 chr4 106157506 SNV C T NONSENSE 1|8597
TET2 chr4 106157653 SNV G T NONSENSE 1|8599
TET2 chr4 106157700 SNV T G NONSENSE 1|8599
TET2 chr4 106157807 DEL C FRAMESHIFT 3|8251
TET2 chr4 106158113 DEL G FRAMESHIFT 1|8253
TET2 chr4 106158157 SNV C T NONSENSE 1|8599
TET2 chr4 106158441 DEL C FRAMESHIFT 21|8233
DNMT3A chr2 25459834 SNV C A NONSENSE 1|8599
DNMT3A chr2 25466830 DEL T FRAMESHIFT 1|8115
DNMT3A chr2 25467468 SNV G C NONSENSE 1|8599
DNMT3A chr2 25468163 SNV C A NONSENSE 1|8599
DNMT3A chr2 25468917 DEL TCGTACA FRAMESHIFT 20|8234
DNMT3A chr2 25469529 DEL C FRAMESHIFT 12|8226
DNMT3A chr2 25471030 DEL GGCT FRAMESHIFT 69|8185
Supplemental Table 4: Frameshift and nonsense variants in TET2 and DNMT3A on Exome Variant 
Server. Variants were called against the reference transcript NM_017628.4 and NM_022552.4 for TET2 and 
DNMT3A respectively.
























Supplemental Figure 3: Autosomal Heterozygozity BBMRI. The proportions of heterozygous SNV genotypes 
and overall numbers of identified SNVs per sample within the BBMRI study. Again the grey area marks the 3 SD 
thresholds, indicating again that sample GS0000018542-ASM exhibits a genomic make up that is very distinct from 
the remaining participants of the BBMRI study. Such an elevated heterozygozity again points to either a distinct 
ancestry or a sample contamination. Due to the consistent appearance of sample GS0000018542-ASM as a major 
outlier, we decided to remove it from further analyses.

























Supplemental Figure 4: Singleton Check LLS. Depicted are the proportions of singletons (SNVs unique for 
one sample) and overall numbers of identified SNVs per sample within the LLS study. The 3 SD deviation of the 
expectation is indicated in grey. Slightly elevated proportions of unique SNVs are observed for GS00456-DNA_C06, 
GS00354-DNA_E03 and GS00398-DNA_CO3. 
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Supplemental Figure 5: Autosomal Heterozygozity LLS. The proportions of heterozygous SNV genotypes 
and overall numbers of identified SNVs per sample within the LLS study. The 3 SD deviation of the expectation 
is indicated in grey. Slightly lowered proportions of heterozygous SNVs are observed for GS00354-DNA_H06, 
GS00354-DNA_F01, GS00456-DNA_E11, GS00456-DNA_C05 and GS00398-DNA_A05. Noteworthy is that none of 
the samples overlapped with the outliers that came forward in the singleton check. Various types of artefacts such 
as mixed ancestry, sample pollution, variation in total read depth or just biological variation might explain slight 
deviations in both the singleton and heterozygozity proportions. However, since outliers where not consistently 
picked up in both tests, we decided not to exclude any samples.






























Supplemental Figure 6: Multidimensional Scaling. MDS was performed with Plink using 10,000 randomly 
selected common SNVs (MAF ≥ 5%) to inspect the data for signs of differences in population substructure. Sample 
space was reduced to four dimensions and all combinations thereof are plotted. Long-lived cases are displayed in 
red, population controls in blue. No apparent substructure was observed.
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The genetic propensity for an attenuated thyroid function and lifespan extension co-
occur in long-lived families and suggest the existence of a pleiotropic genetic mechanism 
underlying human longevity as well as attenuation of the thyroid function. Attenuation 
of the thyroid function is even more profound in long-lived sibships whose parents also 
exhibited an excess survival compared to their respective birth and sex cohorts, and 
thus suggests an enrichment of variants explaining the pleiotropic relation in sibships 
with this marked family history (FH(+)). Linkage analyses among all 415 nonagenarian 
sibships from the Leiden Longevity Study (LLS) identified suggestive linkage at chr13q34 
(LOD=2.96) that was highly specific to the 239 FH(+) sibships (LOD=3.35). The FH(+) subset 
was characterized by significantly lowered levels of serum free triiodothyronine (fT3) and 
its interaction with prospective survival thereof. Subsequent fine mapping of the 1-LOD-
drop 13q34 region by QTL analyses on serum fT3 levels using variants from whole genome 
sequencing data identified a fT3 lowering haplotype tagged by the rs9515460 minor C 
allele, that also associates with prospective survival. Hence, we hereby report chr13q34 as 
a novel locus harbouring variants underlying lifespan regulation as well as an attenuated 
thyroid function.




Attenuation of the thyroid function has 
been implicated in life span extension 
in rodents1-3, as well as in several large 
longitudinal human cohort studies4-6. 
Active thyroid hormone, triiodothyronine 
(T3), and its precursor, thyroxine (T4), 
are produced by the thyroid gland under 
influence of thyroid stimulating hormone 
(TSH), and are both key factors in the 
regulation of the basal metabolic rate and 
cardiac output. A mildly lowered thyroid 
function (subclinical hypothyroidism), 
marked by an increased serum level of 
TSH and a reduced level of free T4, has 
been associated with a lowered risk of 
cardiovascular disease from middle age 
onward6 and a decreased cardiovascular 
mortality in the oldest old4. Interestingly, 
first-degree relatives of long-lived persons 
have, compared to the general population, 
an increased probability of becoming long-
lived themselves7-9, while exhibiting from 
middle age onward an attenuated thyroid 
function10 and an improved cardiovascular 
health7-9. Moreover, attenuation of the 
thyroid function seems to be more profound 
in long-lived families with a family history 
of excess survival, as compared to long-
lived families without such a marked 
family history11. These findings suggest a 
genetic mechanism for human longevity 
in which a life-long survival advantage, 
especially with respect to cardiovascular 
mortality, is promoted by attenuation of 
the thyroid function. 
The relation of the active thyroid 
hormone itself with respect to 
cardiovascular mortality is less clear, 
possibly because serum T3 as a marker 
integrates cues from both the endocrine 
system, through conversion of T4, as 
non-thyroidal routes12. Parle et al. finds 
levels of free T4 (fT4) and free T3 (fT3) to 
inversely correlate with the level of TSH in 
hyperthyroid patients aged over 60 years, 
but observes a significant association 
with cardiovascular mortality only for 
TSH and not for fT4 nor for fT313. In 
contrast, Gussekloo et al. finds significant 
associations with mortality for TSH, 
fT4 and fT3 in patients aged above 85, 
but only reports an inverse correlation 
between levels of TSH and fT4, and not for 
TSH and fT34. More importantly, whereas 
lowered fT4 levels confer a protective 
effect, they find lowered levels of fT3 to 
convey an increased risk on mortality 
and argue that the association of fT3 with 
mortality can be explained by disability 
at baseline. Thus, whereas the findings of 
Parle et al. and Gussekloo et al. agree on the 
protective effect of high serum TSH levels, 
they disagree on the relation between 
thyroid parameters, thereby questioning 
the causality of fT3 in conveying the 
protective effect on life span regulation. 
Since the fT4 precursor also exhibits a very 
modest regulatory capacity, but is present 
in a much higher abundance, it raises the 
possibility that the life-prolonging effects 
of an attenuated thyroid function are 
either totally dependent on or directly 
transmitted trough serum fT4. Genetic 
research on the main parameters of the 
thyroid system e.g. TSH, fT4 and fT3, 
may shed light on the causal mechanism 
relating an attenuated thyroid function to 
life span regulation.
The genetics of thyroid homeostasis, 




have been studied with varying degrees 
of success. The genetic influences on 
the phenotypic variation of the main 
parameters involved in thyroid metabolism 
have been shown to be moderate to strong 
(30-60%)11,14. Furthermore, genome 
wide associations studies (GWASs) have 
identified over 60 genome-wide significant 
loci associated with serum levels of either 
TSH or fT415-19. However, despite this strong 
evidence for genetic variation to influence 
the phenotypic variation in thyroid 
metabolism and the strong indications that 
attenuation of the thyroid system, at least 
with respect to TSH, leads to a prolonged 
life span, little evidence has been reported 
for genetic variations to affect both traits. 
An important exception is the work by 
Atzmon et al. reporting two common 
variants upstream of the TSH receptor gene 
(TSHR) to be enriched amongst the oldest 
old in the Askhenazi Jewish population, as 
compared to middle aged controls, while 
also marking increased TSH serum levels20. 
Neither of these two variants, however, was 
re-identified in any GWAS on either serum 
TSH levels15-19 or human longevity21-24, 
suggesting considerable heterogeneity in 
both traits. In summary, whereas genetic 
approaches have been able to relate 
common variants to phenotypic variation 
in each of TSH, fT4 and life span regulation 
separately, little evidence exists to date 
for genetic factors influencing both the 
thyroid metabolism and human longevity.
Here we study the genomes of members 
of long-lived families of the Leiden 
Longevity Study (LLS) for the presence of 
rare variants that explain the pleiotropic 
interactions between an attenuated thyroid 
function and human life span regulation. 
To this end, we focussed on nonagenarian 
sibships of the Leiden Longevity Study 
(LLS) with parents exhibiting the 
largest excess survival relative to their 
respective sex and birth cohort specific 
life expectancies11. Since long-lived 
sibships with this marked family history 
(FH(+)) exhibit an even more attenuated 
thyroid function, as compared to long-
lived sibships without such a marked 
family history (FH(-))11, we hypothesize 
the FH(+) subset to be enriched for genetic 
determinants underlying familial longevity 
by attenuating the thyroid function. To 
this end, we performed affected sibling 
pair analyses to identify genomic regions 
exhibiting linkage for familial longevity 
in the whole study, and show that one 
of the suggestive signals (chr13q34) is 
explained by significant linkage among the 
FH(+) sibships specifically. Since the FH(+) 
sibships are characterized by significantly 
lower fT3 levels, as compared to FH(-) 
sibships, which moreover seems to affect 
their prospect of survival, we hypothesize 
the 13q34 locus to harbour variants 
underlying human lifespan regulation 
by lowering serum fT3. Subsequent QTL 
analyses for loci associating with serum 
fT3 employing variants from whole 
genome sequencing data residing in 
chr13q34, identified a serum fT3 lowering 
haplotype tagged by the minor C allele of 
rs9515460_T<C. This serum fT3 lowering 
haplotype was also shown to associate with 
prospective survival in a 10 years follow 
up. Hence, we hereby report chr13q34 
as a novel locus harbouring variants 
contributing to lifespan regulation as well 
as an attenuated thyroid function.




3.1 Demographic and thyroid 
characteristics
Demographic and thyroid characteristics 
in all 415 nonagenarians sibships of the 
Leiden Longevity Study (LLS), the 239 
sibships enriched for family history of 
extended survival (FH(+)), the 176 non-
enriched sibships (FH(-)) and the 214 
unrelated nonagenarians from enriched 
families selected for whole genome 
sequencing (SEQ_FH(+)) are given in Table 
1 (Experimental Procedures 1). Previously, 
we showed that a family history of excess 
survival, as indicated by a lower Family 
History Score, significantly associated with 
higher levels of serum TSH and lower levels 
of serum fT4 and serum fT311. Although 
all thyroid parameters show directions of 
correlation consistent with those reported 
earlier, the current dichotomization into 
two subsets of sibships yielded significant 
differences in baseline levels for serum 
TSH (NFH(-)=344, NFH(+)=482 β=1.06, 95% 
CI 1.00-1.12, p=0.039) and serum fT3 
(NFH(-)=348, NFH(+)=492, β=-0.10, 95% 
CI -0.19--0.01, p=0.026), but not for serum 
fT4 (p=0.17, see Experimental Procedures 
2 and 3.1). This suggests that in the current 
setting, we have most power to identify 
genetic determinants underlying lifespan 
regulation and an attenuated thyroid 
function through influencing either serum 
TSH or fT3 levels.
3.2 Prospective survival of study 
subsets and thyroid parameters
We compared the prospective survival 
above 90 years between the FH(-) and 
FH(+) subsets and between the FH(-) and 
the SEQ_FH(+) subsets, but found no 
significant differences, indicating that 
a family history of excess survival has a 
negligible effect on the survival beyond 
age 90 (Experimental Procedures 3.2). 
Except for a suggestive association in the 
FH(-) subset, serum TSH levels did not 
display any significant associations with 
prospective survival beyond 90 years, 
neither in the whole study nor for any of 
the analysed subsets of the LLS (Table 2). 
However, when investigating the influence 
of the thyroid parameters fT4 and fT3 
on prospective survival, we observed 
significant associations for both these 
thyroid parameters in the whole LLS (ALL) 
and some interesting interactions with 
the FH strata (Table 2). The association of 
fT4 with prospective survival in the whole 
study was explained by the protective 
effect of low serum fT4 levels specifically 
observed in the FH(-) subset. In contrast, 
the association of fT3 with prospective 
survival in the whole study was explained 
by the deleterious effect of low serum fT3 
levels most profoundly observed in the 
FH(+) subset, confirming the observation 
of Gussekloo et al. that low serum fT3 
becomes detrimental in the oldest old 
(Figure 1). Joint modelling of fT4 and fT3 
with prospective survival in the whole 
study and its subsets indicates that these 
associations are independent (data not 
shown). From these findings we conclude 
that the FH(-) subset seems to exhibit 
relations between the thyroid parameters 
and prospective survival that are very 
similar to those reported by Gussekloo et al. 
for the oldest old in the general population1. 





In contrast, the FH(+) subset, selected 
for their genetic propensity of excess 
survival, displays relationships between 
thyroid parameters and prospective 
survival that is governed solely by levels of 
serum fT3. Together these findings suggest 
that family history, as reflected by the FHS, 
is not so much a marker of prospective 
survival beyond age 90, but instead it may 
indicate a distinct mechanism through 












931 (37.4% male) 540 (36.7 % male) 391 (38.4% male) 214 (37.9% male)
Age at inclusion 
[years]
92.9 (91.5 – 94.8) 93.1 (91.5 – 95.1) 92.8 (91.4 – 94.7) 93.7 (91.8 – 95.5)
Follow-up time* 
[years]
3.4 (1.5 – 5.8) 3.4 (1.5 – 5.6) 3.4 (1.6 – 6.0) 4.0 (1.8 – 6.1)
Number of deaths 
[N, %]
863 (92.7%) 504 (93.3%) 359 (92.0%) 200 (93.5%)
Age at censoring
[years]
97.1 (94.6 – 99.9) 97.2 (94.8 – 99.9) 97.0 (94.3 – 99.6) 97.9 (95.7 – 100.2)
TSH availability
[N, %]
826 (88.7%) 482 (89.3%) 344 (88.0%) 206 (96.3%)
TSH 
[mU/L]
1.52 (0.98 – 2.42) 1.64 (1.03 – 2.61) 1.38 (0.93 – 2.15) 1.58 (1.04 – 2.43)
FT4 availability
[N, %]
840 (90.2) 493 (91.3%) 347 (88.8%) 209 (97.7%)
FT4
[pmol/L]
15.9 (14.4 – 17.5) 15.8 (14.2 – 17.5) 16.1 (14.6 – 17.6) 15.9 (14.3 – 17.3)
FT3 availability
[N, %]
840 (90.2%) 492 (91.0%) 384 (89.0%) 208 (97.2%)
FT3
[pmol/L]
4.0 (3.7 – 4.4) 4.0 (3.6 – 4.4) 4.1 (3.8 – 4.5) 4.0 (3.7 – 4.3)
  * at February 2014
Table 1: Baseline characteristics of the studied study subsets. Baseline characteristics of the whole 
Leiden Longevity Study (ALL) and the currently defined subsets: FH(+): 239 nonagenarian sibships with a marked 
family history of an extended survival into old age; FH(-): 176 nonagenarian sibships without such a marked family 
history; SEQ_FH(+): 214 independent index cases selected from the 239 sibships exhibiting a marked family history 
(FH(+)) of whom the whole genome has been sequenced previously (Chapter 4 of this thesis).



























































Table 2: Prospective survival on thyroid parameters. Prospective survival on TSH, fT4 and fT3 in a 10 years 
follow up performed in the whole Leiden Longevity Study (ALL) and the currently defined subsets: FH(+): 239 
nonagenarian sibships with a marked family history of an extended survival into old age; FH(-): 176 nonagenarian 
sibships without such a marked family history; SEQ_FH(+): 214 independent index cases selected from the 239 
sibships exhibiting a marked family history (FH(+)) of whom the whole genome has been sequenced previously 
(Chapter 4 of this thesis). HR indicates the hazard ratio for mortality.
3.3 Linkage analysis identifies 13q34 
as a longevity locus
To identify genomic regions harbouring 
variants predisposing to familial longevity 
and an attenuated thyroid function, affected 
sib pair analyses were performed on all 
nonagenarian sibships (ALL) and the FH(+) 
and FH(-) study subsets (Experimental 
Procedures 4). The locus displaying the 
largest disparity in linkage results between 
FH(+) and FH(-) in presence of suggestive 
linkage in the whole study was found at 
13q34 (rs752342 at 120 cM; LODALL=2.96; 
LODFH(+)=3.35; LODFH(-)=0.28, Figure 2 and 
Supplemental Figure 1). The 1-LOD-drop 
interval in the FH(+) subset is 8.36 cM at 
chr13:110,823,340-113,522,717 (GRCh37/
hg19 coordinates) and harbours 16 RefSeq 
genes: (part of) COL4A1, COL4A2, COL4A2-























Low free T3 (234)
High free T3 (258)
Figure 1:  Prospective survival of fT3 in FH(+). 
Kaplan-Meier curves of fT3 in the 239 sibships with 
a marked family history of an extended survival into 
old age (FH(+)): A clear mortality risk is observed for 























Figure 2: Linkage results at chr13q34. Significant linkage for familiar longevity was established at locus 
13q34 in the FH(+) subset. Linkage was computed using the 239 sibships with the most profound family history of 
longevity (FH(+): N=540, LODmax=3.35 at rs752342, red), all 415 sibships (ALL: N=931, LODrs752342=2.96, black dotted), 
and the remaining 176 nonagenarian sibships without a marked family history (FH(-): N=391, LODrs752342=0.28, 
grey).
ANKRD10, ARGHEF7, TEX29, SOX1, SPACA7, 
TUBGCP3, C13orf35 and (part of) ATP11A 
(Supplemental Figure 2 and Supplemental 
Table 1). Linkage at chr13q34 is highly 
specific to the FH(+) subset, which are 
more hypothyroidal as compared to the 
FH(-) subset, e.g. higher TSH and lower 
fT3, and exhibit a thyroid prospective 
survival profile solely depending on serum 
fT3. We therefore hypothesize that this 
locus contributes to a family history of 
excess survival by harbouring variation 
attenuating the thyroid function, through 
constitutively lowering levels of serum fT3.
3.4 Next Generation Sequencing 
identifies an intergenic variant under 
the linkage peak marking lowered 
serum levels of fT3
Thus far we have observed that 
nonagenarians sibships with a marked 
family history of excess survival (FH(+)) 
exhibit a deviating thyroid prospective 
survival profile, that seems to largely 
depend on only levels of serum fT3. To 
investigate whether any variants in 
the chr13q34 region could explain this 
deviating thyroid function observed in 
the FH(+) subset, we obtained the whole 
genome sequence of 214 unrelated index 
cases from the FH(+) subset, termed 
the SEQ_FH(+) subset (Table 1 and 2, 
Experimental Procedures 1.2). Depending 
on DNA availability, the sibling that showed 
the most extended life span was preferably 
included for sequencing to further enrich 
the SEQ_FH(+) study subset for longevity 
variants.
Using this data, we performed two 
types of association tests with serum 
fT3 levels. First, we employed a sliding 
window of 25kb, 50kb, 100kb, and 150kb 
to bin and jointly associate common and 
rare variants in 13q34 (Nvariants=15,612) 
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to fT3 levels using the Sequence Kernel 
Association Test (SKAT-O25, Experimental 
Procedures 3.3). Though none of these 
tests achieved significance (α ≤ 0.05) after 
Bonferroni correction, it is noteworthy 
that highest significance was obtained 
using the broadest window size (150kb) at 
a genomic position roughly coinciding with 
the maximal linkage score (Supplemental 
Figure 3).
Common Single Nucleotide Variants 
(SNVs) (MAF ≥ 5%, N=5,997) residing in 
the 13q34 candidate region were tested for 
association with serum fT3 levels using a 
standard regression model (Experimental 
Procedures 3.4). Using this approach, we 
identified one independent association 
with serum fT3 levels that passed the 
Bonferroni correction (rs9515460, T/C, 
β=-0.52, 95% CI -0.73--030, p=3.43×
10-6, Supplemental Figure 4 and 5 and 
Supplemental Table 2). The identified 
SNV is in full disequilibrium with two 
neighbouring SNVs rs80043005 and 
rs74128254 and is situated between TEX29 
(266 kb) and SOX1 (459 kb). Thus, within 
the 214 individuals selected for sequencing 
(SEQ_FH(+)), taken from sibships with a 
marked family history of excess survival 
(FH(+)), carriers of the rs9515460-C allele 
exhibit lower fT3 (Figure 3), potentially 
explaining the lower fT3 levels in the FH(+) 
subset as compared to the FH(-) subset.
3.5 Rs9515460 association with fT3 
serum levels confined to siblings that 
contribute to linkage at chr13q34
Next we questioned whether the 
association of rs9515460 with serum 
level of fT3 is confined to sibling pairs 
contributing to the linkage at chr13q34 
or is observed in the complete LLS 
nonagenarian cohort independent of IBD 
status or FH assignment. For this purpose, 
we performed Sequenom MassArray 
genotyping (Experimental Procedures 
5) on rs9515460 in all 415 nonagenarian 
sibships in the LLS study. Sequenced 
genotypes of rs9515460 in the SEQ_FH(+) 
cohort were in perfect concordance with 
those obtained with Sequenom. Whereas 
evidence for association of fT3 with 
rs9515460 was validated in the whole 
FH(+) subset (β=-0.23, 95% CI -0.40--0.07, 
p=0.006), such association was not found 
in the FH(-) subset (p=0.32), nor in the 
whole LLS (p=0.21). This either implies 
that the observed association of fT3 serum 
levels with rs9515460 in the FH(+) subset 
is a spurious finding, or alternatively, that 
not rs9515460 itself, but rare variants 
specific to the FH(+) subset and linkage 
disequilibrium with rs9515460 are causal 
for the lowered serum fT3 level.
To investigate whether the association 
of rs9515460 with fT3 can be explained 



















Figure 3:  Rs9515460: A QTL for fT3 on chr13q34. 
Within the individuals selected for sequencing 
(SEQ_FH(+)), the 24 rs9515460-CT carriers have a 





rs9515460 we employed the Identical 
By Descent (IBD) status at chr13q34. 
Nonagenarian sibships that have inherited 
identical strands of DNA from their parents 
(IBD2), while carrying the rs9515460-
CT genotype should be enriched for 
fT3 lowering variants, as compared to 
sibships that inherited different strands 
of DNA (IBD0), but by coincidence carry 
the rs9515460-CT genotype. Thus to 
investigate whether there is a significant 
interaction between the rs9515460 SNV 
and IBD status at chr13q34, we selected 
those sibling pairs being IBD2 at the 
marker with the highest linkage signal 
(rs752342), while carrying the rs9515460-
CT genotype. In total, 12 sib pairs fulfilled 
these criteria, 9 of which were included 
with 1 sibling in the SEQ_FH(+) subset. 
When stratified by rs9515460 genotype 
(CT or TT) and IBD status (IBD0 or IBD2) a 
significant lower fT3 level was observed in 
the 12 sibling pairs (IBD2-CT) as compared 
to the remaining sibling pairs in the whole 
LLS carrying CT, but not linking (IBD0-CT) 
or not carrying CT (IBD0-TT and IBD2-
TT) (β=-0.41, 95% CI -0.62--0.21, p=6.33×
10-5, Figure 4). Since this shows that the 
fT3 lowering effect of the rs9515460-CT 
genotype is conditional on IBD status, these 
results indicate that not the rs9515460 
SNV itself, but rare variants in linkage with 
rs9515460 explain the association with 
serum levels of fT3.
3.6 Variation at rs9515460 
associates with prospective survival in 
nonagenarians
In population-based studies of elderly above 
85 years4,26, low serum fT3 associates with 
a poor prospect of survival, presumably
not so much as a causal factor but because 
it marks frailty among the elderly. Since 
the rs9515460-CT genotype seems to tag 
a fT3 lowering phenotype, we investigated 
whether carriership of the rs9515460-CT 
allele associates with a poor prospective 
survival beyond age 90 and again observed 
interesting interactions with the FH strata 
(Table 3). Whereas the rs9515460-CT 
genotype significantly associates with 
a poor prospective survival in the FH(+) 
subset (HR=1.47, 95% CI 1.11-1.95, p=0.008, 
Figure 5), it does not for the FH(-) subset 
(p=0.98). This can be explained by the 
fact that the rs9515460-CT genotype only 
marks a fT3 lowering haplotype enriched 
in the FH(+), but not in the FH(-) subset. 
This would imply that the association of 
rs9515460-CT with a poor prospective 
survival is also explained by rare variants 
in linkage with the rs9515460-CT allele.
To confirm whether the association of 
rs9515460 with mortality is also dependent 
on IBD status at chr13q34, we repeated 














86/91 19/19 158/179 22/24
Figure 4: IBD × rs9515460 genotype 
interactions for fT3. FT3 serum levels in 
nonagenarians of all 415 sibships stratified by the 
most contrasting IBD statuses (IBD0 or IBD2) and 
rs9515460 genotypes (CT and TT) were plotted for 
the nonagenarians for whom data on fT3 levels were 
available, indicated by the ratios at the bottom.



























Table 3: Prospective survival on rs9515460. Prospective survival on a QTL for fT3, rs9515460, in a 10 years 
follow up performed in the whole Leiden Longevity Study (ALL) and the currently defined subsets: FH(+): 239 
nonagenarian sibships with a marked family history of an extended survival into old age; FH(-): 176 nonagenarian 
sibships without such a marked family history; SEQ_FH(+): 214 independent index cases selected from the 239 
sibships exhibiting a marked family history (FH(+)) of whom the whole genome has been sequenced previously 
(Chapter 4 of this thesis). HR indicates the hazard ratio for mortality.
the survival analysis in the whole study, 
while stratifying for the most contrasting 
IBD statuses (IBD0 or IBD2, as indicated 
by rs752342). Indeed we observe that the 
association of rs9515460 and mortality is 
also confined to the sibling pairs that link 
on chr13q34 (Ntot=313, Ndeath= 274, HR=1.94, 
95% CI 1.23-3.04, p=0.004, Figure 6). Hence, 
both the associations of a lowered serum 
fT3 level as a poor prospective survival 
of rs9515460-CT carriers are conditioned 
on sibling pairs linking on chr13q34. This 
indicates that the rs9515460-CT genotype 
partially tags a fT3 lowering haplotype that 
conveys a poor survival prospect in late 
life. As hypothesized, chr13q34 appears 
to contribute to the familial history of 
excess survival by harbouring variation 
attenuating the thyroid function thereby 
influencing lifespan regulation, however, 
apparently not in a protective sense in the 
oldest old.
4. Discussion
In this paper we report chr13q34 as a 
novel locus harbouring genetic variants 
contributing to lifespan regulation as 
well as an attenuated thyroid function. 
Within this locus, we identified the 
rs9515460_T<C polymorphism as a QTL 
for serum levels of fT3, the unbound active 
thyroid hormone. Nonagenarian minor 
C allele carriers of rs9515460 exhibit a 
significantly lowered fT3 level, which may 
have contributed to their survival to the 
age of 90, as a moderately lowered fT3 level 
at middle age is assumed to be beneficial 
for cardio-metabolic health. Since the 
minor allele rs9515460-C carriers display 
higher mortality risk above the age of 90, 
we conclude that, in concordance with 
literature4,26, low fT3 levels in exceptional 
old age may negatively influence survival.
Like previous genome wide linkage 
studies for longevity, we do not observe 
any overlap with any of the previously 
reported loci 4q2527, 3p24-22, 9q31-34, 
12q2428, 6p12.1, 7q11.21, 14q22.129 or 




19q13.11-q13.3230, suggesting that each of 
the studied populations have their private 
mechanisms leading to the longevity 
phenotype. In contrast to previous linkage 
studies, we have strong indications of the 
nature of the potential private mechanisms 
underlying the longevity phenotype in our 
study cohort. Previously we have shown 
that long-lived families with the most 
profound family history of excess survival 
(FH(+)) are characterized by an attenuated 
thyroid function. Together, these findings 
are a strong indication that chr13q34 
harbours variants that constitutively 
attenuate the thyroid function and thereby 
promote survival, especially in middle age.
Fine-mapping of the chr13q34 region 
was performed by associating each of the 
common variants under the linkage peak 
separately with fT3 and indicated one 
independent significant signal (rs9515460) 
situated between TEX29 (266 kb) and SOX1 
(459 kb). The fact that this association with 
fT3 was conditional on IBD status indicated 
that the rs9515460 was probably not causal 
itself, but tagged a haplotype carrying the 
causal variants. Two aspects about the 
proximal genomic region are noteworthy. 
First, the rs9515460 is situated in the 
first intron of a putative protein-coding 
transcript (RP11-65D24.2) predicted 
by the GENCODE consortium on basis 
of a single spliced testis expressed EST. 
Secondly, nearby GWAS-hits are at 42kb 
and 82kb and respectively associate with 
age at menopause31 and age at menarche32, 
which themselves have been attributed 
to a gene upstream of TEX29, namely 
ARHGEF7 (305kb). ARHGEF7 is known to 
be an activator of FOXO3a33, which is one 
of the most well studied longevity genes 

























Figure 5:  Rs9515460 and prospective survival. 
Kaplan-Meier curves were drawn for rs9515460 
genotypes in the 239 nonagenarian sibships with a 
marked family history of an extended survival into old 
age (FH(+)): Carriers of the rs9515460-CT genotype 
have an increased risk on mortality during a 10 years 



























Figure 6: IBD × rs9515460 genotype 
interactions for prospective survival. 
Kaplan-Meier curves of rs9515460 genotypes in 
nonagenarians of all 415 sibships stratified by IBD 
status. IBD2-TC nonagenarians have an increased risk 
on mortality during a 10 years follow up, as compared 
to the TT genotype carriers or IBD0 sibling pairs.
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upon disruption in multiple organisms34,35. 
Overall, the rs9515460-C allele tags an 
fT3 lowering haplotype and its proximal 
genomic region seems to relate to hormone 
functioning.
As an alternative, we attempted to 
fine map the linkage region by associating 
groups of variants jointly with fT3 levels 
using the Sequence Kernel Association 
Test (SKAT) in conjunction with a sliding 
window for variant grouping. Benefits of 
SKAT lie in its ability to handle mixtures of 
rare and common variants with opposite 
signs of association, thus fitting our 
expectations with respect of the genetic 
heterogeneity in both human longevity 
and an attenuated thyroid signalling. The 
most significant signal (p=0.0032) was 
detected in a window neighbouring the one 
containing the highest observed linkage 
signal (~44.8kb) and coincided with the 
ING1 gene and the first exons of the CARS2 
gene. However, none of the association tests 
performed with SKAT remained significant 
after correction for multiple testing, 
indicating that we might have insufficient 
power in the current study for performing 
joint association analyses of variants.
Since the FH(+) and FH(-) subsets 
show a very comparable prospective 
survival, we concluded that the genetic 
propensity to exhibit excess survival has 
no significant effect on the survival beyond 
age 90, which seems to be counterintuitive. 
Nonagenarian sibships with a genetic 
propensity to exhibit an excess survival 
were selected on basis of a so-called Family 
History Score (FHS), which expresses the 
mean survival advantage of the parents 
of a nonagenarian sibship relative to their 
respective sex and birth cohort specific life 
expectancies. Hence, the FHS relates to the 
probability of the parents of a nonagenarian 
to outlive their sex and age matched peers 
derived from the general population, who 
typically did not live up to age 90, nor their 
age-equivalent of the oldest old. Hence, 
the genetic propensity to exhibit an excess 
survival relates to survival into old age, 
and therefore not necessarily to survival 
of old into oldest old, as these two periods 
in life history are characterized by very 
distinct disease specific mortality rates.
Nonagenarian sibships with the 
most profound family history of excess 
survival are enriched for an fT3 lowering 
haplotype that is assumed to be beneficial 
for survival into old age, but is apparently 
detrimental for survival of old into oldest 
age. This antagonistic pleiotropic effect 
of the fT3 lowering haplotype on human 
lifespan regulation may be explained by 
considering the thyroid axis in relation to 
blood pressure and its subsequent effect 
on cardiovascular mortality. Increased 
thyroid levels promote an increased heart 
rate and cardiac output, leading to an 
increased pulse pressure. Whereas a low 
systolic blood pressure is beneficial from 
middle age onward (65 to 84), as indicated 
by a lower risk on cardiovascular death, it 
becomes detrimental in the oldest old (age > 
84)36. Hence, a haplotype carrying variants 
constitutively lowering fT3 serum levels is 
expected to contribute to human longevity 
by transmitting its beneficial health 
effects prior age 90. The fact that many of 
the health parameters, that distinguish 
members of long-lived families from the 
general population, display such inverse 
health correlations, suggests that the 




genetic mechanism for longevity might 
be common amongst long-lived families. 
Hence, the key to uncover the genetic basis 
for healthy ageing and human longevity lies 
in the knowledge on what conditions and 
life-timing health associated phenotypes 
actually confer their health benefits.
A limitation of the current study is that 
we thus far assumed that carriership of fT3 
lowering haplotype confers a health benefit 
at middle age, especially with respect to 
the cardio-metabolic make up. To test 
whether this hypothesis holds, also in the 
general population, we first need to further 
characterize the fT3 lowering haplotype. 
Once a clearly defined haplotype or the 
causal variants on this haplotype have 
been established, we first will verify 
whether fT3 levels co-segregate with the 
presumed casual variants in the offspring 
of the studied nonagenarians. To verify 
that the causal variants indeed predispose 
to a beneficial cardio-metabolic health 
status at middle age, we will investigate 
whether carriership of the causal markers 
can explain the lowered incidence of 
cardio-vascular morbidity observed in the 
offspring of the studied nonagenarians9. A 
following step would be to generalize these 
observations to the general population in 
multiple cohorts of European decent, to 
validate that the chr13q34 region harbours 
genetic predispositions underlying a public 
mechanism for human longevity marked 
by low serum fT3 levels.
To conclude, we have performed in 
depth genetic analyses to disentangle the 
pleiotropic relation observed in long-lived 
families between the propensity to exhibit 
an excess survival and an attenuation 
of the thyroid function. Using linkage 
analyses followed by QTL analyses for fT3 
on NGS variants within the 1-LOD-drop 
interval, we were able to identify an fT3 
lowering haplotype that might causally 
explain the attenuated thyroid function. 
Unlike previously reported longevity loci, 
that confer their beneficial effect either 
from middle age onward, e.g. APOE-ε2 
allele37, or in late life only, e.g. FOXO3A38-40, 
we hereby report the chr13q34 locus, 
that exhibits an antagonistic pleiotropic 
relation with life span regulation. Whereas 
lowered fT3 levels contribute to cardio-
metabolic health from middle into old 
age, it associates with a poor prospective 
survival in the oldest old. These findings 
collectively warrant further investigations 
into the mechanism how fT3 levels 
in specific and other ageing markers 
displaying inverse health associations in 
general contribute to human longevity and 
lifespan regulation.
5. Experimental Procedures
5.1 Study population: Leiden 
Longevity Study
5.1.1 Study Design: Families participating 
in the Leiden Longevity Study41 have at least 
two siblings meeting four inclusion criteria: 
(i) men are at least 89 years old and women 
are at least 91 years old, (ii) participants have 
at least one living brother or sister who fulfils 
the first criterion and is willing to participate, 
(iii) the nonagenarian sibship has an identical 
mother and father, and (iv) the parents of the 
nonagenarian sibship are Dutch and Caucasian. 
Using these criteria, a total of 421 nonagenarian 
sibships (N=944) have been recruited. For 415 
sibships (N=931) genome wide SNP genotypes22 
for at least two nonagenarian siblings were
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 available for the genetic linkage analyses.
5.1.2 Subset definitions: A so-called Family 
History Score (FHS)11 was computed per sibship, 
which expresses the mean survival advantage of 
the parents of a nonagenarian sibship relative to 
their respective sex and birth cohort specific 
life expectancies. A threshold on the FHS at 
-1.05 was used to assign sibships to either the 
FH(+)(FHS≤-1.05, 239 sibships, N=540) or FH(-)
(FHS>-1.05, 176 sibships, N=391) subset (Table 
1). From the thus created FH(+) subset, 214 
independent cases were selected for sequencing 
using the following criteria: (i) the availability 
of at least 5 µg of genomic DNA from whole 
blood for whole genome sequencing, (ii) the 
participation of children of one of the siblings 
for future research and (iii) the most extended 
lifespan compared to his/her siblings. Thus 
selected participants of the LLS were whole 
genome sequenced according to procedures 
fully described in Chapter 4 of this thesis.
5.2 Thyroid serum parameters
Details regarding the measurement protocols 
for the thyroid serum parameters TSH, fT4 
and fT3 have been described in full detail 
elsewhere10. Serum levels of TSH were 
log10 transformed in order to obtain an 
approximately normal distribution. Outliers 
in thyroid serum parameters were defined 
as observations deviating more than three 
standard deviations of the mean on basis 
of measurements performed in the whole 
population of nonagenarian participants in the 
Leiden Longevity Study (N=859).
5.3 Statistical analyses
5.3.1 Differences in thyroid parameters 
between sub-populations: Differences in 
serum levels of the thyroid parameters TSH, fT4 
and fT3 between sibships with a marked family 
history and without were tested using linear 
mixed models implemented in the lme442 and 
lmerTest43 packages of the statistical language 
R44: 
TP ~ β1 × age + β2 × sex + β3 × status + μ1 × famID       (1)
Where TP indicates the level of a thyroid serum 
parameter, age at inclusion is provided in years, 
sex is provided as 1 (male) or 2 (female), status 
indicates the assignment to sibships with (status 
= 1) or without (status = 0) a family history 
of extended survival and famID indicates the 
family membership. Family membership was 
modelled using a random effect μ1 to account for 
the phenotypic correlations observed between 
family members.
5.3.2 Associations with prospective 
survival: Analyses were performed with 
the Survival package45 of R44 using an age at 
inclusion and sex-adjusted, left-truncated 
Cox proportional hazards model to adjust for 
late entry into the dataset according to age. 
Mortality analyses between different subsets of 
the study were performed using:
λ(t) ~ λ0(t) × exp(β1 × age + β2 × sex + β3 × sel + μ1 × 
famID)                                 (2)
 
Where the covariates age designates age at 
inclusion and is provided in years, sex as either 
1 (male) or 2 (female), sel as either 1 or 2 to 
indicate study subset membership and famID 
indicates the family membership. Again, family 
membership was taken into account to correct 
for phenotypic correlations observed between 
family members and was done by supplying 
the term cluster(famID) in the Cox regression. 
Similarly, mortality analyses on the thyroid 
parameters were performed using:
λ(t) ~ λ0(t) × exp(β1 × age + β2 × sex + β3 × TP + μ1 × 
famID)                                 (3)
Where TP indicates the serum levels of TSH, 
fT4 or fT3. Finally, mortality analyses on the 
rs9515460 SNV were performed using:
λ(t) ~ λ0(t) × exp(β1 × age + β2 × sex + β3 × SNV + μ1 × 




Where SNV indicates the C allele dosage (0,1 or 
2) of the rs9515460_T>C polymorphism.
5.3.3  Sequence Kernel Association 
Test (SKAT-O): To jointly associate groups 
of genotype markers with serum levels of 
fT3, we employed the package SKAT46 of the 
statistical language R44 at default settings and 
used the following formula to describe the null 
hypothesis (containing covariates only):
fT3 ~ β1 × age + β2 × sex                                                  (5)
5.3.4 QTL associations: Associations 
with single genotypic genotypes was done 
for common variants within the 1-LOD-drop 
linkage area (MAF ≥ 5%, N = 5,480), using the 
lm function of the R package stats44, using the 
following model:
fT3 ~ β1 × age + β2 × sex + β3 × SNV                                (6)
Where the covariates age is provided in years 
and sex as 1 (male) or 2 (female). Genotypes 
were recoded to minor allele dosages: 0 
(homozygous common allele), 1 (heterozygous) 
or 2 (homozygous rare allele). Genotype data 
was filtered on missingness (≤ 5%) and MAF (≥ 
5%) with respect to the 208 out of 214 samples 
for which also data on fT3 levels was available. 
Obtained p-values were corrected for multiple 
testing (Bonferroni).
5.4 Linkage analysis
The Illumina 660Quad and Illumina 
OmniExpress arrays have been used for 
genotyping the participants of the Leiden 
Longevity Study. Details on data acquisition 
and pre-processing are have been described 
elsewhere21. For linkage analysis 12,000 
equally spaced SNVs were selected that are 
genotyped on both arrays with a MAF>0.3 and 
a mutual R2<0.4. MERLIN-0.10.247 was used to 
estimated the information content per genome 
and to estimate IBD probabilities in sibling 
pairs without parents. Nonparametric affected 
sibling pair analyses were performed using a 
score test statistic for affected sibling pairs48. 
5.5 Sequenome MassArray 
Genotyping
Genotyping of rs9515460 in the LLS study was 
performed using the Sequenom MassARRAY 
iPLEX Gold. Genotypes were successfully 
measured for 909 out of the 925 participants 
(98.3%). Sequenom genotypes in the 214 
individuals with whole genome sequencing data 
were in perfect concordance with sequenced 
genotypes of rs9515460.
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Supplemental Figure 2: An overview of the 1-LOD-drop interval on chr13q34. The red area indicates 





GeneSymbol EntrezGeneID TxAcc chrom strand start end
COL4A1 1282 NM_001845 chr13 - 110801310 110959496
COL4A2 1284 NM_001846 chr13 + 110959631 111165373
COL4A2-AS1 100874203 NR_046583 chr13 - 111154923 111160526
RAB20 55647 NM_017817 chr13 - 111175413 111214071
CARKD 55739 NM_001242882 chr13 + 111267807 111292342
CARKD 55739 NM_001242883 chr13 + 111267807 111292342
CARKD 55739 NR_040103 chr13 + 111267807 111292342
CARKD 55739 NR_040104 chr13 + 111267807 111292342
CARKD 55739 NM_001242881 chr13 + 111267931 111292342
CARKD 55739 NM_018210 chr13 + 111267931 111292342
CARS2 79587 NM_024537 chr13 - 111293757 111358480
ING1 3621 NM_198217 chr13 + 111364970 111373421
ING1 3621 NM_198218 chr13 + 111365610 111373421
ING1 3621 NM_198219 chr13 + 111365610 111373421
ING1 3621 NM_005537 chr13 + 111367359 111373421
ING1 3621 NM_001267728 chr13 + 111367784 111373421
LINC00346 283487 NR_027701 chr13 - 111516334 111522655
ANKRD10 55608 NM_017664 chr13 - 111530887 111567454
ANKRD10 55608 NR_104587 chr13 - 111530887 111567454
ANKRD10 55608 NM_001286721 chr13 - 111545039 111567454
ANKRD10 55608 NR_104586 chr13 - 111545039 111567454
ARHGEF7 8874 NM_001113511 chr13 + 111767624 111947542
ARHGEF7 8874 NM_001113512 chr13 + 111767624 111947542
ARHGEF7 8874 NM_145735 chr13 + 111767624 111947542
ARHGEF7 8874 NM_003899 chr13 + 111806061 111958081
ARHGEF7 8874 NM_001113513 chr13 + 111839173 111958081
TEX29 121793 NM_152324 chr13 + 111973015 111996594
SOX1 6656 NM_005986 chr13 + 112721913 112726020
SPACA7 122258 NM_145248 chr13 + 113030651 113089009
TUBGCP3 10426 NM_001286277 chr13 - 113139319 113242499
TUBGCP3 10426 NM_006322 chr13 - 113139319 113242499
TUBGCP3 10426 NM_001286278 chr13 - 113153121 113242499
TUBGCP3 10426 NM_001286279 chr13 - 113200796 113242499
C13orf35 400165 NM_207440 chr13 + 113301358 113338811
ATP11A 23250 NM_015205.2 chr13 + 113344643 113541482
ATP11A 23250 NM_032189.3 Chr13 + 113344643 113541482
Supplemental Table 1: Accession numbers of Genes within the 1-LOD-drop interval. Entrez Gene IDs and 
associated RefSeq transcript accessions are provided for genes situated in the 1-LOD-drop interval on chr13q34. 
The 1-LOD-drop interval was determined within the FH(+) subset.
A novel life span regulating locus at chr13q34
109
5
Supplemental Figure 3: Sequence Kernel Association Test (SKAT) in the 1-LOD-drop interval on 
chr13q34. Using the sequencing data in 214 nonagenarians, analyses were performed with SKAT for associating 
groups of SNVs under the linkage peak with fT3. Four different window sizes (25kb, 50kb, 100kb and 150kb) were 
used for grouping neighbouring variants according to a half overlapping tile pattern. Grouped variants were then 
submitted to a joint association analysis with fT3 adjusted for age and sex. Obtained results are indicated by the 
four tracks and display high consistency with respect to genomic position and significance. The highest significance 
after correction for multiple testing (Bonferoni) was observed using the 150kb windows (p=0.00319, 37 tests) for 

































































































Supplemental Figure 4: Association analysis with common variants in the 1-LOD-drop interval 
on chr13q34. Data on fT3 serum levels was available for 208 out of the 214 sequenced nonagenarian genomes. 
Variants were filtered on the minor allele frequency (MAF ≥ 5%) and call rate (CR ≤ 5%) in these 208 genomes and 
associated with fT3 serum levels using a sex and age adjusted linear regression. A total of 5,997 variants within the 
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Supplemental Figure 5: QQplot of absolute t.statistics obtained with single marker associations 
with fT3 on variants within the 1-LOD-drop region on chr13q34.




















chrom position allele beta se tstat pval df
chr13 110991189 G/A -0.251 0.065 -3.871 1.46E-04 204
chr13 111011400 A/T -0.282 0.072 -3.915 1.23E-04 204
chr13 111015628 C/T -0.198 0.051 -3.871 1.46E-04 204
chr13 111015780 C/A -0.198 0.051 -3.871 1.46E-04 204
chr13 111015877 C/T -0.198 0.051 -3.871 1.46E-04 204
chr13 111016124 A/C -0.198 0.051 -3.855 1.56E-04 202
chr13 111016153 C/T -0.199 0.051 -3.875 1.44E-04 203
chr13 111017045 C/T -0.198 0.051 -3.871 1.46E-04 204
chr13 111017784 G/A -0.201 0.052 -3.899 1.31E-04 204
chr13 111018009 G/C -0.186 0.052 -3.580 4.33E-04 198
chr13 111018072 G/A -0.198 0.051 -3.871 1.46E-04 204
chr13 111018132 T/C -0.198 0.051 -3.871 1.46E-04 204
chr13 111018163 T/G -0.198 0.051 -3.871 1.46E-04 204
chr13 111018235 C/A -0.198 0.051 -3.871 1.46E-04 204
chr13 111018666 G/A -0.199 0.051 -3.871 1.46E-04 202
chr13 111018729 C/G -0.199 0.052 -3.823 1.76E-04 200
chr13 111018752 A/G -0.198 0.051 -3.859 1.53E-04 203
chr13 111018909 C/G -0.190 0.051 -3.681 2.98E-04 203
chr13 111019083 T/C -0.198 0.051 -3.871 1.46E-04 204
chr13 111019278 C/A -0.204 0.051 -3.975 9.77E-05 204
chr13 111019472 T/C -0.198 0.051 -3.871 1.46E-04 204
chr13 111019508 C/T -0.196 0.052 -3.793 1.96E-04 202
chr13 111019568 A/G -0.198 0.051 -3.871 1.46E-04 204
chr13 111019895 T/C -0.198 0.051 -3.871 1.46E-04 204
chr13 111019976 C/A -0.198 0.051 -3.871 1.46E-04 204
chr13 111020878 G/A -0.204 0.051 -4.034 7.73E-05 204
chr13 111021623 C/G -0.204 0.051 -4.034 7.73E-05 204
chr13 111025118 A/G -0.191 0.053 -3.628 3.61E-04 204
chr13 111026734 G/A -0.191 0.053 -3.628 3.61E-04 204
chr13 111028978 G/A -0.188 0.052 -3.609 3.86E-04 204
chr13 111029923 G/A -0.194 0.052 -3.760 2.22E-04 204
chr13 111031180 G/A -0.194 0.052 -3.760 2.22E-04 204
chr13 111034542 T/C -0.180 0.050 -3.571 4.45E-04 202
chr13 111315249 G/A 0.178 0.052 3.437 7.17E-04 199
chr13 112256430 C/G -0.516 0.113 -4.562 8.76E-06 203
chr13 112256996 G/A -0.509 0.111 -4.593 7.64E-06 204
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chr13 112261984 G/A -0.517 0.108 -4.775 3.43E-06 204
chr13 112263091 C/T -0.517 0.108 -4.775 3.43E-06 204
chr13 112264614 C/T -0.338 0.094 -3.592 4.12E-04 203
chr13 112265213 G/A -0.517 0.108 -4.775 3.43E-06 204
chr13 112266639 G/A -0.320 0.087 -3.677 3.02E-04 204
chr13 112267153 A/C -0.320 0.087 -3.677 3.02E-04 204
chr13 112267402 G/A -0.320 0.087 -3.677 3.02E-04 204
chr13 112268411 C/T -0.320 0.087 -3.677 3.02E-04 204
Supplemental Table 2: SNVs in the 1-LOD-drop linkage region. The 1-LOD-drop region was determined in 
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A joint interpretation of life-science data 
is required for grasping the etiology of 
complex traits, however, this is challenging 
as the data types and quantities are ever 
increasing. The statistical platform R1 
provides some excellent tools for mapping 
and complex modeling of genomic data2, 
and additionally offers a potent interface to 
several database engines3. However it lacks 
a uniform database design across all data 
sources, which would greatly ease the data 
integration necessary to solve complex life 
science problems.
Here we present an R package, called 
SATORi (Standardized Access To Omics 
in R), for accessing various big omics 
data types from R in a standardized way. 
SATORI organizes data by genomic location 
facilitating an easy annotation to genomic 
features, like genes, pathways or to other 
SATORI databases. Moreover, due to the 
standardized database design, SATORI 
provides generic ways for accessing 
genome-wide data enabling a rapid 
exploration of omics data, while keeping 
source code clear and understandable. 
As a (running) example we applied 
SATORI to analyze methylation4 and SNP 
data5 assayed on two HapMap populations 
consisting of 30 trios of Caucasian (CEU) 
and Yoruban (YRI) origin. We show how 
easy data can be accessed and integrated 
with SATORI, while still having the power 
of the function set in R.
3. Implementation
The SATORI package employs the R plugin 
RSQLite to organize and access data by 
genomic location or measured entity ID, and 
subsequently, represents the associated 
data in a standardized and suitable format 
for performing analyses in R. SATORI 
introduces GVARdb objects to represent 
omics sources to R and different types 
of data sources are stored in specifically 
inherited subclasses of the GVARdb object. 
SATORI currently supports genotype data 
(GWASdb), methylation data (METHdb), 
and imputed genotype data (impGWASdb). 
Purpose-built constructors are defined for 
parsing raw data files of each supported 
data type to build the tables constituting 
the SATORI database (Figure 1A).
3.1 Accessing data stored in SATORI 
databases
Data in GVARdb objects can be accessed 
using the getGVAR function, which allows 
for intuitive queries mimicking normal 
matrix manipulation in R. For instance, 
entity IDs and sample IDs can be used 
to specify the composition of the output 
matrices. 
As an illustration, methylation data is 
stored as methylated and unmethylated 
signals per CpG site per sample (matrices 
M and U in Fig. 1B, respectively). A query 
using a specific CpG entity returns a vector 
containing the methylated and unmethylated 
signals for that CpG site for all samples:





Several wrappers for getGVAR have 
been defined to query data associated to 
particular (pre-defined) genomic features. 
For that, the SATORI database needs to 
be made aware of an entity-to-feature 
mapping (Fig. 1B), which can be created 
and stored using the mapGVAR2FEAT 
function.
For instance, suppose we want to access 
methylation data per cytoband. The genomic 
locations of cytobands can be downloaded 
from UCSC to R and mapped to the GVARdb 
object using:
2> cyto <- getFEATfromUCSC 
(“cytoBand”,“hg18”)
3> mapGVAR2FEAT(methdb,cyto)
From now on, data can be queried using 
a specific cytoband designation, which would 
return a matrix containing the methylated 
and unmethylated signals for the CpG sites 
situated within the requested genomic 
feature for all samples (Fig. 1C):
Access Single CpGsB Access Groups of CpGs C
GVARdb
Standardized Database Design
indx map qc sample metadatafeat2gvar
id        data        allele
1   M1|U1|M2...   U/M
data gvar2feat
sample_id  family  member   father      mother     sex      pop


















Figure 1:  Design and functionality of SATORI. [A] An overview of the SQL tables composing a SATORI 
GVARdb object, including tables for storing data (data), mappings to the genome (map), mappings to genomic 
features (gvar2feat) and sample information (sample). Data points are collapsed per measured entity into single 
strings across all samples allowing a standardized storage and handling across data types (left). The sample 
table can be used to store for instance covariates or the familial relationships (right). [B] A database storing (for 
example) methylation data can be thought of as two big matrices containing the methylated (M) and unmethylated 
(U) signals for all measured CpGs for all samples. Using, for example, code snippet 1, one can access the data of a 
particular CpG, while with code snippet 6, one can find differentially methylated CpG sites. [C] Genomic features 
obtained from, for example, UCSC (cyto) are mapped to the database, after which data can be accessed by feature 
ID. See code snippets 2,3,4 on how to do this using SATORI.
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4> res _ mat <- getGVARbyFeat 
(methdb,“chr1q21.3”)
 Conceptually, there is no difference 
between mapping to annotations 
downloaded from UCSC, to annotation 
databases in R storing transcript locations 
(Carlson, et al., 2013), or to other SATORI 
databases. 
 For example, to map SNP data 
stored in a SATORI’s GWASdb object to our 
methylation data within a 10kb region 
around the CpGs, also use: 
5> mapGVAR2FEAT 
(methdb,gwasdb,flanking=10000)
 From now on, data of SNPs positioned 
within 10kb from a CpG site can be queried 
with the same CpG IDs used to query the 
methylation data. 
3.2 Operations on SATORI databases
Custom R functions can be applied to 
GVARdb objects using dbGVARapply, 
which applies a user-defined R function to 
each entry of the GVARdb object. This is 
done by sequentially loading and applying 
the function to chunks of the database 
(enabling parallel execution or handling 
big data sets).
 As an illustration, differentially 
methylated CpG sites (DM-CpGs) between 
the two HapMap populations can be found by 
applying a Wilcoxon signed-rank test to the 
METHdb object (Fig. 1B)
6> res _ wilcox <- 
dbGVARapply(methdb,FUN=wilcox)
 SATORI also allows applying 
functions to groups of entries using 
dbFEATapply. This function makes use of 
a previously stored mapping to iteratively 
load and analyze grouped data associated 
to genomic features.
 For example, to investigate whether 
the previously identified DM-CpGs are 
confined to certain cytobands, we re-
compute the number of DM-CpGs per region 
given a p-value threshold and report these as 
percentages per cytoband (Fig 1C):
7> res _ p <- dbFEATapply 
(methdb,FUN=perc,p=1e-5)
4 Application
Previous code illustrated the ease with 
which methylation and SNP data could be 
integrated using the SATORI package. To 
illustrate the seamless integration in R we 
investigate the relationship between CpGs 
and their neighboring SNPs within the CEU 
and YRI population by calculating CpG-SNP 
correlations.
 To perform this computation, we 
define a function that queries the data from 
a METHdb and a GWASdb given a CpG ID, 
and computes CpG-SNP pair correlations 
using all shared samples:
# Find shared samples:
8> sampID <- intersect(colnames(methdb),
colnames(gwasdb))
# Get SNP data, for instance cpgID = 
“cg00000292”:





# Get the beta values (M/
(M+U+100)) from the methylated 
data. This indicated to getGVAR 
by the “as.B=T“ argument 
10> MR <- getGVAR 
(methdb,cpgID,sampID,as.B=T)[1,]
# Compute (with pairwise.
complete observations)
11> cor(t(snp),MR,use=”p”)
 Genome plots of chr21q22.11 (Figure 
2) show that DM-CpGs coincide with 
significant CpG-SNP correlations in YRI, 
suggesting a potential crosstalk between 





















































































































































































































Figure 2:  A visualization of the results computed with aid of SATORI on chr21q22.11. In black, the 
significance (-10log(p)) and relative positioning of DM-CpGs between the YRI and CEU populations are depicted. 
Below in pink (YRI) and blue (CEU) correlations between CpG levels and genotypes in cis are displayed, where each 
point represents the most significant correlation (-10log(p)) with a SNP within 10kb. Detailed code for performing 
the analyses and drawing genome plots is provided in the supplemental materials.




With the examples in this paper we 
illustrated the merits of a generic access 
to various big data sources, which 
greatly simplifies integrative analyses 
of life science data. With SATORI the 
user can quickly explore data and test 
novel hypotheses by mapping the data to 
external annotations sources or applying 
user-defined functions to the data. Hence 
SATORI is a useful tool in the integrative 
analysis of omics datasets.
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1.  Main Aims
The aim of this thesis was to develop state-
of-the-art integrative algorithms for the 
comprehensive and robust analysis of omics 
data sets and to apply them to elucidate 
molecular pathways driving human aging. 
Human aging, its relation to health, and 
its effect for life span regulation is largely 
studied through biomarker or genetic 
research, but both are greatly hampered by 
the extreme complexity and heterogeneity 
of the studied trait. Development and 
application of novel methodology better 
capable of handling this complexity and 
heterogeneity is required for making any 
real advances in our understanding of 
human aging. Throughout this thesis we 
set out to devise novel strategies for data 
analysis, while adopting two concepts for 
data integration that are likely to improve 
both the robustness and interpretation 
of the obtained results: the joint analysis 
of omics data and incorporation of prior 
knowledge. In this chapter we will review 
the benefits of adopting novel methodology 
incorporating concepts of data integration 
in biomarker as well as genetic research 
for the advances in our understanding of 
human aging.
2.  Main Findings
The first objective of this thesis 
was to develop methodology for the 
comprehensive and robust extraction of 
molecular biomarker profiles based on 
whole transcriptome expression data. 
In Chapter 2, we investigated the use of 
Protein-Protein Interaction (PPI) data as 
a source of prior knowledge for grouping 
gene-expression data into comprehensive 
modules of functionally related genes and 
their potential to jointly serve as robust 
biomarkers. For this purpose, an algorithm 
for the detection of co-expressed PPI 
modules was developed and we show that 
its application yields highly reproducible 
modules of genes over six supposedly 
heterogeneous studies assayed on breast 
cancer outcome1-6. Though cross-study 
prediction performances were on average 
slightly lower as compared to traditional 
methods for prospective signature 
construction, the gene composition of the 
identified modules was in broad agreement 
with the evidence for the underlying 
etiology of breast cancer reported in 
literature. Hence, the newly developed 
algorithm for construction of co-expressed 
PPI modules leads to robustly identifiable 
and comprehensive molecular biomarkers.
The high consistency with which the 
modules were detected across studies in 
Chapter 2, cleared the way for developing 
a statistical framework for a joint modular 
analysis of transcriptomic datasets, to 
further improve the robustness of the 
detected co-expressed PPI modules. 
In Chapter 3, the methodology for co-
expressed PPI detection was put into a 
meta-analysis framework for module 
inference as well as for the subsequent 
module associations with the studied 
phenotype, in our case chronological age. 
Application of the improved algorithm to 
four transcriptomic data sets measured 
in blood7-9 (~2.500 samples) revealed 
five co-expressed modules of which the 
mean gene expression level associated 




independent study10,11 (~3.500 samples) 
showed that the associations with 
chronological age replicated for four out 
of five identified modules, demonstrating 
the robustness of the presented method 
for biomarker extraction with respect to 
correlations with phenotypes. Remarkably, 
one of the modules contains the ASF1A gene, 
which has previously been identified as 
differentially expressed between members 
of long-lived families and controls12. 
Moreover, using gene expression data of 
nonagenarians of the Leiden Longevity 
Study (LLS, ~50 samples)12, we show 
that the ASF1A containing module also 
associates with prospective survival after 
age 90. Thus, expression of ASF1A and 
its co-expressed module members may 
constitute a novel robust biomarker for 
biological aging.
A second objective of this thesis was 
to develop methodology suited for the 
comprehensive and robust analysis of 
genetic variants coming from whole 
genome sequencing studies into human 
aging and longevity. In Chapter 4, 
we investigated analysis strategies 
that exploit prior knowledge on gene 
membership and impact for grouping and 
prioritizing coding variants. To assess the 
use of such gene-centric analysis strategies 
for identifying robust and interpretable 
genetic loci that affect human aging, we 
used Next Generation Sequencing (NGS) 
data on 218 long-lived cases from the 
LLS13 and 98 population controls14,15. We 
first hypothesized that long-lived cases 
may have a genome-wide depletion of high 
impact protein-altering variants present 
in the germ line, either leading to a better 
functioning or more complete proteome, 
or marking a high fidelity DNA repair 
system16,17. On a genome-wide scale, we 
indeed observed that long-lived cases, 
as compared to the population controls, 
display a significant depletion of variants 
in the coding sequence and especially 
fewer of the highly disrupting frameshift 
insertions and deletions. Validation 
experiments using Sanger sequencing, 
however, could not underpin these 
findings. These experiments indicated 
that an excess of false positive disruptive 
variants in the control group contributed to 
the difference between cases and controls 
rather than a depletion of such variants in 
cases. This was likely caused by a technical 
bias in the sequencing of controls, which 
were measured at a later time point than 
cases, be it at the same Complete Genomics 
platform. The contribution of rare variants 
to familial longevity requires further 
research, ideally in larger studies than the 
ones performed here or by other groups in 
the field.
In Chapter 4 we secondly hypothesized 
that long-lived cases may exhibit a gene 
specific enrichment of rare disruptive 
variants inhibiting gene functioning in 
line with knockout experiments leading to 
life span extension in model organisms18. 
Remarkably, we observed that long-
lived cases carried a significant excess 
of frameshift deletions and insertions as 
compared to the population controls in two 
genes: DNMT3A and TET2. Notably, also 
other categories of disruptive variants, e.g. 
missense and nonsense SNVs, did support 
the genetic burden of disruptive variants 
at these two loci. The protein encoded by 
TET2 is a methylcytosine dioxygenase that 




to 5-hydroxymethylcytosine19, and DNTM3A 
is a DNA Cytosine-5-Methyltransferase 3 
that is involved in de novo methylation20, 
which is essential for the establishment 
of DNA methylation patterns during 
development. Both encoded proteins are 
involved in myelopoiesis21,22, and defects 
in these genes have been associated with 
several myeloproliferative disorders23,24. 
Sequence read evidence for the rare 
disruptive variants in both DNMT3A and 
TET2 suggested that these variants are 
predominantly somatic, rather than germ 
line, and this observation was confirmed 
by Sanger sequencing experiments. 
Interestingly, similar somatic mutations 
in TET2 and DNMT3A have previously been 
associated with an outgrowth of myeloid 
stem cells leading to myeloid dysplasia 
(MDS) and subsequent progression to23,24, 
as well as outcome of acute myeloid 
lymphoma (AML)25,26. Hence, in line with 
literature on the genetics of hematopoietic 
stem cell aging, the genetic burden at 
DNMT3A and TET2 should in effect be 
interpreted as a potential marker of stem 
cell aging rather than a potential heritable 
factor underlying familial longevity. 
In Chapter 5, we abandon the gene-
centric analysis scope for grouping and 
prioritizing variants as employed in 
Chapter 4, and instead use a genomic 
convergence approach27 to limit the 
analysis of NGS variants to those 
originating from genomic regions most 
likely to harbour determinants of human 
longevity. We obtain such regions by 
performing affected sibling pair analyses 
among all families from the LLS, while 
stratifying for the family history of excess 
survival (FH(+)), as we believed this 
selection to further enrich for variants 
underlying human longevity. Importantly, 
the FH(+) families are characterized by an 
attenuated thyroid function as compared to 
long-lived families without such a marked 
family history (FH(-)), which thus suggests 
a pleiotropic relation between human 
longevity and attenuation of the thyroid 
function. The linkage analyses identified a 
2.4 Mb region at chromosome 13q34 with 
significant linkage that was highly specific 
to the FH(+) subset. This finding indicates 
that sibs of the 239 long-lived sibships 
have inherited the identical strands of 
DNA from their parents significantly more 
often than would be expected by chance, 
thus implicating this locus to harbour 
variants underlying human longevity by 
attenuating the thyroid function. 
We next employed NGS data assayed on 
214 selected index cases, maximal one of 
each of the 239 FH(+) sibships, to further 
scrutinize the obtained 13q34 locus 
exhibiting significant linkage for familial 
longevity. To this end, we performed 
fine mapping by using a QTL analysis, i.e. 
genetic association analysis, employing the 
NGS genotypes and a relevant trait. Since 
the case-control comparison in Chapter 4 
had low power due to various reasons (e.g. 
phenotypic heterogeneity, binary trait), we 
used quantitative traits for fine mapping 
that mark the beneficial cardio-metabolic 
make-up of members of long-lived families. 
The FH(+) subset exhibited a significantly 
lower serum free triiodothyronine level, 
the active thyroid hormone itself (fT3), 
as compared to the FH(-)) subset, which 
moreover seemed to affect the prospective 
survival in FH(+) differently as in the FH(-) 




in the following QTL analyses for fine 
mapping the 13q34 locus and found the 
minor C allele of rs9515460 to mark an fT3 
lowering haplotype, potentially explaining 
the attenuated thyroid function.
Thus far we concluded that rs9515460-C 
carriers exhibit an attenuated thyroid 
function, as indicated by their relatively low 
fT3 level and assume this to be beneficial 
to reach the age of 90 years. Whereas 
attenuation of the thyroid function is 
known to associate with a beneficial 
cardio-metabolic make up at middle age28, 
low fT3 is also known to mark a poor 
prospective survival in the oldest old29,30. 
Accordingly, nonagenarian sibships of the 
LLS carrying the fT3 lowering haplotype, 
tagged by rs9515460-C, also displayed a 
significantly poorer prospect of survival 
after age ninety as compared to the 
remainder of the study. This observation 
can be explained by considering the 
thyroid axis in relation to blood pressure 
and the relation with cardiovascular 
mortality thereof. Increased thyroid levels 
promote an increased heart rate and 
cardiac output, leading to an increased 
pulse pressure. Whereas a low systolic 
blood pressure is beneficial from middle 
age onward (65 to 84), as indicated by 
a lower risk on cardiovascular death, it 
becomes detrimental in the oldest old 
(age > 84)31 Hence, variants constitutively 
lowering serum fT3 levels are expected 
to contribute to longevity by transmitting 
their beneficial effects for cardiovascular 
health prior to age ninety.
In Chapter 6, an R package is 
presented facilitating the execution of 
some of the routinely encountered tasks 
in genomic data integration. To generalize 
and standardize the execution of such 
highly similar though demanding tasks 
over different types of omics data sets, 
we implemented the R package SATORi 
(Standardized Access To Omics in R) and 
exemplify its use with publically available 
omics data sets.
To summarize, the research of this 
thesis provided the following insights 
in human aging. First, a number of gene 
networks changes their expression with 
age in such a consistent way that the 
phenotypic consequences can now be 
widely studied (Chapter 3). Secondly, we 
observed that a long life is not necessarily 
hampered by potentially premalignant 
somatic mutations in either TET2 or 
DNMT3A (Chapter 4). Finally, attenuation 
of thyroid function as represented by low 
fT3, may be beneficial at middle age, but 
seems to contribute causally to increased 
mortality above 90 years (Chapter 5).
3. Integrative Omics in 
Biomarker Research into Human 
Aging
3.1 Module biomarkers in 
transcriptomics data analysis
In the first part of this thesis (Chapter 2 
and 3), we show that the robustness and 
interpretability of molecular biomarkers 
for healthy aging extracted from 
transcriptome data sets can be improved 
by incorporating prior knowledge and 
adopting strategies for the joint analysis. 
Although many of the tested modules were 
significantly enriched for one or multiple 
functional Gene Ontology categories, a 




display any significant enrichment at all. 
This type of observation is currently under 
hot debate in the networking field32 and 
basically refers to the question whether 
such modules comprise novel knowledge 
or are more likely to represent artefacts of 
the employed method. Xue et al. show that 
such co-expression modules, in absence 
of any significant functional enrichment, 
are still consistently observed across 
multiple studies in human and even 
mouse33, implying that these modules are 
not spurious findings and thus seem to 
constitute novel knowledge. Hence, results 
coming from network analyses that do not 
overlap with our current knowledge, are 
not spurious findings per se, but instead 
may point to novel contexts in which genes 
jointly perform a potentially unknown 
though apparently important cellular task. 
Correlations in gene expression may 
arise as a result of a shared transcriptional 
program, implying functional relatedness, 
however, it might also arise due to a 
varying cell composition across samples. 
Since cell composition is known to vary 
with age and between breast tumours, we 
expect that parts of the recovered gene 
regulatory networks in fact represents 
changes in cell type composition. Indeed, 
some of the detected modules showing an 
association with the analysed phenotype 
were also enriched for particular cell types 
(Chapter 2 and 3), thus pointing to the 
potential presence of such confounders in 
our analyses. In contrast, such enrichments 
were not observed in the individual gene 
analysis (Chapter 3), which does not imply 
the absence, but merely the lack of power 
to detect such potential confounders. 
Once detected, modules enriched for a 
particular cell type can be regarded as 
its biomarker and can subsequently serve 
as a surrogate variable for correcting the 
analysis (Chapter 3). Such an application 
of our module-based approach closely 
relates to deconvolution-based methods for 
correcting gene-expression data for blood 
composition34,35, with the distinction that 
our method would not rely on calibration 
data sets to appoint genes a priori for 
creating surrogate variables. In effect, 
a modular analysis does not solve the 
problem of shifting cell type compositions 
confounding association analyses, but as 
opposed to an individual gene analysis, 
a modular analysis does have the power 
to discover and provide opportunities to 
adjust for such potential confounders.
The nature of the employed PPI 
resource is greatly influencing the 
outcome of network-based computations. 
For instance, West et al.36 refer to the 
network positions of transcription factors 
(TFs) as peripheral with respect to the 
cellular signalling hierarchy, which can 
be explained by the fact that they do not 
consider DNA-protein interactions in 
their network. Hence, the choice of the PPI 
resource employed (STRING37) is likely to 
have affected the exact composition of the 
obtained modules in Chapters 2 and 3. 
However, the aim of the developed method 
was not to infer complete collections 
of functional relationships, but merely 
to infer sufficient numbers required 
for improving the interpretability and 
robustness of the obtained modules. Hence, 
the presented modules are not necessarily 
exhaustive overviews of all genes involved 
in particular cellular functions, but instead 




functional coherence as judged by the 
intersection of the co-expression data and 
the employed PPI resource.
4. Integrative Omics in the 
Genetics of Human Aging
4.1 Strategies for the analysis of 
whole-genome sequencing data
In the second part of this thesis (Chapter 
4 and 5), we show that the robustness of 
NGS data analysis can be improved by 
adopting either a consecutive use of genetic 
data sources or by applying strategies 
incorporating prior knowledge for the 
grouping and prioritization of variants. 
The availability of NGS data raises the 
opportunity for investigating novel genetic 
variants and their potential relation 
with the aging phenotype in an unbiased 
genome-wide approach. However, in both 
Chapter 4 and 5 we apply rigorous filtering 
of variants prior to the analysis, which may 
appear counterintuitive. Reasons for the 
stringent filtering relate to the statistical 
difficulties encountered when analysing 
NGS discovered variants. Newly discovered 
variants come in great numbers, though 
often only exhibit low frequencies in the 
general population, conveying very limited 
power in association tests. Yet, especially 
the analysis of these very rare variants 
is most interesting, as they have a priori 
the highest probability of conferring a 
profound impact on the phenotype. By 
limiting the number of tests, through 
aggregating (Chapter 4) and filtering 
(Chapter 4 and 5) individual variants, we 
gain additional power in the remaining 
association tests enabling research of the 
role of rare genetic variation in the rate of 
aging and human longevity. 
As an alternative to the stringent 
filtering performed in Chapter 4, one could 
also gain additional power in aggregate 
association tests by down-weighing 
unimportant variants, rather than 
discarding them, as is done in for instance 
the Sequence Kernel Association Test 
(SKAT)38. Since additional power might 
be gained by also including the signal of 
lower impact variants, we investigated the 
application of SKAT in the data presented 
in Chapter 4. Various scenarios were 
investigated, based on inclusion of all 
or only particular variant types (SNV, 
deletion and insertion), expected impacts 
(missense, nonsense, non-stop etc.) and 
aggregations per gene or predefined sets 
of candidate genes taken from literature. 
SKAT applied per gene indicated that the 
baseline scenario using all coding protein-
altering SNVs (missense, nonsense, nonstop 
and misstart) had more power over several 
scenarios in which the analysis was 
limited to subsets of high impact variants. 
Furthermore, the baseline scenario using 
only SNVs had comparable power to the 
scenario in which all variant types were 
included. Noteworthy, additional filtering 
of missense SNVs using ANNOVAR39 
decreased power in all scenarios, though 
generally exhibited comparable rankings 
of top genes to scenarios in which missense 
filtering was not applied. Both the gene-
based as the gene set-based results were 
generally driven by a single rare variant 
(MAF~1%), but not by common (MAF>=5%) 
or multiple singleton observations. This 
common variant generally exhibited lower 




as compared to the population controls. 
Hence, despite the variant weighing based 
on allele frequencies included in SKAT, 
contributions of common or singleton SNVs 
are still ignored. Moreover, in the absence 
of ready-applicable priors for the different 
variant categories, contributions of rare 
high impact variants are totally neglected. 
In effect, a joint frequency-weighed 
association analysis using SKAT in the 
current study does not provide additional 
benefits with respect to the interpretation 
or robustness of the obtained results over 
an association analysis based on individual 
variants.
When limiting aggregate association 
tests to the use of high impact rare variants 
only (Chapter 4) in so called Rare Variant 
Association Studies (RVAS)40, one becomes 
especially vulnerable to bias by sequencing 
errors. Error rates increase with both 
increasing impact and increasing rareness 
of variants, yet we pursued an RVAS 
favouring singleton observations with 
a gene disrupting impact. An important 
motivation for this approach was that 
extensive genotyping experiments with 
the Sequenom Mass Array platform (data 
not shown) following the whole genome 
sequencing of the long lived cases, generally 
displayed a near perfect concordance with 
the NGS genotypes (by Complete Genomics), 
irrespective of the allele frequency or 
predicted impact of the assayed SNV. When 
extending the validation experiments to 
frameshift indels, initially only within 
TET2 or DNMT3A, we found comparably 
high concordance rates, which led us to the 
false impression that all frameshift indels 
were identified with high confidence by 
our whole genome sequencing data. It was 
when validation experiments on random 
subsets of frameshift indels originating 
from the whole genome were performed 
when we first learned that this is generally 
not the case. Hence, we strongly advice 
against conducting RVAS studies within 
a whole-genome framework, and instead 
advice to perform RVAS studies within 
a gene-specific context only, with the 
additional remark that re-sequencing of 
the identified disruptive variants must not 
be omitted.
Thus far, most of the attention in NGS 
experiments has gone to variants in the 
coding domain, due to their ease of inference 
and interpretation, thus providing a 
logical starting point for our research into 
the analysis of NGS variants in Chapter 
4. However, as most of the established 
associations with common SNVs in GWASs 
generally seem to coincide with regulatory 
domains, like enhancers41, rather than 
with coding domains, it seems reasonable 
to assume that the same holds for rare 
variants coming from NGS experiments. 
Therefore, in this thesis we also pursued 
strategies for analysis of rare intergenic 
variants in which expected impact on the 
basis of gene annotations could not serve as 
filtering criterion. For instance, in Chapter 
5 we limited the number of variants 
employing the results of a genome-wide 
linkage study into familial longevity as a 
source of prior information. In conclusion, 
the incorporation of additional omic data 
sources to reduce and guide the number of 
tested hypotheses is highly recommended, 
and is even more required when extending 





4.2 Future prospects for integrative 
omics into the genetics of human aging
Both the gene-centric (Chapter 4) as the 
purely data-driven approach (Chapter 
5) for prioritizing and analysing NGS 
variants have merits and in an ideal 
setting both approaches are applicable. 
The usefulness of an additional gene-
centric approach for the interpretation 
of the NGS results in (Chapter 5) is 
illustrated when incorporating prior 
information on regulatory domains, 
such as ChIA-PET data created by the 
ENCODE consortium42 (Figure 1). ChiA-
PET is a protocol for capturing the 3D 
physical proximity between distant DNA 
domains for elucidating for instance 
enhancer-promotor interactions, thus 
relating non-coding domains to genes. 
Unlike other conformation capturing 
techniques, ChiA-PET includes a Chip 
step, to specifically enrich for distant 
DNA interactions associated with one 
particular species of protein only. Multiple 
ChiA-PET experiments in the NB4 cell line 
on POL2, provide evidence for a physical 
interaction during transcription between 
the intergenic region of CARS2/ING1, 
coinciding with the maximum linkage 
signal and the promotor of IRS2, residing 
outside the linkage area. Interestingly, 
disruption of the IRS2 homologs in the 
fruitfly D. melanogaster43 was found to 
induce longevity, suggesting that the 
intergenic region of CARS2/ING1 contains 
regulatory elements required for the 
transcription of IRS2, which is perturbed 
in members of long-lived families. These 
results show that a gene-centric or even 
candidate approach for analysing NGS data 
into human longevity is sensible, however, 
should not be limited to protein-altering 
variants only. Hence, potential future 
extensions will focus on a gene-centric 
methodology that incorporates prior 
knowledge for including variants residing 
in regulatory domains as to improve the 
NGS analyses on strong candidate genes for 
human longevity.
5. Evidence for Hallmark Aging 
Processes
López-Otín et al.44 described nine hallmark 
processes consistently observed to co-
occur with aging and this thesis provides 
evidence for some of these processes to 
play a role in human aging processes as 
indicated by molecular aging processes 
in whole blood. In Chapter 3, a robust 
age-associated co-expressed module 
was identified reflecting a decline in 
transcription of ribosomal proteins, 
relating to the hallmark process of “loss 
of proteostasis” (Figure 1 Introduction). 
This observation also provides indirect 
evidence for “deregulated nutrient 
sensing”, as ribosomal expression is under 
control of mTOR-insulin-signalling45, 
a pathway responsible for tuning the 
basal metabolism to the availability of 
nutrients. Corroborating evidence for the 
involvement of both processes in aging 
is given in Chapter 5. The main genetic 
leads for a successfully slowed aging are 
CARS2, a gene required for translation 
of novel proteins, ING1, an inhibitor of 
growth or IRS2, an insulin receptor. Hence, 
the hallmark aging processes “loss of 
























































































































































































































































































































































































































































































































































































sensing” seem to play a role in the aging of 
whole blood.
The most significant age-associated 
co-expressed PPI module detected in 
Chapter 3 was enriched for “T-Cell 
Activation” and down-regulated with 
age, probably reflecting the hallmark 
processes “senescence” or “stem cell 
exhaustion” within the lymphoid 
compartment. Interestingly, the somatic 
mutations in TET2 and DNMT3A described 
in Chapter 4 are associated with an 
outgrowth of myeloid stem cells19,22, which 
thereby gradually displace the lymphoid 
compartment, and could therefore explain 
the observed age-associated down-
regulation of genes involved in “T-Cell 
Activation” in Chapter 3. The TET2 and 
DNMT3A mutations also provide indirect 
evidence for another hallmark process of 
aging, namely: “epigenetic alterations”. 
TET2 and DNMT3A are both important 
epigenetic factors involved in DNA 
methylation20,46 and mutations in these 
genes have been associated with aberrant 
methylation levels19,25, and progression 
to23,24 and prognosis of AML25,26. There 
is an on-going discussion whether such 
epigenetics-modifying gene mutations 
are somehow responsible for causing 
the widespread genomic instability 
observed in MDS and AML25,47, which also 
happens to be a hallmark of aging. This 
discussion is triggered by the observation 
of widespread genomic instabilities in 
mice upon knockout of the DNMT1 gene48, 
like DNMT3A a gene involved in DNA 
methylation, which notably was grouped 
in an age associated module enriched for 
DNA integrity identified in Chapter 3. 
Hence, this thesis provides evidence for the 
involvement of the hallmark aging process 
“senescence”, “stem cell exhaustion”, 
“epigenetic alterations” and perhaps 
“genomic instability” in the aging of whole 
blood.
6. Outlook for Research in the 
Molecular Biology of Aging
According to the general expectation, 
future research into the genetics of 
complex traits will increasingly be based 
on NGS technology. However, NGS based 
advances into the genetics of complex 
traits in general and aging in specific 
have been fairly modest, which can be 
partly attributed to the limitations of the 
currently employed sequencing technology 
based on short reads49. With the rapid 
advancements in sequencing technology, 
it is expected that the complications for 
assembly and subsequent variant calling 
arising due to limited length of reads will 
be effectively negated as that in the near 
future the need for a reference genome 
will be omitted. Another development in 
sequencing technology is the decreasing 
quantities required to serve as template 
in the sequencing protocols, and 
currently enables genotyping of DNA 
and quantification of RNA species of 
biomaterials derived from a single cell50. 
Especially for research into aging of 
tissues with a very heterogeneous cell 
type composition, like whole blood, these 
developments are expected to shed many 
new insights. Though improvements in 
sequencing technology will alleviate many 
of the complicating factors of variant 
(Chapter 4 and 5) or expression (Chapter 




data, it does not solve any of the problems 
arising due to the heterogeneity of the 
aging phenotype. Thus in the prospect 
that these advances will create even more 
data points, but not necessarily in more 
individuals, the need for incorporating 
techniques for data integration into the 
analyses of omics data into aging will only 
grow.
With the completion of large 
international efforts aimed at meticulously 
scrutinizing the functional elements in 
DNA and the interactions thereof42,51, 
many exiting opportunities arise for 
the advanced interpretation of genomic 
variants in their genomic context. The next 
step is to assess the phenotypic effects in 
case such molecular circuits are perturbed. 
Data generation initiatives in large human 
bio-banks, like the BBMRI-NL BIOS 
consortium (http://www.bbmri.nl/en-
gb/activities/rainbow-projects/bios) are 
aimed at facilitating this link by collecting 
deep phenotypic information and multiple 
omics data sources all assayed in the same 
individuals. Jointly, these data resources 
would be of great value for translating 
omics findings into human aging on the 
molecular level to effects of health on 
the organismal level, ideally providing a 
mechanistic insight into the molecular 
drivers of human aging.
Family-based study designs are very 
valuable for studying biomarkers and the 
genetics for human aging, as they provide 
the means for controlling the considerable 
amounts of unwanted biological variation 
present in assayed omics data sets. For 
instance, since the genome of every 
individual contains many unique highly 
disruptive variants, each genome is said to 
have a high “narrative potential” as many of 
these variants could provide a compelling 
story how the variant would influence a 
particular trait52,53. Hence, the existing 
literature on NGS analyses on longevity, 
based on the genomes of few exceptionally 
long-lived individuals54-56, should be 
interpreted with extreme caution. Checks 
for co-segregation patterns across multiple 
carefully selected families with a deep 
or wide genealogy would greatly reduce 
the likelihood of reporting such false 
positive findings57. Family based designs 
offer additional benefits for research into 
the genetics of complex traits, especially 
whenever complex traits exhibiting low 
or modest heritabilities are studied, as is 
for instance the case for human longevity. 
The fact that only ~25% of the variation in 
human life span is expected to be caused 
by genetic variations in the population 
at large58, makes selection of suitable 
research subjects for research purposes 
into the genetics of human longevity 
challenging, but imperative. Information 
on family history can be exploited to select 
individuals with a genetic propensity 
to become long-lived13. To maximally 
exploit this concept, historical data will be 
explored in search for families, which have 
long-lived members in several generations. 
The currently living descendants can 
then be investigated for genetic variants 
in common. In effect, investigation of 
multiple members of long-lived families 
may contribute to determine the causality 
of genetic variants.
The identification of biomarkers for 
aging is predominantly studied in cross-
sectional study design employing data 




on a single tissue. In order to get a better 
understanding of the systems dynamics 
that lead to human aging, it is imperative 
that repeated omics measures within the 
same individuals in longitudinal studies 
are available in large sample sizes. So-
called systems approaches are performed 
for studying model organisms to assess 
systems-wide responses to perturbations 
across multiple systemic levels or tissues, 
at multiple time points, using multiple 
omic platforms, while collecting multiple 
phenotypic read out parameters. Ideally, 
this approach would be applied for studying 
human longevity, by collecting data within 
multiple members of families with a genetic 
propensity to become long-lived and in age 
and environmentally matched controls, 
as to identify the molecular drivers into a 
successfully decelerated aging.
Aging is a heterogenic phenotype caused 
by multiple functionally independent 
molecular pathways44. The comprehensive 
assessment of ones overall state of aging, 
therefore, probably requires multiple 
independent biomarkers of biological 
aging. For instance, cardiovascular health 
and aging is marked by factors such as 
blood pressure and total cholesterol level59, 
whereas aging of the neuromuscular 
system is marked by atrophy of muscle 
and neuronal cells60. Hence, methodology 
is required allowing to analyse omics data 
sources in the perspective of a multitude of 
unrelated biomarkers of biological age.
Resources consistently collecting 
and curating lists of longevity genes 
established in model systems, such as 
GenAge61, can be incorporated to serve as 
prioritization or interpretation tools for 
omics analyses into human aging (Figure 
2). Publically available transcriptomic 
resources assayed in multiple organisms 
can be exploited for estimating conserved 
gene regulatory networks, similar as is 
done in Chapter 2 and 3 of this thesis. 
Genes within this network can then be 
prioritized by their proximity to already 
established longevity genes within this 
conserved gene regulatory network. 
Thus obtained novel candidate genes for 
longevity can be validated in knockdown 
experiments in for instance C. elegans or D. 
melanogaster. Genes that extent life span 
upon knockdown serve as input for further 
research into specific cohorts suitable for 














Figure 2:  The paradigm of systems biology 
applied to aging research.
7. Conclusion
We have demonstrated the relevance of 
incorporating concepts of data integration 
for the comprehensive and robust analysis 
of omics datasets for molecular pathways 




able to robustly assess the presence of 
certain hallmark processes of aging to 
occur in human blood, we could mostly 
only speculate on the causality and the 
significance of the crosstalk between 
the different aging processes. To further 
explore both the aspects of causality 
and crosstalk, and thus to get a deeper 
understanding of the systems biology 
of human aging, large-scale systems 
approaches are needed that assay multi-
level omics data in family-based and large 
population-based studies, preferably 
across different tissues and time points. 
Methodology for data integration is 
essential in the analysis of these rich data 
sources required for the elucidation of the 
molecular pathways driving human aging.
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1.1 Waarom onderzoek naar 
veroudering?
Volgens de voorspellingen van het 
Centraal Bureau van de Statistiek zal 
ook in de aankomende decennia de 
levensverwachting van de algemene 
Nederlandse bevolking onveranderd 
blijven toenemen. Helaas zullen deze 
gewonnen jaren doorgaans niet allen in 
goede gezondheid worden doorgebracht. 
Immers, naarmate we ouder worden neemt 
het risico op het krijgen van velerlei zeer 
algemeen voorkomende ziekten, zoals 
verscheidene vormen van kanker, diabetes 
mellitus type II en hart- en vaatziekten 
toe. Naar verwachting zal de aankomende 
vergrijzing van onze samenleving gepaard 
gaan met een toename van dergelijke 
leeftijd gerelateerde ziekten. Fundamenteel 
onderzoek naar de oorzakelijke samenhang 
tussen de verschillende aspecten van 
gezondheid en het verouderingsproces is 
dan ook noodzakelijk.
1.2 Wat is veroudering?
Veroudering wordt gekenmerkt door 
een geleidelijke maar onherroepelijke 
afname van controle en dus functionaliteit 
over alle organisatorische lagen van het 
menselijk lichaam. In tegenstelling tot 
hoe de meeste andere karakteristieken 
van ons lichaam tot stand komen, zoals 
bijvoorbeeld oogkleur of lichaamslengte, 
is veroudering niet vastgelegd in ons DNA, 
maar is het een resultaat van een passief 
proces. De jarenlange blootstelling aan 
stochastische schade bronnen, zoals ultra 
violet licht of vrije radicalen, zorgt voor een 
opstapeling van onvolkomenheden in de 
cel, de kleinste levende bouwsteen van ons 
lichaam, en ondermijnt daarmee geleidelijk 
zijn efficiëntie en incasseringsvermogen. 
Deze slijtage slag vindt plaats in al onze 
cellen verspreid over al onze weefsels 
en vergroot daarmee op den duur de 
vatbaarheid van ons lichaam voor allerlei 
kwalen en ziekten. Dientengevolge stelt de 
opstapeling van onvolkomenheden in onze 
cellen daarmee een limiet aan de duur van 
ons leven.
1.3 Langlevendheid: de sleutel tot het 
verouderingsonderzoek
Alhoewel het verouderingsproces 
zelf onafwendbaar lijkt, is de snelheid 
waarmee dit optreedt niet hetzelfde voor 
elk individu. Zo hebben directe familie 
leden van negentig jarigen, vergeleken bij 
de algemene bevolking, een grotere kans 
om zelf ook deze respectabele leeftijd 
te bereiken. Opvallend hierbij is dat de 
directe nazaten van deze langlevenden al 
op middelbare leeftijd minder kans hebben 
op het krijgen van leeftijd gerelateerde 
kwalen en ziekten, zoals diabetes mellitus 
type II of een te hoge bloeddruk. Enerzijds 
suggereert dit dat zowel de snelheid 
van veroudering als de uiteindelijke 
levensverwachting ten minste gedeeltelijk 
wordt bepaald door erfelijke componenten 
in ons DNA. Anderzijds suggereert dit 
dat de erfelijke componenten die deze 
levensverwachting beïnvloeden ook 
het risico op het krijgen van leeftijd 
gerelateerde ziekten verkleinen. Hieruit 
volgt dat we door een nauwgezette 
bestudering van de factoren die de snelheid 




ook de factoren kunnen identificeren die 
algemeen ten grondslag liggen aan diverse 
leeftijd gerelateerde ziekten.
1.4 Onderzoek naar de factoren van 
veroudering
In het humane verouderingsveld volgt 
men veelal twee onderzoeksstrategieën. 
Enerzijds wordt er gezocht naar factoren 
die vroegtijdig inzicht moeten geven in 
de mate en aard van veroudering. Het 
verouderingsproces verloopt bij iedereen 
anders en deze zogenaamde “biomarkers 
van biologische veroudering” meten ieder 
een ander aspect van dit proces. Anderzijds 
wordt er met verschillende technieken 
gekeken naar de genetische basis van 
factoren die de snelheid van veroudering 
lijken te beïnvloeden. We kijken hiervoor in 
het DNA van langlevenden en onderzoeken 
of bepaalde veranderingen in het DNA 
(variaties) vaker of minder vaak voorkomen 
in de algemene bevolking. Voor beide 
strategieën wordt veelal gebruik gemaakt 
van zogenaamde “omics” meetmethoden, 
die er op gericht zijn om in één enkel 
experiment een zo compleet mogelijk beeld 
te geven van alle veranderingen die de cel 
op dat moment ondergaat. De cel reguleert 
zichzelf op vele organisatorische niveaus 
en voor ieder niveau bestaat er een “omics” 
methode die met behulp van duizenden tot 
enkele miljoenen metingen de staat van 
de cel vastlegt. Een grote uitdaging ligt 
momenteel in het onderling relateren en 
interpreteren van de data verkregen met 
verschillende van deze omics platforms. 
Het werk in dit proefschrift legt zich toe 
op het ontwikkelen van methoden voor de 
geïntegreerde analyse van “omics” data 
bronnen, teneinde een beter en completer 
beeld te krijgen van de moleculaire biologie 
van veroudering. Twee strategieën voor 
data integratie zijn toegepast, namelijk: 1) 
de gecombineerde analyse van meerdere 
data bronnen, 2) de incorporatie van 
voorkennis uit externe informatie bronnen.
2. Integratieve Analyse van 
Genexpressie Data Bronnen
De instructies voor het maken van alle 
bouwstenen van de cel, de eiwitten, 
liggen besloten in ons DNA, dat veilig 
afgeschermd ligt in de celkern. Als nieuwe 
eiwitten worden aangemaakt, wordt eerst 
het daarbij behorende stukje DNA, het 
gen, gekopieerd. Door deze kopietjes voor 
ieder van naar schatting ongeveer 18.000 
unieke genen te kwantificeren kunnen 
we een inzicht krijgen welke genen op dat 
moment door de cel gebruikt worden. Deze 
metingen van de zogenaamde expressie 
van genen wordt onder andere gebruikt 
voor het classificeren van tumoren van 
borstkanker patiënten (hoofdstuk 2 in 
dit proefschrift) of om veranderingen in 
het gebruik van genen met toenemende 
leeftijd te karakteriseren (hoofdstuk 3 
in dit proefschrift). In het eerste gedeelte 
van dit proefschrift ontwikkelen we een 
methode voor een integratieve analyse 
van meerdere genexpressie data bronnen 
om zo de zekerheid en interpretatie 
mogelijkheden van onze bevindingen te 
vergroten.
Uit eerdere studies is gebleken dat in 
het gebruik van genexpressie metingen 
voor onderzoek naar borstkanker 




problemen optreden met betrekking tot 
de interpretatie en reproduceerbaarheid 
van de bevindingen. Dit is enerzijds toe 
te schrijven aan technische aspecten 
van de metingen, bijvoorbeeld de lage 
signaal-ruis verhouding, maar anderzijds 
wordt dit ook veroorzaakt door de 
heterogeniteit tussen de onderzochte 
individuen en de complexiteit van de 
onderzochte lichaamskarakteristieken. 
Om zowel de reproduceerbaarheid als 
de interpretatie van deze genexpressie 
analyses te vergroten hebben we een 
nieuwe integratieve methode ontwikkeld. 
In deze methode gebruiken we meerdere 
studies in een gecombineerde analyse 
om de kracht en consistentie van onze 
bevindingen te bevorderen. Daarnaast 
incorporeren we ook informatie over 
welke genen hun taken gezamenlijk 
uitvoeren in de cel, afkomstig uit speciaal 
voor dit doeleinde opgerichte databases 
en gebruiken ook dit om de consistentie 
van onze observaties te verifiëren. De 
incorporatie van dergelijke gen-gen 
interacties geeft bovendien voordelen 
bij de interpretatie van de resultaten. De 
ontwikkelde methode vereenvoudigt de 
analyse en interpretatie door systematisch 
te zoeken naar groepen van genen, met 
een nauw onderling verbonden biologische 
functionaliteit, gen modules genaamd, 
waarvan alle genen een onderlinge 
consistente relatie met betrekking tot de 
onderzochte lichaamskarakteristieken 
vertonen.
In hoofdstuk 2 passen we de 
ontwikkelde methodologie toe op data van 
borstkanker tumoren en demonstreren we 
de hoge mate van interpreteerbaarheid en 
reproduceerbaarheid van de verkregen 
gen modules. Alhoewel het gebruik van 
gen modules niet leidt tot een verbetering 
ten opzichte van de gangbare classificatie 
van de borstkanker tumoren, komt de 
samenstelling van de gevonden gen 
modules wel sterk overeen met genen die 
al eerder gevonden zijn in borstkanker 
onderzoek. We concluderen dat toepassing 
van de voorgestelde methode de data 
van naar schatting ongeveer 18.000 
onafhankelijke metingen naar enkele 
reproduceerbare en goed interpreteerbare 
moleculaire biomarkers kan reduceren. 
In hoofdstuk 3 breiden we de 
voorgestelde methode verder uit door 
zowel het samenstellen van de modules, als 
de daaropvolgende stap waarin hun relatie 
tot karakteristieken van het lichaam 
wordt onderzocht, wordt uitgevoerd met 
meerdere gen expressie data bronnen 
tegelijkertijd. We passen de vernieuwde 
methode toe op vier genexpressie data 
bronnen in het bloed van bijna 2.500 
individuen en analyseren de gemiddelde 
expressie van de genen in een module 
voor consistente veranderingen met 
leeftijd. We identificeren vijf modules 
waarvan de expressie gezamenlijk 
verandert met chronologische leeftijd. 
In een onafhankelijke studie waarin gen 
expressies zijn gemeten in het bloed van 
ongeveer 3.500 individuen bevestigen 
we de door ons gevonden relaties met 
leeftijd voor vier van de vijf modules. Een 
van de gerepliceerde modules bevat het 
gen ASF1A, waarvan we eerder al hebben 
aangetoond dat dit in andere hoeveelheden 
tot expressie komt in het bloed van directe 
nazaten van langlevenden ten opzichte 
van de algehele bevolking. Bovendien 




ASF1A gen alsmede het gemiddelde van 
de gehele gen module indicatief is voor de 
levensverwachting van ouderen boven de 
negentig jaar, die we gedurende 10 jaar 
gevolgd hebben. De ASF1A module lijkt 
dus een interessante kandidaat als nieuwe 
moleculaire biomarker voor biologische 
veroudering.
3. Integratieve Analyse van 
DNA Sequentie Data Bronnen
Metingen van variaties in de volgorde en 
samenstelling van ons erfelijk materiaal 
noemen we genetische databronnen. Vaak 
gaat het hierbij over zeer kleine variaties 
waarin slechts een enkele elementaire 
bouwsteen van het DNA, een nucleotide, 
vervangen is door een andere. Genetische 
data bronnen kunnen echter onderling 
sterk verschillen in de resolutie en schaal 
waarop de metingen aan het DNA zijn 
verricht. Genetische data bronnen zijn er 
in vele verschillende soorten en maten en 
verschillen onderling sterk in de resolutie 
en schaal waarop de metingen aan het DNA 
zijn verricht. De genetische data bron met de 
hoogst mogelijke resolutie wordt sequentie 
data genoemd, omdat deze letterlijk de 
volgorde van alle basenparen waaruit ons 
DNA is opgebouwd opsomt. Deze methode 
rapporteert per persoon gemiddeld 
ongeveer 3,2 miljoen veranderingen 
verspreid over het gehele genoom ten 
opzichte van een “gemiddeld” genoom, dat 
gebruikt wordt als referentie. De kracht 
van deze methode is echter ook meteen 
zijn grootste zwakte. Hoe onderscheiden 
we de veranderingen die van belang zijn, 
van alle miljoenen overige veranderingen 
die waarschijnlijk geen enkele of slechts 
zeer beperkte consequenties hebben? In 
het tweede gedeelte van dit proefschrift 
richten we ons op het ontwikkelen van 
innovatieve methoden voor de analyse van 
sequentie data bronnen.
De consequentie van een variant in 
het DNA voor het functioneren van een 
cel heeft voornamelijk te maken met de 
positionering ten opzichte van stukken 
erfelijk materiaal die coderen voor de 
eiwitten in de cel. Genetische varianten die 
de eiwitcode veranderen, of zelfs geheel 
verstoren hebben over het algemeen een 
grotere kans om het functioneren van de 
cel te beïnvloeden. In hoofdstuk 4 van dit 
proefschrift incorporeren we informatie 
uit externe bronnen, die voorspelt in 
welke mate een genetische variant een 
gen verstoort. We passen dit analyse kader 
toe op een sequentie databron bestaande 
uit variaties gemeten in 218 langlevenden 
uit de Leiden Langleven Studie (LLS) en 
98 controles uit de algemene Nederlandse 
bevolking. Gebruikmakende van de 
voorspellingen of een variatie al dan niet 
een gen verstoort, hebben we genetische 
mechanismen onderzocht die gezonde 
veroudering en langlevendheid zouden 
kunnen bevorderen. 
 Zo hebben we onderzocht of 
bepaalde genen in langlevenden vaker dan 
verwacht geraakt zijn door zeer ernstig 
verstorende variaties. Uit onderzoek in 
dier modellen is namelijk gebleken dat als 
specifieke genen worden verstoord, dit kan 
leiden tot een significante verlenging van 
hun levensverwachting. We hebben echter 
geen bewijs gevonden dat dergelijke genen 




families verklaarden. Wel vinden we in 
de hoogbejaarden veel zeer verstorende 
varianten in de genen TET2 en DNMT3A. 
Beide genen vervullen een belangrijke rol 
bij de differentiatie van bloed stamcellen 
in de verschillende soorten bloed cellen 
en zijn verstorende varianten in deze 
genen geassocieerd met een afwijkend 
bloedbeeld.
 Diepere inspectie van de metingen 
van de meest verstorende varianten in 
TET2 en DNMT3A liet zien dat waarschijnlijk 
slechts een klein gedeelte van alle 
cellen in het bloed van de onderzochte 
hoogbejaarden deze varianten draagt. 
Dit is een indicatie dat deze varianten 
vermoedelijk tijdens het leven zijn ontstaan 
en dit soort varianten worden somatische 
mutaties genoemd. In eerdere studies is 
van dergelijke somatische mutaties in 
TET2 en DNMT3A al aangetoond dat deze 
samengaan met het onevenredig uitgroeien 
van het myeloide bloedcompartiment 
en zelfs het risico op het ontwikkelen 
van Acute Myeloide Leukemie verhogen 
(AML). Door de hoogbejaarde dragers 
van deze genafwijkingen 10 jaar lang 
te volgen konden we constateren dat 
de levensverwachting van dragers in 
het geheel niet wordt aangetast. Deze 
bevinding impliceert dat bejaarde dragers 
van dergelijke somatische mutaties een nog 
hogere leeftijd kunnen bereiken zonder 
een vorm van bloedkanker te ontwikkelen.
Onze zoektocht naar genetische 
factoren voor langlevendheid zetten we 
voort in hoofdstuk 5 van dit proefschrift 
door een alternatieve strategie voor het 
prioriteren van variaties uit sequentie data 
toe te passen. We doen dit ten eerste door 
informatie uit een additionele genetische 
data bron in onze analyses te incorporeren. 
Voor dit doeleinde gebruiken we de 
resultaten van een genoomwijde koppeling 
analyse (linkage scan) naar familiare 
langlevendheid, waarin wordt gekeken 
naar de overervingspatronen binnen 
langlevende families. We passen deze 
techniek toe op de langlevende families uit 
de LLS, daarbij ook rekening houdende met 
de gemiddelde levensduur van de ouders 
van deze families. Gebruikmakende van 
dit statistisch kader voor linkage analyse, 
tonen we aan dat de genomische regio 
chr13q34 significant vaker dan verwacht 
in een identieke samenstelling wordt 
overgeërfd binnen de langlevende families 
en dat dit effect het sterkst is in de families 
waarvan de ouders ook zelf langer dan 
gemiddeld hebben geleefd. De resultaten 
van deze analyse doet vermoeden dat 
chr13q34 erfelijke factoren herbergt die 
bijdragen aan familiare langlevendheid.
Ten tweede incorporeren we additionele 
informatie over bloedspiegels die 
karakteristiek zijn voor langlevenden, maar 
ook binnen deze groep een onderscheid 
maakt tussen langlevenden met 
langlevende ouders, FH(+), en langlevende 
families met ouders met een gemiddelde 
levensverwachting FH(-). Eerder 
onderzoek heeft namelijk aangetoond dat 
langlevende families waarvan de ouders 
ook langer dan gemiddeld hebben geleefd 
(FH(+)) een tragere schildklier functie 
hebben dan langlevende families met 
ouders met een gemiddelde levensduur 
(FH(-)). Dit suggereert dat de erfelijke 




functie onafhankelijk bijdragen aan 
langlevendheid. 
Vervolgens gebruiken we de reeds in 
hoofdstuk 4 van dit proefstuk beschreven 
sequentie data van de participanten uit 
de LLS voor het nader bestuderen van 
genomische regio chr13q34, waarvan 
we nu vermoeden dat het genen herbergt 
die betrokken zijn bij zowel een trage 
schildklierfunctie als langlevendheid. 
Aangezien deze regio nog steeds meerdere 
duizenden variaties telt in onze sequentie 
data passen we nogmaals een strategie 
toe ter prioritering. We doen dit door op 
systematische schaal voor iedere variatie 
te bepalen of dragerschap van deze 
variatie op chr13q34 in de sequentiedata 
samen gaat met laag fT3 een marker 
van de trage schildklierfunctie. Deze 
analyse laat zien dat dragers van het 
zeldzame C allel van de variant rs9515460 
een veel lagere bloedspiegel van het 
ongebonden schildklierhormoon hebben. 
Mogelijkerwijs verklaart deze variant dus 
zowel de trage schildklier functie als de 
familiare langlevendheid.
In hoofdstuk 6 van dit proefschrift 
presenteren we een nieuw R pakket, 
genaamd SATORi, waarmee vele van 
de integratieve berekeningen aan 
genetische data in dit proefschrift gedaan 
zijn. In dit pakket zijn enkele routines 
geïmplementeerd, die enkele van de meest 
uitgevoerde stappen in een integratieve 
analyse zouden moeten vergemakkelijken. 
Het nut en gebruik van dit pakket wordt 
geïllustreerd aan de hand van enkele 
publiekelijk beschikbare omics data sets. 
4. Conclusie en Toekomst
Het onderzoek in dit proefschrift is er op 
gericht om nieuwe integratieve analyse 
methoden te ontwikkelen en toe te passen, 
teneinde een beter en completer beeld 
te krijgen van de moleculaire biologie 
van veroudering. Het proefschrift bevat 
dus resultaten van twee soorten. Ten 
eerste heeft dit proefschrift integratieve 
methodologie opgeleverd voor een 
gecombineerde analyse van meerdere 
genexpressie datasets. Toepassing 
daarvan heeft enkele robuuste en 
interpreteerbare moleculaire profielen 
opgeleverd, die verder onderzocht kunnen 
worden voor hun potentie als biomarker 
voor biologische veroudering. Ten tweede 
hebben we gewerkt aan methodologie voor 
een integratieve analyse van genetische 
componenten die predisponeren voor een 
vertraagd verouderingsproces. Dit laatste 
bleek moeilijker dan verwacht, niet alleen 
door de omvang en complexiteit van de 
geanalyseerde sequentie data, maar ook 
doordat er van het verouderingsproces 
op hoge leeftijd zelf weinig relatief 
weinig bekend is. Desalniettemin 
hebben we toch enkele zeer interessante 
observaties gedaan met betrekking tot 
het verouderingsproces of de mogelijke 
vertraging daarvan. Enerzijds vinden we 
in de genomen van gezonde ouderen een 
hoge frequentie van varianten die tijdens 
het leven zijn ontstaan, die vermoedelijk 
de samenstelling van het bloedbeeld 
beïnvloeden. Anderzijds vinden we dat de 
genetische locatie chr13q34 waarschijnlijk 
bijdraagt aan langlevendheid door de 




Om verder progressie in het 
verouderingsveld te boeken is niet 
alleen meer onderzoek naar integratieve 
analyses nodig, maar kan er ook veel winst 
geboekt worden met de manier waarop 
data gemeten wordt. Zo wordt verwacht 
dat vernieuwingen in de experimentele 
methodologie van sequentie metingen de 
kwaliteit van zowel de genetische als de 
genexpressie datasets sterk zal verbeteren. 
Tevens kan de waarde van de gemeten 
data nog sterk vergroot worden door een 
nog slimmere experimentele opzet te 
kiezen. Niet alleen kan bijvoorbeeld de 
invloed van de interindividuele variatie 
in de data sterk gereduceerd worden door 
dezelfde mensen herhaaldelijk te meten. 
Ook kan door middel van een uitgebreide 
fenotypering of inspectie van de sterfte 
en geboortecijfers van de familie over 
meerdere generaties uitgezocht worden 
in welke familie de genetische component 
voor langlevendheid het sterkst aanwezig 
is. Beide methoden worden momenteel in 
onze groep toegepast in de acquisitie van 
nieuwe data over veroudering. Een andere 
trend waarvan het verouderingsveld kan 
profiteren is dat er steeds meer grote 
omics datasets publiekelijk beschikbaar 
worden gemaakt, zoals bijvoorbeeld door 
het biobank initiatief BBMRI. Met behulp 
van deze data bronnen kan steeds beter 
onderzocht worden wat de samenhang is 
tussen de verschillende soorten metingen 
zonder dat daar eigen data gecreëerd voor 
hoeft te worden. Een uitdaging voor de 
nabije toekomst ligt in het identificeren 
van gecombineerde biomarker profielen, 
die rekening houden met meerdere 
aspecten van veroudering, bijvoorbeeld 
cognitieve of cardiovasculaire, en zo 
dus een getrouwer beeld geeft van de 
algemene biologische leeftijd. Ook ligt er 
een uitdaging in het efficiënt incorporeren 
van informatie over veroudering uit dier 
modellen teneinde onze zoektocht naar 
de moleculaire biologie van menselijke 
veroudering te versnellen.
In dit proefschrift hebben we het 
belang van data integratie technieken 
gedemonstreerd voor het doen van 
onderzoek naar de moleculaire biologie 
van veroudering. Alhoewel we met behulp 
van integratieve data analyses enkele 
interessante aspecten van veroudering 
hebben ontdekt blijven er echter nog 
vele hiaten bestaan in ons begrip over 
veroudering in relatie tot gezondheid. 
Idealiter zouden we onze kennis over 
veroudering het beste kunnen verdiepen 
door meer omics data met meerdere soorten 
meetmethoden in meerdere weefsels op 
meerdere tijdstippen in dezelfde personen 
te meten. De ontwikkeling van integratieve 
analyse technieken zal onmisbaar zijn voor 
de analyse van dergelijke rijke en complexe 
data bronnen en zal in de toekomst dan 
ook een doorslaggevende rol spelen in het 
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